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New methods of conducting research have been emerging outside clinical 
research. For example, worldwide game players helped to construct protein 
molecular which scientists had been struggling with for 15 years. In these 
examples, researchers leveraged collective intelligence of people who were not 
usually involved in research. My research aims to investigate whether and how 
mobilising collective intelligence could be used in the planning of a 
randomised controlled trial.  
To achieve this aim, I first conducted a scoping review to describe the methods 
of mobilising collective intelligence across different research fields. From this 
scoping review, I proposed a framework for implementing a research project 
using these new methods.    
Second, I conducted a qualitative study involving online survey and semi-
structured interviews to investigators, researchers or coordinators of research 
projects mobilising collective intelligence. Drawing on their experience, I 
provided good practice advice for the governance, planning, and conducting of 
research involving collective intelligence. 
Finally, I developed a proof-of-concept study using case vignettes to leverage 
patients’ collective intelligence to improve trial organisation. Patients 
proposed several suggestions to improve the logistical organisation of trials. 





In conclusion, the work in this thesis provides the first comprehensive 
accounts of methods used to mobilise collective intelligence across different 
research disciplines. The proof-of-concept study provided an example of 
leveraging patients’ collective intelligence to explore ideas and perspectives to 
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Chapter I. Introduction 
1.1. Rationale for the thesis 
Evidence based medicine is defined as the integration of clinical expertise and 
patients’ values with the best available external evidence obtained from 
systematic research. However, the quality of clinical research used to generate 
evidence has been increasingly questioned. It has been estimated that billions 
of dollars of investment in clinical research had been wasted due to avoidable 
problems in clinical trial planning. This includes the pursuit of research 
questions which do not address the priorities of patients and clinicians and the 
inappropriate design of clinical research, with “unrepresentative samples, 
small samples, incorrect methods of analysis, and faulty interpretation” (1).  
These issues could be prevented if clinicians, patients, methodologists and 
biostatisticians were involved in setting research agendas and designing 
clinical research. Meanwhile, mobilising collective intelligence through 
crowdsourcing is an emerging method which has been used to solicit the 
contributions to research, not only of researchers across different research 
disciplines, but also public members. This innovative method could be used to 
involve diverse stakeholders in clinical trial planning to contribute to tackling 
research waste.   
1.2. Aims and objectives of this thesis 
1.3. Thesis structure 
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The central aim of this thesis was to investigate whether and how mobilising 
collective intelligence could be used in clinical trial planning. The research was 
guided by three main objectives which were to: 
1. Identify and describe methods of mobilising collective intelligence 
through crowdsourcing in different research fields and propose a 
framework to implement them. This involved a scoping review of 
research projects which used methods of mobilising collective 
intelligence (Study One). 
2. Identify barriers to mobilising collective intelligence, strategies to 
overcome these barriers and provide good practice advice for planning 
and conducting research using collective intelligence. This was 
undertaken using a qualitative approach with an online survey and 
semi-structured interviews (Study Two). 
3. Evaluate the impact of mobilising collective intelligence on the planning 
of clinical trials. This was addressed through a proof of concept study 
using case vignettes to mobilising collective intelligence of patients and 
public members in clinical trial design (Study Three).  
1.3. Thesis structure 
The thesis is structured in six chapters. Chapter 1 introduces the aims and 
objectives of the thesis. Chapter 2 provides a review of background literature 




Chapters 3 presents the scoping review which described research using 
methods of collective intelligence across different research disciplines and 
developed a framework for implementation of collective intelligence projects.  
Chapter 4 presents the qualitative study which aimed to identify barriers to 
mobilising collective intelligence, solutions to overcome these barriers and 
seek for good practice advice from researchers experienced with collective 
intelligence. 
Chapter 5 describes the proof of concept study which applied the methods of 
collective intelligence to solicit contributions from patients and members of 
the public to improve clinical trial design. 
Chapter 6 concludes the thesis by summarising the results, discussing the 










Chapter 2. Background literature 
2.1. Evidence-based medicine and randomised controlled 
trial 
2.1.1. What is evidence-based medicine? 
Evidence-based medicine was first coined by David Sackett and Gordon Guyatt 
in the 1990s to encourage clinicians to integrate external evidence obtained 
from systematic research into their clinical practice to provide optimal care for 
patients (2, 3).  Although the term evidence-based medicine was first defined 
in the 1990s, the development of evidence-based medicine well predated the 
1990s. Historical literature shows the work of clinicians and researchers who 
used evidence to inform their patient care. For example, James Lind conducted 
the first clinical trial to provide evidence of the cause and treatment for scurvy 
in the eighteenth century, while John Snow used evidence from observational 
data to identify causes of transmission of cholera in the nineteenth century.  
In 1962, the US Food and Drug Administration (FDA) issued a legal regulatory 
framework requiring rigorous testing of clinical trials in human beings to 
provide evidence of efficacy of new drugs. This regulatory requirement led to a 
tremendous increase in the number of clinical trials, thus created a large 
amount of medical literature (Figure 1). 
2.1. Evidence-based medicine and randomised controlled trial 
6 
 
Figure 1. The number of published trials from 1950 to 2010 (reproduced from 
Bastian et al, 2010, (4)) 
However, unsystematic clinical experience with intuitive reasoning based on 
physiological knowledge remained dominant in practice. For example, it took 
ten years after evidence of benefits was established before practitioners started 
to use thrombolytic therapy for treating myocardial infarction (5). A recent 
systematic review showed that the proportion of recommendations supported 
by high-quality evidence in clinical guidelines released by American College of 
Cardiology/American Heart Association has not increased overtime despite 
the increased efforts in conducting clinical research (6, 7). As such, evidence-
based medicine should be reinforced to ensure that clinical practice is based 
on scientifically trustworthy empirical evidence.   




Evidence-based medicine consists of five main components: asking an 
answerable question, searching for the best evidence, critically appraising the 
evidence, integrating the evidence with clinical expertise and patients’ values, 
and evaluating performance (Table 1). 
Table 1. The five basic components of evidence-based medicine (reproduced 
from Swanson et al, 2010 (8). 
Step 1 Converting the need for information (about prevention, diagnosis, 
prognosis, therapy, causation, etc.) into an answerable question 
Step 2 Tracking down the best evidence with which to answer that 
question 
Step 3 Critically appraising that evidence for its validity (closeness to the 
truth), impact (size of effect), and applicability (usefulness in our 
clinical practice) 
Step 4 Integrating the critical appraisal with our clinical expertise and 
with knowledge of a patient’s unique biology, values, and 
circumstances 
Step 5 Evaluating effectiveness and efficiency in executing steps 1-4 and 
seeking ways to improve for next time 
 
The main difference between evidence-based medicine and traditional 
medicine is that evidence-based medicine considers the best evidence and 
critically appraising validity of the evidence, while traditional medicine 
corporates evidence in the practices without verifying its trustworthy. A simple 
2.1. Evidence-based medicine and randomised controlled trial 
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hierarchy of evidence was proposed to support practitioners in evaluating the 
evidence (9). The randomised controlled trial is considered as the clinical study 
design providing the most valid evidence, certainly in comparison with 
observational studies. However, researchers soon recognised that randomised 
controlled trials were also subject to bias and that more critical tools should be 
used to assess methodological issues that could influence the quality of 
evidence. As such, the GRADE classification of the quality of evidence was 
developed to provide a structured and transparent system for assessing the 
quality of evidence (10, 11). Table 2 presents criteria to assess the quality of 
evidence. 
Table 2 Quality of evidence assessment (reproduced from Guyatt et al, 2011 
(12)). 
 
Study design Quality of 
evidence 
Lower if Higher if 
Randomised trial → High Risk of bias 
-1 Serious 
-2 Very serious 
Inconsistency 
-1 Serious 
-2 Very serious 
Indirectness 
-1 Serious 
-2 Very serious 
Large effect 
+1 Large 
+2 Very large 
Dose response 











 Very Low Imprecision 
-1 Serious 




-2 Very likely 
+1 Would reduce a 
demonstrated effect 
or 
+1 Would suggest a 
spurious effect when 
results show no 
effect 
 
2.1.3. Randomised controlled trial 
The randomised controlled trial is a clinical research design in which sample 
are randomly assigned to one or several intervention groups to compare these 
interventions with a control group receiving a placebo or conventional 
treatment. Table 3 describes main features of a well-designed randomised 
controlled trial. Participants, clinicians and researchers might be blinded to 
treatment group to avoid the influence of their treatment preference on 
outcome assessment. Although observational studies such as case control 
studies, cohort studies can provide evidence of association between 
intervention and outcomes, they cannot rule out other factors that might 
interfere this association. By using a comparison group, randomisation and 
blinding, randomised controlled trials can minimise the effect of these factors.  
Table 3. Features of a well-designed randomised controlled trial (reproduced 
from Kendall et al, 2003  (13)). 
• The sample to be studied will be appropriate to the hypothesis being 
tested so that any results are appropriately generalisable. The study 
will recruit sufficient patients to allow it to have a high probability of 
2.1. Evidence-based medicine and randomised controlled trial 
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detecting a clinically important difference between treatments if a 
difference truly exists. 
• There will be effective (concealed) randomisation of the subjects to 
the intervention/control groups (to eliminate selection bias and 
minimise confounding variables). 
• Both groups will be treated identically in all respects except for the 
intervention being tested and to this end patients and investigators 
will ideally be blinded to which group an individual is assigned. 
• The investigator assessing outcome will be blinded to treatment 
allocation. 
• Patients are analysed within the group to which they were allocated, 
irrespective of whether they received the intended intervention 
(intention to treat analysis). 
• Analysis focuses on testing the research question that initially led to 
the trial (that is, according to the a priori hypothesis being tested), 
rather than “trawling” to find a significant difference. 
 
The quality of a randomised controlled trial is assessed by two main indicators: 
internal and external validity. Internal validity is the extent to which the 
differences observed between control and intervention group are attributed to 
the intervention. Flaws in design, conducting and reporting of randomised 
controlled trials can lead to bias, whereby the results deviate from the truth. 
Cochrane Collaboration has developed a tool to assess risk of bias in five 
domains related to design and reports of trials: selection bias, performance 




the ability to generalise the results of randomised controlled trial into general 
population (15). Although randomised trials are designed to eliminate bias and 
increase internal validity, it is uncertain to what extent the result of the trial 
can be translated into clinical practice. External validity depends on several 
factors such as the selection of clinical trial participants and patients’ 
treatment preferences (15).  
2.2. Avoidable waste in the production of research evidence 
With the advent of the evidence-based medicine movement and increasing 
requirement from regulatory boards, global investment in clinical trials has 
risen rapidly. The number of clinical trials registered on clinicaltrial.gov in 
2010 was about 83,000. By May 2019, there were more than 300,000 trials 
registered (16).  It was estimated that US$ 44.2 billion was invested in clinical 
trials globally in 2018 and this number is expected to grow to US$ 65.2 billion 
in 2025 (17). However, a tremendous increase in the investment in clinical 
trials does not necessarily translate into producing more usable evidence. 
Research agendas are heavily shaped by industry with little attention to 
patients’ needs. Ioannidis has recently stated that “evidence-based medicine 
has been hijacked” and “clinical evidence is becoming an industry 
advertisement tool” (18, 19). Chalmers and Glasziou estimated that 85% of 
investment in biomedical research is wasted (20). A recent series on Lancet 
identified waste in all stages of research including irrelevant research priority 
setting, inappropriate research design, and inaccessible and unusable research 
reports (21-25).  
2.2. Avoidable waste in the production of research evidence 
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2.2.1. Research waste caused by ignorance of users’ need  
To provide evidence for decision making, research should answer questions 
which are important to patients and other stakeholders such as clinicians, 
funders and policy makers. However, patients and clinicians are not usually 
involved in research priorities setting which leads to the gaps between research 
and practice. A study showed that only 9% of surveyed patients with knee 
osteoarthritis indicated research on oral and injection treatment as their first 
priority, but 59% of published research on knee osteoarthritis were evaluation 
of oral and injected pharmaceutical treatment (26). The James Lind Alliance 
is an initiative aiming to engage patients and the public in all phases of clinical 
trials, particularly in setting research agenda through Priority Setting 
Partnerships (PSP). PSPs bring together patients, clinicians and researchers to 
identify the top 10 important research questions for a specific therapeutic area 
that future research should address (27). However, a recent scoping review 
showed that only 20% of clinical research in dialysis addressed top 10 research 
priorities identified by a PSP organised by the James Lind Alliance  (28). 
Similarly, in the field of oncology research, two of the three highest priorities 
defined by patients, which were supportive and palliative care, early detection 
and prevention, were covered by less than 15% of research funded by UK 
cancer research institute (29). This persistent gap between patients’ needs and 
research topics raises questions about the value of research, and whether 
research results can be translated into clinical practice and health policy to 




2.2.2. Research waste caused by ignorance of trial participants’ 
experience 
Clinical trials are expensive to conduct, time consuming and burdensome for 
patients. A quarter of clinical trials are prematurely discontinued which is a 
substantial source of waste in research (30). A systematic review of 
discontinued trials listed 28 reasons for premature discontinuation. Of these, 
high burden trials with many visits, invasive procedures, long questionnaires, 
approaching patients in inconvenient situations were some of the reasons 
demotivating participants (31). Further, burdensome trials might also increase 
the frequency of missing data due to dropouts, which might bias the estimate 
of the treatment effect  (32). These could have been prevented by pilot studies 
to estimate the burden to participants and identify strategies to improve 
participants’ experience, thus increasing their motivation to participate in 
trials. Complex informed consent forms and language barriers are other 
reasons for difficulties in recruitment and retention of clinical trials. A review 
showed that nearly 50% of trial participants could not understand the 
information related to randomisation and placebo, and 45% were unable to 
name at least a risk of participation explained in consent forms (33). There is 
a lack of efforts to help patients have better informed choices. The meta-
analysis showed that the understanding of patients on informed consent has 
not improved for the last 30 years. Even for patients who participated in a trial, 
one out of six still felt informed consent form complicated (33). 
Further, follow up visits are often organised inconveniently for patients, which 
creates unnecessary barriers for patients to complete trials. Patients have to 
2.3. Stakeholder involvement to increase research value 
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travel in rush hours to clinics, look for parking places and wait for hours to 
finish an examination and fill out questionnaires. These inconveniences 
disrupt their daily life and have negative impacts on their work and income 
(34).  Although patients spend time and efforts on answering study 
questionnaire, outcomes which are perceived as important by patients such as 
functionality, social and emotional wellbeing, and adverse reactions are not 
always measured in clinical trials (35). A systematic review of 112 clinical trials 
in critical ill patients identified only 27 trials assessing patient-important 
outcomes and only six of them measured outcomes related to quality of life and 
functional disability (36). Clinical trials are designed by clinical trialists, 
methodologists and statisticians, while patients whose daily lives are directly 
affected by the participation in the trial are less often involved in trial design. 
This waste of research due to ignorance of participants’ experience when 
planning clinical trials could be ameliorated by involving patients early in the 
conception of trials.  
2.3. Stakeholder involvement to increase research value 
To ensure that clinical trials answer high priority questions, and evidence 
generated from clinical trials are aligned with information needs in healthcare 
practice, patients and other healthcare stakeholders should be involved in 
planning and conducting clinical trials. Stakeholder involvement in clinical 
research is defined as “ an iterative process of actively soliciting the knowledge, 
experience, judgement and values of individuals selected to represent a broad 
range of direct interests in a particular issue, for the dual purposes of creating 




decisions” (37). Stakeholders who can contribute to clinical research are 
“individuals, organisations or communities that have a direct interest in the 
process and outcomes of a project, research or policy endeavour”. Table 4 lists 
different categories of stakeholders who could contribute their experience and 
knowledge to planning and conducting clinical trials (38).  
Table 4. Stakeholders who can engage in clinical trial planning and 
conducting (reproduced from Deverka et al, 2013 (37)) 
Category Description 
Patients and the public Current and potential consumers of patient-
centred health care and population-focused 
public health, their caregivers, families, and 
patient and consumer advocacy 
organizations. 
Providers Individuals (e.g., nurses, physicians, mental 
health counsellors, pharmacists, and other 
providers of care and support services) and 
organizations (e.g., hospitals, clinics, 
community health centres, community-
based organizations, pharmacies, EMS 
agencies, skilled nursing facilities, schools) 
that provide care to patients and populations. 
Purchasers Employers, the self-insured, government and 
other entities responsible for underwriting 
the costs of health care. 
Payers Insurers, Medicare and Medicaid, state 
insurance exchanges, individuals with 
deductibles, and others responsible for 
2.3. Stakeholder involvement to increase research value 
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reimbursement for interventions and 
episodes of care. 
Policy makers Government, Department of Health and 
Human Services, Congress, states, 
professional associations, intermediaries, 
and other policy-making entities. 
Product makers Drug and device manufacturers. 
Principal investigators Other researchers and their funders. 
This list of stakeholders is not exhaustive and does not require researchers to 
involve all these categories of stakeholders in their research. Researchers could 
decide the type of inputs and perspectives that would be the most beneficial 
for their research. Patients with their personal experience can provide their 
unique perspectives to ensure research questions are relevant to their 
healthcare needs and to make research designs more pragmatic. Inputs from 
other stakeholders such as payers, policy makers and clinicians, are also 
important to ensure that research is useful for decision making.  
2.3.1. Conceptual model for stakeholder involvement in clinical 
research.  
Patients and other stakeholders can be involved at several different stages of 
planning and conducting clinical research. Table 5 describes the stages where 





Table 5. Engagement activities in each stage of planning and conducting 
clinical research (reproduced from Forsythe et, 2016 (39)) 
Stage of the research process Engagement activities  
Topic solicitation, agenda 
setting and development of 
research questions 
• Provide input on the research topic, 
prioritization/agenda setting and how to 
frame the research question 
• Selection of outcomes studied 
Proposal development • Provide input on lay/plain language 
summaries for funding applications 
• Solicit or amass funding 
• Identify and build partnerships with 
researchers 
• Provide support for IRB approval process 
Method/study design • Select study design 
• Select or develop data collection tools 
Recruitment • Recommend strategies for more 
successful recruitment 
Data collection • Deliver the research data instrument or 
conduct participant interviews 
• Develop and host biobanks or registries 
that serve as sources of data 
Data analysis • Participate in coding the data and data 
analysis 
• Suggest themes for qualitative analysis 
2.3. Stakeholder involvement to increase research value 
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Results review, interpretation, 
and translation 
• Interpret research findings 
• Highlight most patient-relevant findings 
• Identify implications of results for health 
care delivery 
 
Dissemination • Communicate results to other patients, 
community, and researchers 
To support researchers in engaging stakeholders in clinical research, Deverka 
et al developed a conceptual model for stakeholder involvement in clinical 
research (Figure 2) (37). This conceptual model describes a process starting 
with the inputs i.e. contribution of stakeholders which are processed by the use 
of both quantitative and qualitative techniques to generate outputs, which are 
the decisions related to research planning and conducting. It is important to 
note that the inputs of the model are not only evidence from literature, but also 
personal knowledge and experience of stakeholders. The method used to 






Figure 2. Conceptual model of stakeholder engagement in comparative 
effectiveness research (reproduced from Deverka et al, 2013 (37)). 
This conceptual model describes three key components of involving 
stakeholders in clinical research, while enabling flexibility in the choice of 
methods to engage and process information contributed by stakeholders. In 
addition, by emphasising the value of personal experience, all stakeholders 
could see the role of their contribution in research.  
2.3.2. Patient and public involvement in clinical research 
The prevalence of patients and public member is uneven across countries and 
depends relatively on the policy of the funders. A systematic review of 23 
clinical trials having patients and public involvement showed that nearly half 
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of them (10/23) came from the United States, 9 studies from the United 
Kingdom, and only three studies from other countries in Europe. (39). In 
Western Europe, the movement of patient and public involvement was quite 
active, however, it mainly happened in a small group of institution. In the 
United Kingdom, researchers involved patients and public members with the 
main reason to fulfil requirements from funders (40). As clinical trials have an 
important role to provide robust evidence to inform clinical practice, patients 
and public involvement should also be involved in the planning and 
conducting of clinical trials to ensure that trials are addressing questions 
relevant to patients, and the design of trials reflects patients’ needs and 
preference. The value of patient and public involvement in the design and 
conduct of research is gaining wider recognition. Patient and public 
involvement is defined as research undertaken “with” or “by” patients or 
members of the public, rather than “to”, “about” or “for” patients (41). This 
active involvement in research is different from passive participation in clinical 
trials as a study “subjects” with no or limited scope to contribute to designing 
and conducting research. Patient and public involvement is also different from 
public engagement activities, which aim to increase public awareness of 
research through communication activities of researchers to public. The aim 
of patient and public involvement is to increase research value by identifying 
relevant research questions and create appropriate research from patients’ 
perspectives. Indeed, studies reported that public involvement helped to create 
a mutual respect between researchers and public members and consequently 
increase acceptability of research in community (42). Patients and public 




appropriate recruitment strategies and develop user-friendly data collection 
tools that should be considered when designing trials (43). They also 
collaborated with researchers to identify top research priorities to overcome 
challenges in trial recruitment and retention (44, 45). More research 
evaluating impacts of patient and public involvement on trial planning and 
conducting are needed (46). A study within a trial showed that advertisement 
of patient and public involvement in trial recruitment did not improve 
recruitment rate. However, a meta-analysis of 26 studies showed that patient 
and public involvement had a modest positive impact on trial recruitment and 
retention (47).  
Funders in the UK, the USA and Europe have been encouraging public 
involvement in research. The Patient Centred Outcomes Research Institute 
(PCORI) in the USA is a research funder supporting research led by patient 
and public members (48). In the UK, NIHR stipulate that researchers must 
involve patient and public in the development of funding application, design 
and conduct of research (49). INVOLVE is an initiative funded by NIHR to 
support research with patient and public members. In Europe, EUPATI is a 
collaborative project connecting pharmaceutical industry, academia, not-for-
profit, and patient organisations (50). The project focuses on educating and 
training patients to enhance their knowledge on medical research, and thus 
increase their confidence to effectively contribute to research.  
Despite the increasing recognition of value of public involvement, there are 
still barriers to its implementation in research. As there is no one-size-fit-all 
approach for patients and public involvement, researchers have found it 
challenging to identify appropriate methods to effectively involve patients and 
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public members in making decision related to research (46, 51). Researchers 
have also found it  difficult to integrate opinions of patients and public 
members, when patients and public members had contrasting ideas with 
researchers (42). Further, researchers are also concerned about how to select 
patients and public members and to involve in research to represent opinions 
of other patients and public members. Additionally, concerns about conflict of 
interest when patient organisations increasingly receive financial support from 
industry have raised questions about the transparency and independence of 
patients’ contribution to research (52, 53). On the other hand, it is noted that 
public involvement might also be a negative experience for patient and public 
members who are involved, if the method used is inappropriate (54). For 
example, patient and public involved in research have reported instances when 
they have not been listened to, or their opinions were not considered seriously. 
Patients want more transparent processes for selecting who represents them, 
as they have noted that researchers sometimes tend to select patients who 
researchers feel comfortable with. Further, people who involved in research 
also shared concerns that their opinions  could not represent the perspective 
of other patients (55). Patients and public members reported difficulties of 
communicating with researchers due to the use of scientific language and 
insensitivity of researchers when interacting with patients and public (56). 
Patients and public members who involved in research also commented on the 
burdensome procedures such as filling in complicated application forms and 
obtaining references to be able to contribute their opinions (57, 58). They also 
reported that involvement in research was time consuming, and they felt 




meetings.  These issues highlight the need to explore different methods to 
access a diverse group of patients and public members and improve their 
experience with the process.  
2.4. A new research method - Collective intelligence 
2.4.1 Definition of collective intelligence. 
New ways of planning and conducting research have emerged recently 
involving large numbers of diverse participants. For example, participants, 
who are usually not directly involved in research, now contribute their new 
research ideas, their skills and knowledge to the analyse clinical trial data. For 
example, an initiative mobilized 1636 patients contributing more than 3000 
ideas to improve health care and the health system (59).   These new methods 
of planning and conducting research are based on the concept of collective 
intelligence.  
Collective intelligence is defined as “shared intelligence emerging when 
mobilising people who are usually not involved in the research process to work 
on a specific task (60). Two necessary conditions for collective intelligence to 
occur are: “1) A group has the capability to overcome challenges through 
shared or individual processing of information; 2) This capability allows the 
group to come to results superior to the results that could have been reached 
by conventional methods or by one member of the group alone” (61). These 
conditions allow individuals in a group to process information either 
collectively as a group, or separately as independent individuals, in ways that 
the aggregated results of their works have greater impacts than a mere sum of 
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individual works. Researchers often collaborate and interact with other 
researchers within or outside their team. However, with the development of 
web 2.0 application, they can connect to people from all walks of life and 
leverage their knowledge and skills to accelerate research. Three pillars of 
collective intelligence are outreaching to achieve diversity of opinions, an 
aggregation mechanism to synthesize information, and interaction among 
group members to synergize their ability.  
With the rapid growth of research on collective intelligence, there are 
numerous literatures which propose different terms to describe collective 
intelligence. Although terms such as crowdsourcing, citizen science and open 
innovation all refer to organisational models which leverage collective 
intelligence, there are some distinctions between them. Crowdsourcing is a 
model in which the knowledge and skills of diverse individuals are leveraged 
to complete a specific task or solve a specific problem set by an organisation. 
It combines a bottom-up, open, creative process with top-down organisational 
goals (62). Amazon Mechanical Turk (MTurk) is an example of crowdsourcing 
where task givers offer distributed workers low per-task payment in exchange 
for completing discrete tasks. Citizen science is a subtype of crowdsourcing 
focusing on public involvement in research. In citizen science, public members 
voluntarily complete tasks such as collect data, code or label data to help 
scientists advance their research as well as increase public’s understanding in 
science (63). Although crowdsourcing allows individuals to contribute to a 
specific task, not all crowdsourced tasks require participants to use their 
knowledge or “intelligence” to complete the tasks. For example, crowds share 




knowledge or skills. In such cases, crowdsourcing does not necessarily 
generate collective intelligence (64-67).  
Open innovation is another organisational model of collective intelligence 
which recognizes that problem-solvers are unlikely to work in a single firm and 
“valuable ideas can come from inside or outside the organisation” (68). People 
from diverse backgrounds and diverse settings can work collaboratively to 
generate better outcomes. The difference between crowdsourcing and open 
innovation is that the tasks in the former are governed and pre-specified by the 
task givers, while the latter emphasizes the collaboration between individuals 
from different entities to create concepts and solutions. Open innovation is a 
strategic direction that private sectors have been undertaking to exchange 
technology and human resources for business development. Public sectors are 
also increasingly adopting this approach to collaborate with external parties. 
 2.4.2. Collective intelligence in research 
Methods of collective intelligence have been increasingly used in research 
across different disciplines. Kaggle and Innocentive are platforms where 
individuals from all over the world can contribute to solve research problems 
in all disciplines such as computer science, technology development, health 
care (69, 70). Climatecolab is an online community with 120,000 participants 
who contribute research ideas to address the challenges of climate change (71). 
Game players on Foldit succeeded in constructing a protein model which 
scientists had been struggling with for 15 years (72). There are certain 
literatures summarising the application of collective intelligence in health 
research to solve empirical research problems, acquire and analyse data, and 
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boost medical education (73). For example, a competition on developing 
algorithms to monitor the progression of amyotrophic lateral sclerosis resulted 
in 37 algorithms developed by researchers worldwide. Two of these algorithms 
were shown to outperform the algorithm used by ALS physicians (74).  SPRINT 
is another data challenge which attracted 200 teams and individuals all over 
the world participated to analyse data from Systolic Blood Pressure 
Intervention Trial (58). Clinical trials are facing complex challenges such as 
identifying research priorities and research questions relevant to patients, 
improving recruitment and retention, reducing burden of trial participation 
and implementation, enhancing transparency in clinical trial data analysis and 
data sharing (73). that require diverse perspectives of different stakeholders 
and patients and public members such as Collective intelligence could be a 
promising method for soliciting patients and public’s contribution in clinical 
trials. For example, a collective intelligence project included nearly 500 
participants contributing research ideas in maternal, new-born, child health 
and nutrition. Participants sent more than 4000 ideas which were then 
grouped into 373 research options ranked by priority. This exercise helped 
funders and the Indian government to understand which questions were 
important to health consumers to prioritize funding (75). An alliance for 
clinical trials in oncology created an online platform to welcome all general 
public members share their ideas and concepts for possible further study (76). 
Transparency Life Sciences, a private company, created a platform for trial 
protocol builder where researchers, clinicians, patients and public members 
can comment to improve a clinical trial protocol. The contribution of collective 




primary endpoints and statistical analysis plan (77). These promising 
examples of application of collective intelligence suggest that this method 
could be used to involve diverse stakeholders such as patients, public members 
and professionals in other fields to improve clinical trial planning, and thus 
reduce research waste. 
 2.5. Summary 
New forms of planning and conducting research are needed to tackle the 
methodological challenges that clinical research is facing. Patients, public 
members and other professionals should be involved in clinical research to 
ensure that research addresses high priority questions, uses rigorous methods 
and improves experience of clinical trial participants. Methods of collective 
intelligence have been used in other fields to involve diverse individuals in 
research. In order to apply this emerging method in clinical research, it is 
important to understand the framework to implement this method; barriers to 
its implementation, good practice and solutions to overcome these barriers; 
and evaluate its impact on improving clinical research. In the next chapters, I 






Chapter 3 Developing a framework 
for mobilising collective intelligence 
3.1. Background 
In the previous Chapter, I explained the crucial role of evidence-based 
medicine in clinical practice. I also provided an overview of challenges that 
evidence-based medicine encounters due to the lack of diversity in the 
planning and conducting of research. These challenges highlight the need to 
identify new ways to integrate perspectives of diverse stakeholders in 
identifying research questions, choosing study designs and conducting 
research.  
In other research fields, new ways of doing research based on the concept of 
collective intelligence with crowdsourcing have been successfully 
implemented. However, these methods are still relatively new in clinical 
research. To determine whether and how we can apply the methods of 
collective intelligence in clinical trial planning, it is important to have an in-
depth understanding of how these methods have been used in other fields and 
develop a framework for implementation. To address this objective, we 
conducted a scoping review to describe methods used to mobilise collective 
intelligence across different research fields. 
3.2. Method 
3.2.1 Rationale 
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Methods of mobilising collective intelligence have been used in different 
research fields to involve large and diverse groups of participants in research. 
Although there have been some documents describing methods of collective 
intelligence, these literatures focused on one organisational model of collective 
intelligence in a specific research field such as crowdsourcing in health 
research (64). In order to support researchers in the choice of methods of 
collective intelligence, it is important to map the methods that have been used 
across research fields. While systematic reviews aim to synthesise evidence to 
answer a particular research question in a specific research field, scoping 
reviews enable researchers to identify and map available evidence on a broad 
topic (78, 79). In a scoping review, researchers are able to use evidence from 
research using heterogenous designs in different disciplines (79, 80). Another 
difference between a scoping review and a systematic review is that a 
systematic review aims to use only the best available evidence to answer a 
specific question. In contrast, a scoping review provides an overview of all 
available evidence related to the topic  (78). Thus, a scoping review was 
considered to be the most suitable approach given the broad aim of this study. 
3.2.2. Study design 
Drawing on the framework proposed by Arksey and O’Malley and Joanna 
Briggs Institute (80, 81), we conducted the scoping review in four steps: 1) 
identifying relevant literature, 2) study selection, 3) data charting, 4) data 
analysis and reporting results. 
3.2.2.1. Identify relevant literature 




In this study, we defined collective intelligence with crowdsourcing as shared 
intelligence emerging when people who are usually not involved in the 
research process are mobilised to work on a specific task (60).  
Search strategy and information sources 
We searched the English-language articles in the following standard 
databases: PubMed, Web of Science; Scopus; EBSCO Business Source 
Premier; EBSCO Academic Source Premier; publication resources of the 
Centre for Collective Intelligence, Massachusetts Institute of Technology 
(MIT) (search date December 03, 2016); and Google Scholar (January 11, 
2017).  
We also hand-searched databases of funders who support innovation in health 
research such as PCORI, NIHR, Robert Wood Johnson, Horizon 2020, FP7 
and Laboratory for Innovation Science at Harvard (search date December 03, 
2018). We searched Google Scholar for Wikimedia, Wikiproject Medicine, and 
Task Exchange by Cochrane (search date December 03, 2018).  
Search terms were: collective intelligence, crowdsource/ crowdsourcing/ 
crowdsourced, open innovation, peer production. To increase the precision of 
the search, search terms were limited to the titles of articles. The search 
strategy for each database is presented in Table 6 and Table 7. We did not 
restrict the search by publication date, study design, or study setting.  
Table 6 Search strategy for PubMed, Web of science, EBSCO business source 
premier and EBSCO academic source premier 
Search strategy 
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1. “Collective intelligence” (Title) 
2. Crowdsourc* (Title) 
3. “Open innovation” (Title) 
4. “Peer production” (Title) 
5. #1 OR #2 OR #3 OR #4 
 
Table 7 Search strategy for Scopus, Google scholar 
Search strategy 
1. “Collective intelligence” (Title) 
2. Crowdsourc* (Title) 
3. “Open innovation” (Title) 
4. “Peer production” (Title) 
5. #1 OR #2 OR #3 OR #4 
6. Methods (Title – Abstract – Keyword) 
7. Components (Title – Abstract – Keyword) 
8. Design (Title – Abstract – Keyword) 
9. #6 OR #7 OR #8 
10. #5 AND #9 
11. #10 NOT (simulation) NOT (computational) NOT (study protocol) 





We screened retrieved literature and selected relevant articles based on the 
following criteria; 
Inclusion criteria: 
‒ Collective intelligence was described clearly in the methodology section 
of the document, including how it was organised, who participated and 
governance rules for groups.  
‒ Participants consciously acknowledged that they were involving in 
collective intelligence initiatives. 
‒ Collective intelligence was used to make decision, solve problems and 
create innovation or new strategies. 
Exclusion criteria 
‒ We excluded citations without abstract. Articles, which were not 
original research (i.e. editorial, commentary, perspective), were 
excluded. Conference papers, and protocols without results were 
excluded. 
‒ We excluded activities that involved crowdsourcing which only aimed 
to collect spatial data via mobile devices and where the activities 
involved sending information without judgement (e.g. uploading 
photos on social media). 
‒ Due to the wide contextual differences, we excluded research on using 
collective intelligence to improve business strategy of firms. 
‒ Literature reviews were excluded from this analysis, but we reviewed 
the reference list to identify eligible original studies. 
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‒ We excluded studies which used mathematical models to simulate 
different virtual scenarios of collective intelligence. 
Identification process 
One researcher (VN) screened the titles and abstracts of all retrieved citations 
and the full text of all relevant citations identified. A second reviewer checked 
10% of excluded citations to ensure the quality of the process. Overall, 300 
reports were double checked; disagreements were resolved after discussion 
(Cohen’s kappa coefficient = 0.97 [95% confidence interval (CI) 0.954–
0.986]). 
3.2.2.3. Data charting process  
We applied content analysis to inductively develop themes and categories for 
each domain. We classified the methods described in each article by answering 
the following questions: what the reasons for using collective intelligence were; 
who participated and what were their motivations; and what was the process 
of mobilising collective intelligence in terms of organization, communication, 
evaluation of participants’ contributions and decision making. We also relied 
on the framework from Massachusetts Institute of Technology’s Centre for 
Collective Intelligence and published work on crowdsourcing to ensure that 
our themes described essential domains to understand methods of collective 
intelligence (64, 82). First, two researchers (VN, IB) read a set of 20 articles to 
identify themes describing the methods used for each domain. The two 
researchers then met to reach consensus on the themes to be included in a data 
extraction form. Second, one researcher (VN) used this initial set of themes to 




checked the data collected and the themes to ensure that the themes covered 
the information needed. Then, two researchers (VN, LG) extracted data from 
a set of 33% of articles included, with consensus achieved in case of 
discrepancies (pooled Cohen’s kappa coefficient = 0.63 [95% CI 0.42–0.83]), 
and one researcher (VN) extracted data from all remaining articles included. 
Any new themes identified during data extraction were recorded and discussed 
with the senior researcher (IB), thereby refining and enriching the list of 
themes. 
Data items 
We extracted the following data from the titles, abstracts, methods, results and 
conclusions of retrieved reports: 
Publication characteristics: title, year of publication, author, type of article 
(reports of original research, methodological papers), field of study (computer 
science and technology, biomedicine and other fields including economics, 
finance and business; environmental science; education; media and 
communication; psychology and social science), and funding sources. 
Methods of CI: To understand the methods of collective intelligence, we 
extracted information for seven domains: (1) reasons for using collective 
intelligence, (2) type of participants and methods of recruitment, (3) 
motivation, (4) type of participants’ contribution, (5) type of interaction 
between participants, (6) methods to evaluate participants’ contribution and 
decision-making on what ideas or solutions to use, and (7) challenges of 
collective intelligence reported by authors and authors’ satisfaction with 
participants’ contributions. 
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3.2.2.4. Data analysis 
Data extracted from articles were coded by content analysis and inductively 
grouped to create categories. We used R v3.4.2 (the R Foundation Statistical 
Computing, Vienna, Austria) to compute frequencies and percentages for each 
method.  
3.2.3. Ethical consideration and data sharing 
The study used publicly available data. Thus, there is no risk of ethical violation 
and there is no restriction on data sharing. The data from this study are 






3.3.1. Study identification and general characteristics 
We retrieved 3,780 citations from the electronic search and excluded 3,395 
based on titles and abstracts. Two further articles were excluded as the full 
texts could not be found. After reviewing the reference lists of literature 
reviews retrieved from the search, we identified five more eligible articles. We 
assessed the full texts of 383 articles, and 145 articles from 145 projects were 
eligible for data extraction (Figure 3): 49 from biomedicine, 47 from computer 
science and technology, and 49 from other fields. Overall, 89 projects received 
funding from not-for-profit organizations (i.e., funding from academic 
institutions, non-governmental organizations, philanthropic and charity 
organizations, public funders) (83), 13 from for-profit organizations and 2 
from crowdfunding; 41 articles did not report funding sources.  
  






3569 citations identified 
374 citations included 
383 full texts evaluated 
145 articles included 
Hand search databases of public funders: 
PCORI, NIHR, Laboratory for Innovation 
Science at Harvard, Stanford MedicineX, 
UDHC, Robert Wood Johnson Foundation, 
Horizon 2020 
211 citations/projects identified after 
removing duplicate 
3195 excluded based on titles 
and abstracts 
• Conference abstract: 877 
• Not original article of research 
using collective intelligence: 
1259 
• Data collection of geo-
locations: 270 
• No abstract: 268 
•  Model to simulate different 
scenarios: 107 
• Literature review: 81 
• Not English: 59 
• Not relevant: 274  
 
5 articles selected from 
reference lists of 
literature reviews 
2 full texts not found 















238 articles excluded 
• 99 not describe the 
process of using 
collective intelligence 
• 139 used crowdsourcing 
to collect data and 
perform micro-task  




3.3.2. Reasons for using collective intelligence 
From 145 included articles, we identified and classified the following four main 
reasons for using collective intelligence: 
- Create intellectual outputs (n=65 projects, 45%): Participants 
contribute to the creation of health education materials, clinical trial 
protocols, prognostic models, software, articles, and policies.  
- Generate ideas (n=38, 26%): Participants contribute to new ideas for 
research and development. For example, Harvard Medical School 
launched idea challenges to generate new research questions on type I 
diabetes (84). 
- Conduct evaluations (n=10, 7%): Participants evaluate the quality of the 
ideas/work. Collective intelligence is mobilised to critically appraise 
research quality. 
- Solve problems (n=25, 17%): Participants solve a practical problem and 
propose solutions to difficulties given by organizers. For example, 
collective intelligence of experts from 26 different European countries 
is being mobilised for the clinical diagnosis of very rare genetic 
syndromes of multiple congenital anomalies (85). 
Six articles (4%) described mobilising collective intelligence for both 
generating ideas and conduct evaluations; one article (1%) aimed to create 
intellectual outputs and conduct evaluations. Table 8 provides examples for 
each reason for using collective intelligence in biomedicine. 
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Table 8 Examples of projects using collective intelligence by each reason 
Reasons for using collective 
intelligence 
Example 
Create intellectual outputs - DREAM challenge is an open science initiative. It leverages 
collective intelligence to use data from clinical trials to 
create predictive models (e.g., prognostic model of survival 
rate, prediction model of treatment response) (86, 87). 
- A project used crowdsourcing to mobilise 60 
physicians/researchers and 42 patients/advocates to 
develop a protocol for a cancer trial (88). This pilot project 
led to the creation of an online community of doctors and 
patients to develop protocols of clinical trials called 
Transparency life sciences (89). 
Generate ideas - Harvard Medical School launched idea challenges to 
leverage collective intelligence from the community to 
generate new research ideas on type I diabetes (84). 
- Researchers used a creative contributory contest to ask 
community members to contribute new ideas for an HIV 
testing campaign (90).  
Conduct evaluation - CrowdCARE is an initiative that mobilises the knowledge 
and skills of the crowd to critically evaluate the evidence 
from health practice to facilitate evidence synthesis (91). 
Solve problems - DYSCERNE used crowdsourcing to create a network of 




clinical diagnosis of very rare genetic syndromes of 
multiple congenital anomalies (85). 
- Foldit and Phylo are online games that allow users to 
manipulate the structures of proteins to solve problems of 
the order and structure of nucleotides in proteins to help 
cure diseases (92, 93).  
 
3.3.3. Type of participants and methods of recruitment 
Participants could be classified into three categories: (1) open public (n=110, 
76%) (everyone can contribute regardless of their background); (2) experts in 
the field (n=21, 14%); and (3) defined groups (n=14, 10%) (a specific 
population relevant to the research topic, such as students or patients). 
Participant demographic information (e.g., sex, education, economic status) 
was reported in only 16 articles (11%). The number of participants contributing 
to the projects was reported in 59 articles (41%). When reported, the median 
number of participants who contributed to the projects was 242 [Q1–Q3: 111–
535]. 
The methods used to recruit participants were reported in 50 articles and 
included creating a Website or mobile phone applications, combined with an 
open call in social media platforms (60%) (88, 94-96), using personal 
networks and offline communities (22%) (97-99), targeting online 
communities (PatientsLikeMe, www.reddit.com) (6%) (100-102), contracting 
with crowdsourcing intermediary platforms (i.e., online platforms connecting 
organizations wishing to leverage collective intelligence with a readily available 
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community) (InnoCentive, Kaggle) (6%) (84, 86, 103), and recruiting on 
crowdsourcing marketplaces (Amazon Mechanical Turk) (6%) (104, 105).  
3.3.4. Motivation 
In total, 108 articles (74%) reported the incentives or intrinsic factors used to 
motivate participants to take part in the projects. Financial incentives were the 
most common (n= 42, 39%) (94, 103, 106, 107), followed by recognition from 
the network (n= 8, 7%) (85, 108) and access to data (n= 2, 2%) (109, 110).  
Intrinsic motivation could sometimes have a role; for example, participation 
in a project could arise from individuals’ sense of belonging to a network (n= 
17, 16%) (90, 111), personal interest in the topic and gaining new knowledge 
(n= 17, 16%) (112, 113), fun (n= 12, 11%) (92, 114, 115), and altruism (n= 4, 4%) 
(98, 116). Six articles (6%) reported a combination of both incentives and 
intrinsic motivation.  
 
3.3.5. How participants contributed to the projects 
We identified four methods by which participants contributed to projects: 
independent contribution (collection) (i.e., participants work independently to 
complete small pieces of work) (n=50 projects, 34%) (88, 99, 101); competition 
(i.e., participants submit their work independently, only good solutions are 
selected and rewarded) (n= 33, 23%) (90, 94, 103); the use of a game to collect 
independent contributions from participants while creating fun and 
enjoyment (n= 16, 11%) (92, 114, 115); and collaboration (i.e., participants work 




(117, 118). One project (1%) combined competition with independent 
contribution (119). Participants joined the competition to generate ideas, then 
the community was involved in evaluating the ideas independently. Four 
projects (3%) combined competition with collaboration: the project first 
organized a competition, then held a workshop at which the leading teams 
collaborated to create better solutions (100, 120-122). Table 9 provides 
examples of each type of contribution in biomedical projects. 
Table 9 Main features of types of participants' contributions 




- Transparency life science is a platform 
that mobilises clinicians and patients in 
clinical trial protocol development. A 
clinical trial protocol is divided into 
several items (i.e., inclusion, exclusion 
criteria, intervention, sample size). 
Clinicians, patients and relatives 
independently review and contribute to 
improve the items. Their contribution 
is aggregated to create a complete 
protocol that is reviewed again by 
community members for final approval 
(88).  
- Work is divided into small 
pieces; participants can 
work independently. 
- There is a mechanism for 
aggregating contributions 
from all participants (e.g., 
averaging, voting) 
Competition - DREAM challenges 
(http://dreamchallenges.org/) are 
competitions in biomedical sciences 
that use open clinical trial data to 
- Gives a well-defined 
problem to solve 
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answer fundamental questions in 
biological science and human health. 
DREAM challenges last from 3 to 6 
months. Anyone interested can join 
DREAM challenges. Teams who have 
the best-performing models will receive 
a reward (107). 
- Researchers in Guangzhou, China 
organized a creative competition 
whereby participants contributed their 
ideas to develop a campaign to increase 
the HIV testing rate. Overall, 96 
submissions were received after 39 
days. A photo gallery was organized to 
celebrate the top five submissions. 
Winners were invited to join a panel of 
experts in the field of sexual health as 
recognition for their skills and 
knowledge (90). 
- Gives clear criteria for 
evaluation to recognize 
innovative ideas 
- Provides a strong 
communication plan for 
before, during and after 
the competition. Uses 
different channels to 
publicize the competition 
in advance and provide 
real-time updates. 
- Gives time to participants 
to understand the problem 
such as organizing an 
introduction workshop, 
providing a dataset, and 
tutorials for training. 
- Provides a forum for 
participants to exchange 
ideas and form their 
teams. 
- Rewards for winners. 
Play games - MalariaSpot (http://malariaspot.org/) 
is a Web-based game in which 
participants detect malaria parasites in 
digitized blood samples. By playing 
games, participants recognize which 
- Web-based, mobile-based 
applications accessible to a 
wide range of participants 





blood images contain parasites and the 
types of malaria parasites. The results 
from the games help researchers 
increase the accuracy of malaria 
diagnosis (115). 
- Phylo (http://phylo.cs.mcgill.ca/) and 
Foldit (http://fold.it/portal/) are Web-
based citizen science games allowing 
participants without a significant 
background in biology to contribute to 
the development of protein structures. 
The games are designed as small tasks 
with different level of difficulties. By 
playing the games, participants actually 
solve a problem in protein structures 
(92, 93). 
- Creates different levels of 
complexity 
- Real-time updates and 
leader boards are used to 
increase engagement from 
participants 
Collaboration - DocCHIRP is a crowdsourcing network 
of medical doctors that mobilises the 
collective intelligence of their members 
to search for solutions to their medical 
questions (123).     
- Work is not able to be 
divided into independent 
pieces. 
- Provides a platform for 
discussion, a way to 
record ideas from all 
participants (i.e., Wikis), 
and a moderator who 
supports the discussion. 
- Provides tools to navigate 
ideas contributed by 
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participants (i.e., text 
analysis) to identify 
patterns of ideas; 
automatic team matching  
3.3.6. Interactions between participants and organizers 
In 64 articles (44%), participants did not have any interaction with other 
participants or organisers (stand-alone). For 54 projects (37%), participants 
could receive feedback from other participants and for 20 (14%), from 
organisers. Other methods for interaction between participants and organisers 
included online focus group discussion (n=7, 5%). 
3.3.7. Evaluation of participants’ contribution and decision-making 
process 
Although 98 (68%) articles claimed that authors were satisfied with 
participants’ contributions, only 89 (61%) reported methods to evaluate the 
contribution and decision-making for selecting the best contributions. We 
identified two main categories: evaluation and decision by an independent 
panel (n=63, 43%) and evaluation and decision by end-users (target 
customers, community members) (n= 26, 18%). For example, Harvard 
Medical School launched an idea competition on diabetes and used a panel of 
142 faculty members to review the 150 submissions and select the best one 
(84). In Dell’s IdeaStorm, community members gave points to each idea (111); 




3.3.8. Challenges of mobilising collective intelligence 
Among 145 articles reviewed, only 13 mentioned the challenges encountered 
when using collective intelligence. Most of the challenges concerned two main 
issues: (1) implementation of collective intelligence projects and (2) 
sustainability (Table 10).  
Regarding challenges in implementation, two articles discussed difficulties in 
recruitment and participant retention (123, 124). Two articles described 
challenges in communicating with participants, including lack of a platform 
for exchanging ideas among participants, dominant voices in the discussion, 
unclear communication from organizers causing mistrust and a feeling of 
being exploited, and unclear idea expression from participants, which slowed 
the idea selection (111, 125). Two articles emphasised the importance of 
making the research questions understandable to participants and provided 
participants with adequate information to address the problems posed (94, 
126). One article discussed the issues of selecting inappropriate comparison 
standards when evaluating participant contributions (127).  
Seven articles highlighted the challenges in sustaining the integration of 
collective intelligence in traditional business models, including resources and 
changes in the organization’s culture when integrating new ideas from 
participants (111, 121); increased workload for organizers to prepare tasks for 
participants, screen and select the best solutions (123, 128); and the need for 
policies on data sharing and how participants could access data contributed by 
other participants (123, 129). 
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Table 10 Challenges during the process of collective intelligence and 
proposed solutions 
Challenges Proposed solutions 
Challenges in recruitment 
Attracting a large number of participants 
and keeping them motivated 
Combine extrinsic motivation (i.e., financial 
rewards, recognition) with intrinsic 
motivation. There are different ways to 
trigger intrinsic motivation [i.e., using 
games to make taking part in tasks 
enjoyable for participants (115), 
encouraging participants to develop their 
knowledge, providing tutorials and giving 
participants opportunities to practice and 
develop new skills (94)].  
Challenges in communication 
Feeling of disappointment when 
participant’s ideas are not implemented, 
feeling of being exploited 
Communicate clearly to participants the 
goals of organization, how the ideas will be 
used to contribute to the organization and 
community, and the implementation plan. 
Lack of platform for idea sharing Create an online platform for participants 
to share ideas. Combined with automatic 
text analysis to provide real-time feedback, 
create a classification to keep track of all 




Dominant voices in the discussion Provide options for being anonymous in the 
discussion and a moderator to manage the 
platform, resolve conflicts, flag dominant 
voices, and arrange categories of ideas 
without intervening in the discussion. 
Challenges in sustainability 
Difficulties in integrating ideas of 
participants in a business model 
Communicate clearly the goals of the 
organization, what the organization is 
looking for. 
Time and resources required for 
screening and selecting ideas of 
participants 
Assign a dedicated staff member to 
moderate and manage the classification of 
ideas, and thereby accelerate the evaluation 
process. 
Lack of policy for data sharing Predefine terms of participation and 
communicate with participants for 
agreement on data sharing. 
 
3.3.9. A framework to mobilise collective intelligence 
Figure 4 presents types of participants, how participants contributed to projects, 
interactions among participants, and the evaluation of participants’ 
contributions and decision making according to the different reasons for using 
collective intelligence. To generate evaluation and solve problems, 
independent contributions were used often, with mostly no interaction among 
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participants. In contrast, competition was often used to generate ideas, and 
participants were able to exchange ideas and receive feedback from each other. 
To create intellectual products, participants collaborated with each other and 
were able to receive feedback from other participants and organizers to 
improve their products. 
 
Figure 4 Differences in methods of mobilising collective intelligence by 
reasons for using collective intelligence 
Considering all the information recorded, in Figure 5 we propose a framework 
of the process of mobilising collective intelligence. The framework describes 






Figure 5 Framework of process of mobilising collective intelligence 
. 
3.4. Discussion 
This scoping review provides an in-depth description of methods mobilising 
collective intelligence with crowdsourcing and proposes a framework to 
implement these methods in research.  
In this review we defined collective intelligence with crowdsourcing as shared 
intelligence that emerges when people who are usually not involved in research 
are mobilised to work on a specific task. Some literature considers 
crowdsourcing used to collect data and perform simple tasks as a kind of 
collective intelligence (82, 130). However, in this study, we focused on research 
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harnessing collective intelligence whereby participants contribute their 
intellectual abilities.  
Collective intelligence relies on the principles of the wisdom of the crowd and 
“swarm” intelligence. The wisdom of the crowd theory states that decisions 
resulting from the aggregation of information from a large crowd of 
independent individuals are often better than those from any single member 
of the group (131). Wisdom of the crowd is particularly relevant to evaluation 
and decision making. Swarm intelligence emerges when the interaction of 
independent individuals produces better problem-solving abilities than a 
single individual (132, 133). Swarm intelligence is used to generate ideas, solve 
problems and create intellectual products. 
By applying principles of collective intelligence and by using an online 
interface to crowdsource to a large population, clinical research might be 
accelerated and enriched by innovation. Collective intelligence can be applied 
to support different stages of clinical research (e.g., identify research 
questions, design interventions, develop research protocols, analyse data and 
appraise research quality). Examples include a Harvard Medical School 
challenge to leverage the wisdom of crowd to identify pioneering ideas for type 
I diabetes research (84). Similarly, the New England Journal of Medicine 
launched the SPRINT data challenge to give data scientists across the world 
the opportunity to access to and analyse clinical trial data (134). Cochrane 
crowd and CrowdCARE are initiatives that use the power of the crowd to 
reduce the research burden and accelerate the process of evidence synthesis 




To our knowledge, this scoping review is the first study to systematically 
describe the methods of mobilising collective intelligence with crowdsourcing 
in published research across different fields. Our results show that some 
essential information is missing from reports of research involving collective 
intelligence. Half of the articles did not report the number of participants 
contributing to the project, and demographic information on participants was 
reported in just 10% of articles. This hinders verification of claims made about 
the diversity of participants and whether participants’ backgrounds and 
experience were appropriate to tackle the research problem. There are several 
potential risks of bias related to mobilising collective intelligence that we 
discuss in Table 11.  
Table 11 Potential risks of mobilising collective intelligence 
• Internal validity 
Because most of the projects are open to the public, participants might not have 
adequate skills and knowledge to contribute meaningfully to research. They 
might also have conflicts of interest that researchers cannot verify. This might 
have severe consequences if the contribution of unqualified participants 
influences decision making, especially when it leads to changes in healthcare 
practices. Some projects added an extra step to assess the ability of participants. 
For example, the SPRINT data challenge had a qualification round to ensure 
that participants had certain skills to tackle the research problem (134). This 
issue emphasizes the importance of an independent evaluation panel for 
objective assessment to adequately evaluate participants’ contribution. 
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• External validity 
Clear guidance is lacking on how many participants are needed to obtain 
relevant results. In our sample, the number of participants who actually 
contributed to the projects varied considerably, from 37 to 6200. This raised 
questions about the external validity of the contributions of participants, and 
whether ideas or solutions generated and voted for by participants would be 
applicable to the community. 
• Risks related to privacy and personal data 
There are certain risks for participants when joining collective intelligence 
projects. When registering to be a member on intermediary platforms, 
participants might have to disclose their knowledge, but the platforms can use 
this knowledge without proper acknowledgement (136). Similarly, ethical 
questions have been raised about online communities when data contributed 
voluntarily by patients has been sold for financial interests without informing 
patients (137). 
• Intellectual property 
Participants in projects funded by academic institutions were not required to 
transfer exclusive copyright to organizers, and their contributions could be 
publicly accessible (84), whereas in projects funded by for-profit organizations, 
participants were obligated to transfer the copyright to organizers in exchange 
for monetary rewards. The latter case might imply some ethical risks. 




submissions, but in some cases, claimed ownership of all of submissions, which 
might cause a sense of mistrust in participants (138). Hence, organizations 
should ensure the transparency of the terms of intellectual property. 
The literature on collective intelligence might entail risk of reporting bias. 
Overall, 68% (98/145) of articles stated positive outcomes from mobilising 
collective intelligence, but only 9% reported difficulties encountered. In all, 
28% (40/145) did not report sources of funding. Most retrieved publications 
were funded by not-for-profit organizations (61%), indicating that projects 
using methods of collective intelligence funded by for-profit-organizations 
might be underreported. Hence, funders and researchers must be encouraged 
to publish their research to contribute to the knowledge base and thereby assist 
methodological improvement. 
This scoping review has some limitations. First, I restricted the search to 
keywords in titles to reduce the number of irrelevant articles, so I might have 
missed some reports that contained keywords elsewhere in the text. However, 
the aim of the study was to provide a description of different methods of 
mobilising collective intelligence rather than exhaustively review all relevant 
articles or report multiple repetitions of the same methods. Second, I focused 
on published literature, and some projects involving collective intelligence may 
not result in a classical scientific publication. Third, because no validated tool 
for critical appraisal of collective intelligence was available, I did not assess the 
quality of research reports. 
3.5. Summary 
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In this scoping review, 145 research articles have been identified to describe 
the methods of mobilising collective intelligence. The review shows that 
research involving collective intelligence have been developed in a range of 
ways. However, the reporting of these research is suboptimal as some key 
features of the methods used were not always reported in the published 
articles. This highlights a need to develop a reporting guideline for research 
involving collective intelligence to enable quality assessment and ensure 
reproducibility of research.  
Furthermore, the rationale for the choice of mobilising collective intelligence, 
barriers to using these new methods and good practice advice for these projects 
were not documented in the published reports. This information is important 
to help us better understand why researchers decided to involve collective 
intelligence in their research, their experience with the new methods and what 
the best ways to mobilise collective intelligence. These important issues will be 





Chapter 4 Good practice advice for 
mobilising collective intelligence 
4.1. Background 
In the Chapter 3, I described a scoping review of 145 research projects using 
methods of collective intelligence to involve diverse stakeholders in research. 
From the scoping review, I proposed a framework to mobilise collective 
intelligence in research which classified four organisation methods to solicit 
participants’ contribution, types of participants and how to recruit them, and 
ways to evaluate participants’ contribution. The framework also highlighted 
some risk factors that might impede the quality of research involving collective 
intelligence. 
However, the publications on collective intelligence did not investigate the 
experience of researchers who used these new methods. In this Chapter, I 
present a qualitative study of researchers experienced with mobilising 
collective intelligence which aimed to identify the barriers to mobilising 
collective intelligence, ways to overcome these barriers and provide good 
practice advice for planning and conducting research mobilising collective 
intelligence across different disciplines. 
4.2. Method 
4.2.1. Reflexivity 
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It is noteworthy that researchers’ social position, personal experience and 
beliefs can influence their choice of research method, interaction with research 
participants and the  knowledge that ensues from research (139). Hence, being 
reflexive and transparent about researcher’s identity and beliefs is crucial 
when describing the way data are collected and interpreted.  
Before starting the PhD thesis, I was a pharmacist and working as a research 
coordinator managing the planning and conduct of clinical trials in a clinical 
trial unit in a low-middle income country. The work allowed me to interact 
with diverse stakeholders such as principle investigators, clinicians, nurses, 
patients and regulators. I highly valued the involvement of nurses and patients 
in the organisation of the trials to make trial procedures more convenient for 
patients and reduce unnecessary burdens. However, in that context, the 
involvement of nurses and patients happened at a fairly late stage when the 
trials had been approved and implemented. As a result, patients’ and nurses’ 
suggestions could only be adopted after a protocol amendment, which 
sometimes significantly delayed the benefits of better trial procedures reaching 
trial participants. Further, the rigid application of trial regulations from high 
income countries without taking into account the context of a low-middle 
income country also caused certain challenges for trial implementation. With 
this experience, I commenced the PhD work to look for new ways to involve 
diverse stakeholders in research planning, especially ones whose voices are 
less heard such as patients and practitioners.   




To answer a research question, researchers should consider which methods 
should be used to collect, analyse and interpret the data and how to justify the 
choice of these methods. Relevant here is the concept of research paradigm 
(140, 141). A research paradigm consists of three components: 
− Ontology: the nature of the phenomena, what is the knowledge to be 
known; 
− Epistemology: the relationship between the researcher and the 
knowledge, how researchers interpret the phenomena; 
− Methodology: the procedures of acquiring information to explain the 
phenomena.  
There are different research paradigms that researchers use to conduct their 
research such as positivism, critical realism, pragmatism, interpretivism as 
presented in Table 12). 
Table 12 Research paradigms adapted from Guba and Lincoln (1994) (142), 
Denscombe (2008) (143) and Kivunja and Kuyini (2017) (144) 
Research 
paradigm 




driven by natural 
laws 
The biases and 
values of the 







Theories shape our 
inquiry into reality 
to identify causal 
mechanism of 
social events and 
 Scientific inquiry is 
driven by theories 
of the observer 




















Reality is the 
practical effect of 
ideas (no 
commitment to any 






the freedom of 
choice to select 
procedures that 






Reality is created 
by individuals and 
groups 
All scientific 
inquiry is related to 
the values of the 
observer including 







Given the practical aim of the study to understand the process of mobilising 
collective intelligence and to provide practical knowledge to researchers who 
want to apply these new methods, pragmatism is a suitable research paradigm 
for the work presented in this chapter. Pragmatism focuses on the impact of 
knowledge obtained from research in a given context. In contrast to positivism 
or interpretivism, which require researchers to make a discrete choice between 
quantitative and qualitative approaches, pragmatism welcomes the use of both 




The experiences of researchers who have used methods of mobilising collective 
intelligence across research disciplines is an important source of knowledge 
which can help us to better understand these new methods. A qualitative 
approach in which research participants can freely express their personal 
experience and practice will allow me to explore barriers and facilitators to 
mobilising collective intelligence and identify important but unanticipated 
issues. Thus, to address my research question, I conducted a qualitative study 
of researchers with experience of collective intelligence methods across 
different research disciplines. In order to approach a larger number of 
researchers who had experience with collective intelligence and located in 
different countries, I decided to use a pragmatic approach by combining both 
semi-structured interviews and an online survey with open-ended questions. 
When analysing qualitative data, researchers can use a deductive approach to 
confirm their assumptions or an inductive approach to explore new concepts 
which have not been determined. In this study, my approach was partly 
deductive guided by the framework synthesised in the Chapter 3, but also 
inductive to explore new themes relevant to collective intelligence. 
4.2.3. Study design 
To explore researchers’ experience with collective intelligence, I conducted 1) 
a multinational online open-ended survey, which allowed me to access the 
perspectives of a diverse group of respondents involved in collective 
intelligence, and 2) semi-structured interviews, which allowed for more in-
depth exploration of respondents’ perspectives on this fairly new topic.  
4.2.3.1. Sample and recruitment 
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I recruited principal investigators and project coordinators experienced in 
running collective intelligence projects. I purposively sampled these 
researchers, seeking diversity in terms of their experience of different 
collective intelligence methods and their disciplinary backgrounds. I identified 
i) authors of articles reporting a project using collective intelligence (146); ii) 
researchers in the network of European citizen science association (42); and 
iii) invited speakers from collective intelligence conferences (147, 148). I also 
used snowball sampling, asking respondents to send us email addresses of 
colleagues active in the field of collective intelligence. 
An invitation email (Appendix 2) was sent via Mailjet (50) to researchers and 
project coordinators whose email addresses were available. The invitation 
contained a link to the first page of the survey, through which they indicated 
their consent (Appendix 3). Two reminder emails were sent to non-
respondents. 
I invited a purposive sample of 24 researchers to semi structured interviews 
via personalised emails. As researchers who responded to the survey were 
mainly from the field of computer science, for the semi-structured interviews, 
I purposively invited researchers who had used collective intelligence in 
biomedical research to increase the diversity of the sample and the relevance 
of their research context to our main aim of applying collective intelligence in 
clinical research. Additionally, I also contacted researchers who were 
recommended by survey respondents as experts in the field of collective 
intelligence to gain in-depth knowledge about these new methods.  




The survey was developed using the framework that resulted from the scoping 
review presented in Chapter 3 (146), after which it was piloted (Appendix 4). 
It comprised five closed-ended questions to identify respondents’ background 
and expertise, and four open-ended questions exploring their motivation, and 
their experience with mobilising collective intelligence, particularly the 
barriers they encountered and their solutions (Table 13). Finally, respondents 
were asked to provide three pieces of advice to a colleague planning to use 
collective intelligence in a project for the first time.  
To promote interaction between survey participants I also asked them to rate 
and comment on the advice that other respondents had entered. The advice 
shown to each respondent was randomly selected from the pool of advice 
provided by previous respondents.  
Table 13 Open-ended questions in the online survey 
• What are the benefits of collective intelligence that made you 
decide to use it in your project? 
• What were the most important factors contributing to the 
success of mobilising collective intelligence in your project? 
• What were the most challenging issues you had to face when 
using collective intelligence in your project and your solutions 
for those challenges (e.g. difficulties in identifying and 
motivating participants, designing tasks for participants, evaluate 
quality of participants’ contribution, decision making)? 
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• What three pieces of advice would you give to a colleague who 
intends to use collective intelligence in a project for the first time? 
Please read the advice from another participant (an answer from 
another participant is displayed) 
What do you think of this advice?  
 
4.2.3.3. Semi-structured interviews 
I sent individuals who expressed an interest in being interviewed an 
information sheet about the study. Interviews were conducted according to 
participants’ convenience (e.g. face-to-face, telephone, teleconference 
(gotomeeting.com) and oral informed consent was obtained before the 
interview started (Appendix 5:, Appendix 6:). 
I used a conversational approach with a semi-structured interview guide to 
allow interviewees to freely describe their experience and share their insights 
on important issues that I might not have had anticipated (149). The interview 
topic guide covered key questions in the survey questionnaire and was used to 
guide the conversation with interviewees and ensure the consistency in data 
collected (Appendix 7) (150).  Consistency does not mean that I asked 
questions in the same way to each interviewee but to ensure that the 
conversations with interviewees covered the general research topic. Prior to 
the interview, I read the publications of interviewees to tailor questions and 
prompts to their specific projects and the methods they had used to mobilise 
collective intelligence. During the interview, I tried to build rapport with 




depth information about the planning and conduct of interviewees’ research 
using collective intelligence. I also encouraged interviewees to discuss 
differences of opinion regarding the implementation of collective intelligence. 
For example, while one interviewee shared that it was expensive to organise a 
competition as a way to mobilise collective intelligence, another interviewee 
claimed that the use of competitions to mobilise collective intelligence was 
cost-effective. I also prompted each interviewee about the context of their 
research in order to understand factors that might lead to their differing 
opinions and experiences.  
All interviews were conducted in English. These were audio recorded, 
transcribed verbatim by a native English-speaking transcriber and I 
anonymised the transcripts. Interviews lasted between 22 minutes to 1 hour 
(median: 34 minutes). After each interview, I wrote a summary of the interview 
to record reflections on the interview and initial thoughts for the analysis. 
4.2.3.4. Analysis 
Our analytical approach was pragmatic to provide insights on the methods of 
mobilising collective intelligence, but broadly interpretive in treating 
respondents’ reports as subjective accounts of their experience when using 
these methods. Analysis of open-ended survey responses and interview 
transcripts was thematic, drawing on the framework analysis (151, 152). The 
analysis was partly deductive with some aspects being informed by the 
previous literature on collective intelligence, but also inductive to identify new 
themes and ensure that the analysis was grounded in the data. I led the 
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analysis. Two senior researchers BY and IB periodically reviewed transcripts 
and commented on the developing analysis. 
Open codes and categories were developed by constant comparative approach, 
reading and re-reading data and considering it in the context of other data 
from the same respondent and in the context of the wider dataset (153). An 
initial framework of themes and sub-themes was developed based on the first 
eight interview transcripts, and then imported into NVivo to code the 
remaining transcripts and survey entries. The framework was further refined 
throughout the process of analysis.  
Data saturation was examined by the theme accumulation curve which 
presented the number of distinct themes generated against a number of units 
of analysis used to generate those distinct themes (Appendix 8) (154). 
Respondents’ survey comments on the advice provided by other respondents 
were categorized as “agree” (i.e., positive comments), “disagree” (i.e., negative 
comments) and “neither agree nor disagree” (i.e., neutral comment or did not 
directly comment on the idea in the answer). I and another researcher (NN) 
independently assessed the content of each comment and discussed this to 
reach consensus. I received 129 pieces of advice. One hundred of these were 
commented upon by other respondents with 28 being commented on twice, 
resulting in 128 comments. Most comments (77%, 98/128) agreed with the 
advice provided by respondents and only 9% (12/128) disagreed. I summarize 
the advice which commentators disagreed with in (Appendix 9). 
The themes described in the results section below are derived from both 




surveys to explicate the findings and our interpretation of the data. 
Interviewees are indicated by ‘I’ and survey respondents by ‘S’; ‘[…]’ denotes 
text removed for brevity. Research disciplines of interviewees and survey 
respondents are listed in (Appendix 10).  
4.2.3.5. Securing study quality 
Lincoln and Guba proposed four criteria to assess the trustworthiness of 
qualitative research: credibility, transferability, dependability and 
confirmability (155). Credibility corresponds to the concept of validity in 
quantitative research which presents the confidence in the findings of the 
study. In this study, credibility was assured by examining the consistency of 
the data between the survey and the interviews, and across respondents from 
different research disciplines. I involved different researchers in the data 
analysis process to constantly review the development of the coding framework 
(156).  
Transferability corresponds to external validity in quantitative research which 
examines the extent to which qualitative findings can be applied to other 
contexts. To ensure transferability, I took into account the contextual 
information, survey and interview respondents’ background when analysing 
the data as well as presenting the findings (157). The survey also allowed 
participants to express their opinion on the advice provided by other 
participants, which helped me ascertain that certain advice was applicable in 
different contexts.  
Dependability corresponds to the concept of reliability in quantitative research 
and describes whether data are collected in a consistent, logical manner, and 
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research process is well-documented (158). Closely related to dependability, 
confirmability assess the accuracy of data interpretation and that the findings 
are grounded in the data (158). To ensure dependability and confirmability, 
senior researchers closely supervised the data collection process by reading the 
transcripts of the first five interviews for quality control. Senior researchers 
were also involved in data analysis process to ensure divergent interpretation 
of the data. We regularly discussed the data to identify new themes and refine 
the coding framework. The anonymised data of the survey is publicly available, 
and the anonymised transcripts of the interview will be provided upon request 
to ensure transparency of research process.  
4.2.3.6. Ethical consideration and data sharing 
The study received ethical approval (Ref: 17-386) from French National 
Institute of Health and Medical Research (INSERM) Ethic Committee 
(IRB00003888) (Appendix 11). 
The anonymised data from the online survey is available on Zenodo, an open 
access research data repository at https://doi.org/10.5281/zenodo.3462583. 
Anonymised transcripts of interviews are kept electronically in a secure file 
store in laboratory of the METHODS team of CRESS-UMR1153. The 





4.3.1. Respondent characteristics 
Of 157 people who clicked the survey link, 65 participated in the survey. Of the 
24 people who were purposively invited for interview as they used collective 
intelligence in biomedicine research and were recommended as experts in the 
topics, 17 participated. Of those who were not interviewed, two were unable to 
schedule an interview within the time frame of the study, two advised the 
interviewer to contact another team member responsible for the projects, two 
did not respond, and one was unable to be interviewed in English. Table 14 
presents demographic characteristics of survey respondents and interviewees. 
Survey participants were mainly from the field of computer science (43%), 
while interviewees were mainly involved in biomedicine and healthcare (59%). 
They mostly mobilised collective intelligence to solve research problems (70%) 
and generate new ideas (46%).  
Table 14 Respondent demographics 




N = 65 (%) a 
N = 17 (%) N = 82 
(%) 
20 – 29 4 (6) 0 (0) 4 (5) 
30 – 39 27 (42) 1 (6) 28 (34) 
40 – 49 19 (30) 11 (65) 30 (37) 
50 – 59 8 (12) 3 (18) 11 (13) 
≥ 60 4 (6) 2 (12) 6 (7) 
Location 
N = 65 (%) a 
N = 17 (%) N = 82 
(%) 
Europe 42 (65) 11 (65) 53 (65) 
North America 18 (28) 6 (35) 24 (29) 
Asia 2 (3) 0 (0) 2 (2) 
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Research field b N = 65 (%) a 
N = 17 (%) N = 82 
(%) 
Computer science 28 (43) 2 (12) 30 (37) 
Biomedicine and healthcare 9 (14) 10 (59) 19 (23) 
Engineering and technology development 9 (14) 0 (0) 9 (11) 
Economics, commercial, business 
development 7 (11) 
2 (12) 9 (11) 
Education and information studies 7 (11) 0 (0) 7 (9) 
Environmental science 5 (8) 2 (12) 7 (9) 
Psychology and social science 5 (8) 0 (0) 5 (6) 
Laws, politics, and governance 4 (6) 1 (6) 5 (6) 
Other 10 (15) 0 (0) 10 (12) 
Purpose of using collective intelligence in 
their projects b 
N = 65 (%) a N = 17 (%) N = 82 
(%) 
Solve problems (i.e., participants propose 
solutions to difficulties given by 
organizers) 
44 (68) 13 (76) 57 (70) 
Generate ideas (i.e., participants 
contribute to new ideas for research and 
development) 
32 (49) 6 (35) 38 (46) 
Evaluate ideas (i.e., participants evaluate 
the quality of the ideas/work) 
23 (35) 1 (6) 24 (29) 
Create intellectual outputs (i.e., 
participants create health education 
materials, clinical trial protocols, 
prognostic models) 
16 (25) 1 (6) 17 (21) 
Other 10 (15) 0 (0) 10 (12) 
a Two missing data 
b Respondents selected more than one option. 
4.3.2. Researchers’ motivations for mobilising collective intelligence  
Participants reported trying the methods of collective intelligence as a new way 
of doing research because traditional research methods no longer fitted their 
needs (Table 15). They commented that research questions were becoming 
very complex, unlikely to be solved within a single discipline, and traditional 
models of research, where each team worked in relative isolation impeded 




Respondents also noted the personal “pleasure” they derived from working “in 
teams with other people” (I10). Collective intelligence helped make research 
more enjoyable and helped them “to find some bridge, to… better understand 
each other, work closely together and this has some huge impact.” (I02) 




How collective intelligence can address 
the issue 
Research questions were 
becoming more complex 
and the answers could 
not be found from a 
single discipline. 
Collective intelligence provided the opportunity 
to work with people with different types of 
expertise and integrate their skills to solve 
problems from different angles. 
Knowledge is distributed in different domains 
and some 'wicked' questions cannot be 
answered within a single discipline or sector, 
i.e. we need both different science disciplines as 
well as expertise from the practice and policy 
sector. (S75) 
Current research was 
conducted inefficiently by 
“repeating efforts” (I06 ). 
Collective intelligence allowed researchers to do 
research as collective efforts where different 
approaches to a research question could be 
collectively and thoroughly evaluated to avoid 
redundant efforts. 
In science, often we are developing solutions 
independently and we are kind of repeating 
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erm… efforts, […] an alternative is to post a 
problem or a question to the research 
community and then just see what kind of 
solutions people come up with, and possibly 
combine these solutions and that you could call 
collective intelligence. (I06) 
As research questions 
became more complex, 
conducting research 
required longer time. 
Researchers would not 
have enough time to 
investigate different 
aspects. “It takes for 
hundreds of years… you 
will never [be able to] 
explore everything”. 
(I08) 
With a large community contributing, 
researchers were able to finish work within 
shorter timescales. 
Draw on the experiences and expertise of a 
varied group of people to advance and 
implement ideas that would take a significantly 
longer time to solve as an individual. (S104) 
It was more costly to 
work with experts in the 
field and took longer to 
engage them. 
Mobilising contribution from a wide community 
was cheaper than working with experts in the 
field yet could achieve the same outcomes.  
Our organization has done over 300 crowd-
based challenges and has found success in 80-
90% of those challenges with cost and schedule 




4.3.3. Barriers to mobilising collective intelligence  
While collective intelligence brought numerous benefits, respondents found 
aspects of collective intelligence challenging. These challenges in part arose 
from the novelty of the method and complexity in engaging the community 
(Figure 6). 
Figure 6 Barriers to mobilising collective intelligence 
 
Lack of evidence-based guidelines on methods of mobilising 
collective intelligence 
Use of collective intelligence through crowdsourcing in research is relatively 
new. Some respondents reported that they had delved into this method before 
they had become fully aware of the concepts of collective intelligence, 
crowdsourcing or citizen science. Respondents also recounted challenges they 
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had faced in their projects due to lack of evidence for an “optimal method” 
(I14) and noted the absence of a methodological guide for them to follow.   
Complexity in recruiting and engaging the community of 
participants 
Respondents believed that some potential collective intelligence participants 
had “a lot of prejudice” (I03) towards collaborating with people from different 
fields and it was “not easy to make them to participate” (I02) in collective 
intelligence projects. Interviewee I06 working in the field of biomedicine spoke 
of the difficulties he had experienced in motivating industrial partners to work 
with academic institutions in his challenge contests. He commented that 
collective intelligence participants had concerns about the ownership of the 
research, intellectual property of the solutions created, and about the negative 
reputational consequences if their solutions performed poorly. 
Respondents described difficulties in “retaining all the people that sign up…to 
get them to actually participate” (I09), as most participants joined collective 
intelligence as a side project or “an unfunded kind of project” (I12). They also 
believed that many potential collective intelligence participants were “not 
confident enough” (I07), which hindered their contribution.  
Respondents reported situations when participants had tried to cheat or 
behaved aggressively which adversely influenced the community and 
demotivated other participants. Interviewee I04 shared his experience with 
this disruptive behaviour, when organising challenge contests for data 
analytics: They will make different identities…and…submit hundreds 




from [participating]…but [they] don't have the solution. He explained that 
this disruptive behaviour partly arose from the competitive nature of a contest, 
adding that participants might be under pressure from their organisations to 
win international contests to enhance the reputation of their organisations.  
Difficulties in disseminating the solutions generated by collective 
intelligence  
Respondents found it challenging to disseminate and implement the findings 
of their collective intelligence projects to the relevant communities, as funders 
and beneficiaries were unfamiliar with this emerging method. These 
challenges arose partly from the “prejudice” of researchers (I03) that people 
who were outside of the field might not have sufficient capacity to create 
solutions. Interviewee I15 spoke of his difficulty in persuading funders to 
sponsor the further development of solutions generated by collective 
intelligence participants in a challenge contest that he had organised.  
The third challenge…was getting people to recognise that these solutions 
existed and were available…there is a reluctance to use crowdsource and 
open source solutions like this. (I15) 
4.3.4. Good practice advice for planning and conducting collective 
intelligence projects 
In describing their projects, respondents reflected on the solutions that they 
had considered or used to overcome these barriers. We also explicitly sought 
their advice on what they perceived to be good practice in planning and 
conducting collective intelligence projects. In the sections that follow, we 
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present respondents’ advice and good practice recommendations for collective 
intelligence projects covering three main themes: project governance, 
planning and conduct of collective intelligence projects (Figure 7).  
Figure 7 Good practice advice for planning and conducting research 





The project governance 
Establishing a coordination team 
Respondents advised researchers to establish a coordination team dedicated 
to supporting projects mobilising collective intelligence. They suggested that 
the coordination team should include people with diverse expertise to bring 
more “insights” (I01) to the project and help with “getting leadership and 
[funders] on board” (S23). Respondents also encouraged researchers to 
involve stakeholders and representatives from potential collective intelligence 
participant groups in planning, designing and conducting collective 
intelligence projects. Respondent S62 suggested that “Listen very carefully to 
your participants and work with them. Ensure mutual benefits in your design 
and co-create the project”. Respondents advised that the involvement of 
participants’ representatives from early stage would help identify mutual 
research interests between participants and researchers, design appropriate 
tasks and develop effective communication strategies to engage potential 
participants. Respondents also emphasized the importance of including people 
with experience in communication in the team to support recruitment and 
engagement activities with collective intelligence participants. 
Create a set of common rules 
Respondents suggested that the coordination team should create a set of 
common rules for collective intelligence participants to encourage mutual 
respect and constructive contributions. They mentioned the use of “diplomatic 
quality control” (I03) to flag up aggressive or disruptive behaviour from 
participants and to try to create a participatory and friendly environment for 
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others to freely contribute their work. They also suggested preparing a 
resolution plan to resolve conflicts between collective intelligence participants. 
Planning a collective intelligence project  
Identify the research question  
Respondents commented that an early step in research involving collective 
intelligence was to identify “an interesting problem” (I06) with “high scientific 
value” (I04) that would gain from the involvement of a large and diverse 
community.  
It is number one that there is a problem out there worth solving […], a project 
that it makes sense to try and bring in… people outside of the normal kind of 
scope or expertise area for it. (I15 – biomedicine and healthcare) 
They noted that identifying “just difficult enough” (I06) problems, and 
“putting yourself in the participants’ [positions]” (I08) was crucial to create 
appropriate research problems to gain buy-in from target communities. 
Interviewee I15 working in the field of biomedicine and healthcare described 
how a dynamic process involving “a lot of conversations” was part of the 
process of establishing whether the community would be interested in the 
research problem.  
“We knew there were a lot of people…working on it [the research topic] and 
no one had come up with an optimal solution and we felt like there were 
enough people who would be interested…, but that didn’t come from us just 
sitting in a room alone. We actually reached out to many of the people… to 




Identify communities of participants 
The choice of the communities was also considered by respondents as a key 
factor in ensuring successful mobilising of collective intelligence. Respondents 
suggested identifying communities who “have most contact with these 
problems” (I05).  They explained that “you need to have champions of the 
cause… if you are doing something on Alzheimer’s, finding a person … who 
has Alzheimer’s, who their mother, father has Alzheimer’s and who has a 
personal vested interest and a strong…passion for the cause” (I14).   
They emphasised two important characteristics of the community – diversity 
and independence. Diversity in participants was thought to be important in 
order to generate novel solutions to the research problem. Diversity could be 
achieved by involving a larger number of participants with various disciplines. 
“The more participants you have, the more likely some of them will come with 
the new idea.” (I04). Similarly, maintaining the independence of participants 
as they worked on the research problem was crucial to “free the minds and let 
[participants] think freely” (S104), allow “outside of the box thinking” (S146) 
and ensure that participants could voice ideas without being influenced by a 
dominant opinion. 
Decide incentives to engage participants 
Respondents suggested offering a combination of both extrinsic motivators 
such as authorship and access to the data, and intrinsic motivators such as 
making tasks enjoyable, offering participants the opportunity to gain new 
knowledge, and find meaningful outlets for their skills. They described some 
innovative activities to engage participants.  
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“Some of the things that we have done have been really fun, and really 
brought the community together…to create…a sense of community…like the 
24-hour citation screening challenges.  Where we have had hundreds of 
people, online at the same time, all with a specific target to try and reach 
within 24 hours… and those have been hugely exciting, really popular.” (I17) 
Interestingly, some respondents tried to “avoid monetary prizes” (I14) as they 
believed that “the crowd may only be interested in the compensation and 
therefore, may take short-cuts or cheat if the task allows for that” (S153). 
Instead, they suggested offering research partnership, mentorship or training 
as ways to benefit participants’ professional development. 
Determine methods to evaluate solutions created by collective intelligence 
and decision making 
Respondents emphasized the need to “set up objective methods to validate the 
results” (S65), for example, by establishing a panel with diverse expertise to 
comprehensively evaluate contribution of participants. They also 
acknowledged the need to allow enough time for evaluation, given the large 
number of participants, and advised involving the crowd in the evaluation to 
increase the efficiency of the process. Automating screening of participants’ 
contributions was also suggested to reduce workload for the panel when doing 
evaluation. 
Conducting collective intelligence projects 




 Respondents highlighted the need to design a user-friendly interface to “make 
it really easy for people to contribute even if they have only got a minute free” 
(I17). They explained that “the design of the interfaces or platforms which 
people will use is often overlooked but can influence the results or the ease of 
data collection” (S25).  
They also advised researchers to prepare training materials and offer tutorials 
to explain the project to participants and equip them with essential skills. 
However, they noted that the training should avoid providing participants with 
examples which could hinder participants’ creativity.  
Respondents also recommended “verifying if it [the task and interface] works 
on small scale” (S16) and gradually scaling up. The pilot phase could help 
researchers to foresee any technical and ethical issues related to data collection 
and participants’ identities, which could be addressed before a large number 
of collective intelligence participants enrolled. 
Create a clear description of the research problem 
“Crafting” (I14) a clear description of the problem in a language relevant to 
those communities was considered as a key step to help collective intelligence 
participants understand the project objectives and judge whether they had the 
relevant skills to participate.  
“Good communication of a complex objective or complex data set…is not… 
always easy...if there is something that you don’t even understand, …you 
won’t put your time in that challenge.” (I10) 
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Respondent S20 also suggested dividing the objectives into concrete 
deliverables with clear requirements for participants’ contributions. “In order 
for the collective to provide “intelligence” as opposed to noise, one must be 
very careful about what one measures… If the measures are ambiguous to 
the participants, or if there exists a short-cut for the participants to satisfy 
immediate goal without actually contributing to the overall big picture, many 
participants will find this short-cut and will explore it”.  
Organize communication activities to recruit participants 
Respondents described how they had organized various communication 
activities to recruit participants via advertisements on social media (e.g., 
Google, Facebook, websites), and announcements in scientific publications.  
Several saw working with an intermediary online platform which had a readily 
available online community as a practical approach for those who were new to 
collective intelligence. They advised researchers to partner with local 
organisations such as non-governmental organisations, universities and 
patient organisations and organise face-to-face meetings to connect directly 
with participants. 
 Engage participants through responsive communication 
To engage participants effectively, respondents believed that communicating 
frequently with collective intelligence participants, even having someone 
available “24/7” to guide them and give feedback on their contributions. 
Respondents believed this would improve the quality of participants’ 
contributions and increase their commitment. Further, through responsive 




resources participants needed to develop an implementable solution. Although 
virtual communication helped in ensuring responsive communication, 
respondents advised supplementing this with face-to-face engagement events 
to increase trust and create a sense of community among collective intelligence 
participants. 
Disseminate solutions created by collective intelligence to beneficiaries and 
collective intelligence participants 
Respondents advised researchers to diversify the dissemination of their project 
findings through multiple channels, and make the results open access to public 
through social media. 
Respondents suggested involving leaders of organizations from the beginning 
of the projects to ensure their support for implementation of solutions 
generated by collective intelligence. They encouraged other researchers using 
collective intelligence to “show their results” (I02), “evaluate” (I13), and “be 
transparent about mistakes” (I17) and saw rigorous evaluation of collective 
intelligence as necessary to provide evidence of its usefulness to stakeholders, 
“so that it gets recognised and funded properly” (I13). 
4.4. Discussion 
My study has shown that researchers were interested in looking for efficient 
methods of conducting research, leading them to try collective intelligence. 
Researchers believed that by involving large numbers of participants with 
various disciplines, they could find more innovative solutions to research 
problems in shorter time with fewer costs compared with conventional 
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methods. They indicated that participants’ contributions could be solicited to 
solve problems, generate new research ideas, evaluate ideas and create 
intellectual outputs. Researchers embarking on collective intelligence projects 
for the first time learnt through the process and gradually improved their 
methods. In the scoping review presented in Chapter 3, only 12/145 articles 
described challenges in mobilising collective intelligence mainly in recruiting 
and retaining participants, whereas researchers in this qualitative study often 
emphasized challenges, and noted previously undescribed challenges such as 
the disruptive behaviours of collective intelligence participants. They also 
highlighted the needs to develop evidence-based guidelines to standardise 
methods of mobilising collective intelligence. Drawing on the experiences of 
researchers across different fields and with experience of different collective 
intelligence methods, I have provided solutions and good practice advice to 
support researchers in the planning and implementation of their collective 
intelligence projects. This advice will help researchers to prepare structures 
and processes for their projects, plan essential steps in their research, and 
foresee and develop strategies to overcome the barriers.  
Despite increasing recognition of value of collective intelligence in research 
(159, 160), there are still examples of inappropriate methods being used to 
mobilise collective intelligence (161). For example, a project involving 
crowdsourcing in Rwanda failed to recruit and engage participants because 
researchers mainly used social media for recruitment and requested 
participants to use a complicated tool to collect data (162). However, at the 
time the project took place, community members in Rwanda were not 




These issues could have been mitigated if representatives of the target 
communities had been involved from the outset as members of the project 
coordination team to advise on the conception and design of the collective 
intelligence project. A NASA competition to name a new node of the 
International Space Station was misled when an influential person called on 
the community to vote for his own name (163). These examples emphasised 
the necessity of sharing experiences of researchers who have implemented 
collective intelligence projects to help future collective intelligence projects 
avoid methodological mistakes and outputs that are biased by group thinking 
or lack of diversity in the project team.  
Several efforts to define and standardise methods of collective intelligence in 
specific fields are available. These include a practical guide on using challenge 
contests to crowdsource ideas and solutions for health research from the 
World Health Organization,  and a list of toolkits compiled by the European 
Association of Citizen Science for researchers carrying out citizen science 
activities whereby members of the public collect and classify data via 
independent contribution (164, 165). In this qualitative study, I explored the 
experience of researchers who used one or more of these four methods in 
diverse disciplines, rather than focusing on one specific method to identify the 
barriers that researchers might encounter in different contexts. Good practice 
advice from researchers across disciplines could benefit researchers in 
planning and conducting future collective intelligence projects using one of 
these four methods within and outside health research.   
In the scoping review in Chapter 3, I mapped different methods used in 
mobilising collective intelligence. In this Chapter, I used a qualitative study to 
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explore researchers’ motivations for using collective intelligence, their choice 
of methods and what considerations guided their planning and conduct of 
research involving collective intelligence. By using an online survey and semi-
structured interviews with a purposive sample of international researchers 
who had experience of implementing a range of different collective intelligence 
methods, I gained a breadth of perspectives. Respondents to the survey and 
interviews came from diverse disciplines with some of them identifying 
themselves as multi-disciplinary researchers. The survey allowed a degree of 
interaction between researchers, which aided the analysis and interpretation 
of the results. By identifying areas that researchers agreed on, this helped us 
to ascertain what barriers and strategies were applicable across different 
disciplines. Additionally, the semi-structured interviews allowed researchers 
to explain about the context of their research and describe in-depth their ideas 
and methods for addressing problems in mobilising collective intelligence. 
My study has some limitations. The online survey allowed participants to freely 
express their opinions, but I was unable to probe to clarify the information 
written and gain deeper understanding of their context. Furthermore, my 
survey and interview samples were mainly researchers who had published 
their collective intelligence projects. Therefore, I am uncertain about how far 
the findings are relevant to unpublished collective intelligence projects. 
Additionally, although I interviewed and surveyed researchers who had 
experience of running collective intelligence projects, I did not interview 
collective intelligence participants.  Such data could provide further valuable 





In this qualitative study, 82 respondents participated in an online survey or 
semi-structured interviews about their experience with running collective 
intelligence projects. They suggested that mobilising collective intelligence 
could help to involve diverse stakeholders to answer complex questions which 
requires multidisciplinary efforts. Mobilising collective intelligence could also 
save time and cost when conducting research. They also shared several barriers 
to mobilising collective intelligence which mainly arose from the novelty of the 
methods. The good practice advice that we derived from respondents’ accounts 
aims to support researchers to overcome these barriers when planning and 
conducting research involving collective intelligence effectively. 
In the next chapter, I will present a proof of concept study which used these 
lessons from researchers experienced with collective intelligence and the 
framework developed in the Chapter 3 to mobilise collective intelligence in 









Chapter 5 Mobilising collective 
intelligence in clinical trial planning 
5.1. Background 
There are several factors that can influence patients’ decision to take part and 
remain in a trial. A survey of 12, 427 individuals who had participated in a 
clinical trial across 68 countries showed that patients’ decision depended on 
not only potential benefits, risks of trials, and type of interventions, but also 
practical logistics and organisation of trials such as location of research centre, 
length of their participation and whether they would be informed of results at 
the end of trials (166). The informed consent process plays a key role in 
ensuring patients have a good understanding of the trial and can make an 
informed choice. Patients also expressed the importance of the way inform 
consent was managed by choosing an appropriate time, giving patients time 
to reflect and discuss with their relatives. (167, 168). Additionally, poorly 
organised follow-up visits also discouraged patients to remain in the trials. 
Nearly 50% of trial participants surveyed said that trial participation 
disrupted their daily life. Patients also expressed their disappointment due to 
inadequate feedback of trial results. Ninety percent of patients indicated that 
they wanted to receive summary of study results. However, only 50% of them 
received such a summary (166). Patients’ contribution to research conception, 
design, conduct and dissemination could help to improve these aspects of trial 
organisation and conduct to improve patients’ experience with trial 
participation  (169-172). Funding agencies have acknowledged the benefits of 
patient involvement in research and increasingly encourage researchers to co-
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produce research with patients (173). The question about patient involvement 
in research has changed from “why to involve patients in research” to “how to 
involve patients in research” (41). Several funding agencies have provided 
methodological guidance for patient involvement in different stages of 
research (172). Further, new ways of involving patients in the conception of 
clinical research based on the methods of mobilising collective intelligence 
have emerged. For example, an initiative collected inputs of 42 patients 
together with 60 doctors/ researchers to develop a trial protocol. The inputs 
from patients and doctors led to important modifications of eligibility, dose, 
and trial endpoints   (174).  
In this Chapter, I present a proof-of-concept study to leverage patients’ 
collective intelligence to improve the organisation of clinical trials, with the 
ultimate aim of enhancing patients’ experience of trial participation.  There 
are a range of domains that can influence patients’ experience with trial 
participation such as experience with intervention, experience with trial 
personnel (175). In this study, I focused on patients’ experience with trial 
procedures, informed consent, follow-up visits and receiving trial results in 
particular, as the contribution from patients to improve these procedures 
could potentially be used in a wide range of trials without limitation on type 
of interventions or study personnel.  
5.2. Method 




To develop this proof-of-concept study, I followed the framework developed in 
Chapter 2 (Figure 8) and the good practice advice synthesised from 
researchers’ accounts of their experience as reported in Chapter 3. This 
indicated that the people who are central to clinical trials - patients - should be 
asked for their preferences and opinions to improve the organisation of clinical 
trials. I anticipated that independent contribution (i.e. collecting participants’ 
contributions individually and independently) would be the most suitable way 
to solicit patients’ ideas, because this allows patients to contribute their ideas 
freely without feeling pressure from other stakeholders such as researchers or 
clinicians. A steering committee involving methodologists, clinical trialists and 
patient representatives was established to support the implementation of the 
study. Methodologists and clinical trialists were from Methods in Research on 
Research (MiRoR) training network. They have extensive experience in 
planning and conducting clinical trials. One patient representative in France 
and one in the UK also participated to support the development of the project. 
They had experience in research planning and reviewing research proposals. 
In order to solicit patients’ ideas to improve the organisation of clinical trials, 
I used an online vignette-based survey. Vignettes have  traditionally been used 
in a number of areas, including in medical training to evaluate clinical practice, 
and have been increasingly used in research to address topics such as 
identifying the best trial designs for methodological questions (176-179). In 
this study, vignettes were case scenarios of real clinical trials that had assessed 
pharmacological treatments. These vignettes explained to patients what a 
clinical trial is and what patients are expected to do when participating in the 
clinical trial. Then participants were asked a set of directed questions to elicit 
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their preferences for different ways of organising trials. An online survey 
format allowed me access to a diverse group of patients who could contribute 
their opinions independently. Although patients were not able to interact with 
each other which might lead to important insights, this approach enhanced the 
independence of patients without influence from other participants to avoid 
group thinking.  
 
Figure 8 Planning of the proof of concept study according to framework of 
mobilising CI 
5.2.2. Participants  
Patients were recruited from an online community of patients, ComPare. 
ComPare is an e-cohort of nearly 36,000 patients with chronic diseases in 
France who contribute their information about their diseases, quality of life 
and treatment adherence. The e-cohort is coordinated by Dr. Tran Viet Thi and 
Professor Philippe Ravaud at the hospital Hotel Dieu, Paris, France. 
Participants in ComPare have contributed to research on burden of treatment 
and proposed new ideas to improve medical care (180). Dr. Tran Viet Thi and 
a team of administrators are responsible for the communication with patients 
in ComPare. When researchers want to conduct a research project with 
ComPare, they must submit a study protocol to the scientific committee of 




researcher to disseminate study materials to patients. Patients can also send 
their questions about the research project to the administrating team.  
5.2.3. Vignette-based survey development 
The vignette-based survey was developed in three steps: i) I performed a 
systematic search for protocols of real clinical trials testing pharmacologic 
treatment; ii) with the support from the steering committee, I developed 
vignettes based on these trials that summarised the main tasks that patients 
would be asked to complete when participating in the trials; iii) I worked 
together with an informatician from ComPare to create the questionnaire to 
deliver the vignettes. In the vignettes, I highlighted to patients that these were 
hypothetical trials and they were not being asked to take part in a trial.  
Clinical trial protocol search 
To develop case vignettes, I systematically searched for protocols of clinical 
trials which meet the following criteria: i) phase 3 randomised controlled 
trials; ii) on-going trials or recently completed (2017 onward); iii) evaluating 
pharmacological treatments; iv) targeting chronic diseases with high number 
of available patients in ComPare such as osteoporosis, osteoarthritis, asthma 
and cardiovascular diseases, diabetes and endometriosis; v) different routes of 
drug administration with the possibility of self-administered i.e. oral, 
subcutaneous injection, inhalation. I conducted the search on clinical trial 
registry www.clinicaltrials.gov. For asthma, diabetes and endometriosis, there 
was no suitable protocol available on www.clinicaltrials.gov; hence, I  
conducted a search on PubMed for recently published randomised controlled 
trials in New England Journal of Medicine (2016 onward) (Table 16). 
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Table 16. Protocol search strategy 
Search strategy on clinicaltrials.gov Search date 
Osteoporosis, phase 3, study protocol 26 August 2019 
Asthma, phase 3, study protocol  26 August 2019 
Osteoarthritis, phase 3, study protocol  27 August 2019 
Cardiovascular disease, phase 3, study 
protocol 
27 August 2019 
Search on PubMed  
((asthma AND NEJM AND randomised 
controlled trial)) AND ("2018/01/01"[Date 
- Publication]: "3000"[Date - Publication]) 
13 November 2019 
((diabetes AND NEJM AND randomised 
controlled trial)) AND ("2016/01/01"[Date 
- Publication]: "3000"[Date - Publication]) 
27 February 2020 
((endometriosis AND NEJM AND 
randomised controlled trial)) AND 
("2016/01/01"[Date - Publication]: 
"3000"[Date - Publication]) 
27 February 2020 
 
Selection criteria for the trials were: 
- Parallel design 
- Follow-up duration is at least one year 





- Clinical trials are exclusively on patients less than 18 years old 
- Clinical trials testing treatments for secondary conditions (e.g. 
osteoporosis induced by using glucocorticoids) 
- Trials conducted exclusively in Asia, Africa and Latin America 
- Trials testing medical devices 
- Trials recruiting exclusively from a specific population (e.g. Black, 
Hispanic, Asian population in the United States) 
Six protocols targeting common diseases in ComPare were chosen for vignette 
development (Table 17). 
Table 17. Protocols selected for vignettes development 
Trial title Route of administration 
of treatment 
Study to Determine the Efficacy and Safety of 
Romosozumab in the Treatment of 
Postmenopausal Women With Osteoporosis 
Subcutaneous injection 
Study of the Analgesic Efficacy and Safety of 
Subcutaneous Tanezumab in Subjects With 
Osteoarthritis of the Hip or Knee. 
Subcutaneous injection 
RCT of the efficacy and safety of an ICS/ LABA 
reliever therapy regimen in asthma 
Inhalation 
REVEAL: Randomized EValuation of the Effects 
of Anacetrapib Through Lipid-modification 
Oral 
Empagliflozin and progression of kidney disease 
in type 2 diabetes 
Oral 
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Treatment of endometriosis-associated pain 




Each vignette was structured in two parts. The first part described the clinical 
trial, patient population recruited in the trial, and description of the new 
treatment. The second part described the procedure of the trial including three 
main steps: i) informed consent; ii) follow-up visits; iii) receiving results when 
trial completes. In each step, participants were able to indicate their 
preferences regarding how the clinical trial should be organised. We proposed 
three different ways to organise each step of the trial: 
a) following the traditional organisation of trials with all procedures of 
informed consent, follow-up visits at research centres as described in the 
original protocols.  
b) following a new organisation of trials where patients could participate 
in the trial from their home. They could sign informed consent 
electronically, answer follow-up questionnaires online, have video calls 
with study doctors, and do examination tests at a laboratory nearby. 
c) combining both models with some on-site visits at research centres and 
some home-based visits. Patients can decide which visits take place at the 
research centre or at home. 




For each choice, we described what patients would be asked to do, how much 
travel would be involved, and how they would be able to communicate with 
trial investigators. 
Previous literature on collective intelligence discussed the limitation of 
providing examples of solutions when soliciting participants’ ideas, as it might 
decrease the diversity of their ideas (164). We nevertheless decided to allow 
patients to make choices, instead of asking open-ended questions. Each 
clinical trial is a specific context and patients might not have participated in 
several clinical trials or be in a position to put forward their ideas about 
different ways of organising clinical trials. An open-ended question to ask 
patients to suggest solutions might be too challenging for patients. 
Additionally, by providing examples, we aimed to facilitate patients to propose 
feasible ideas which trialists would be able to implement in clinical trials. 
Further, as there is no clear evidence of which way of organising clinical trial 
is best to reduce research burden, we believed there is no risk of influencing 
patients’ opinions by providing examples. 
Each participant completed one vignette (Appendix 13-19). After the 
participant indicated their preference for how the clinical trial should be 
organised, participants were asked about the likelihood that they would 
participate in a trial which was organised at the hospital, at their home or 
combination of both.  
The survey was first developed in English, then translated in French and sent 
to patients’ personal accounts on ComPare. 
5.2.4. Motivation to engage participants 
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Although from the scoping review, financial incentives were often used in 
research projects mobilising collective intelligence, we decided to not provide 
monetary incentives to participants for several reasons. First, we did not 
collect any identifying data or IP addresses of participants, and so there might 
be a risk that individual participants would complete the survey several times, 
which would have biased the results.  
Second, the literature has shown that patients are motivated to participate in 
research for  altruistic reasons, their interest in the topic of their illness, their 
wish to bring patients’ perspectives to research, and their interest in 
contributing to scientific knowledge (63, 181). In the invitation letter, we 
therefore emphasised the value of patients’ contributions to the project, how it 
will help research and other patients in the future. When designing the task 
and the interface, we also tried to make sure that completing the task was not 
time consuming and onerous for patients. 
Further, it is also important to engage participants and keep them updated 
about the progress of the project. Participants could therefore contact the team 
via a contact form on their personal account with ComPare.  
5.2.4. Data analysis 
Demographic information and quantitative analysis 
In the end of the survey, participants answered several demographic questions 
which we anticipated might influence their decision making, such as area of 





Quantitative data on patients’ preferences regarding the traditional or new 
models of trial organisation were aggregated to calculate proportion of each 
model. Chi-squared tests, or Fisher’s exact tests when appropriate, were 
utilised to test the independence of categorical variables.  
Qualitative data analysis 
Analysis of participants’ answers to open ended questions about their ideas for 
how clinical trials should organised were informed by thematic analysis. Data 
were imported into NVivo to facilitate the coding process. One researcher (VN) 
performed open coding and proposed initial themes. Senior researcher (IB) 
reviewed the analysis process and discussed to refine the themes identified.   
5.2.5. Ethical considerations and data security 
Ethical approval 
ComPare received approval from the CCTIRS (Advisory Committee on 
Information Processing in Health Research) No 16.395 date 07/07/2016 and 
was authorised by CNIL (Commission Nationale de l'Informatique et des 
Libertés: French independent administrative control authority for the 
protection of personal data) No 916397 date 25/11/2016.  
The protocol of this research received ethical approval from Inserm’s 
Institutional Review Board (Comité d’Évaluation Éthique, IRB 00003888) 
reference 19-580 (Appendix 12) and was approved by the scientific committee 
of ComPare.  
Informed consent 
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Patients in ComPare gave their consent to participate in research proposed by 
the platform. The administrator team first sent an email to eligible patients to 
ask if they wished to participate in this research project. We then sent the 
vignette-based survey to patients who indicated their agreement.  
Confidentiality and data management 
The database was managed by an IT engineer in the ComPare team. The 
databased was stored in a secure placed in INSERM METHODS team of Centre 
de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS-
UMR1153).  
Patients’ personal data were collected according to the research protocol of 
ComPare. In this project, we only accessed de-identified data of patients with 
the permission from the scientific committee of ComPare.  
Data sharing 
After the results of this study are published in a peer-reviewed journal, the de-
identified data of this study will be available on request to academic 
researchers who have to submit a protocol to the scientific committee of 
ComPare and sign a data use agreement. 
5.3. Results 
5.3.1. Study population 
We sent invitation emails to 2315 patients in the Compare e-cohort explaining 
the objectives and potential impact of this study. 834 patients responded 
positively to our invitations. We then sent to this group the survey containing 




answered the vignette-based survey (Table 18). Respondents mainly lived in 
France (621/628, 99%) ranging from 21 to 84 years old (median: 55, IQR: 44 
– 64). 68% of respondents lived in an urban area. Nearly 60% of respondents 
could reach a university hospital within one hour of driving from their place of 
residence.  
























































Unemployed 51 (8%) 18 
(14%) 
2 (2%) 7 (12%) 4 (5%) 10 (8%) 10 (7%) 

























4 (7%) 10 (13%) 28 
(22%) 
31 (20%) 
Other 12 (2%) 5 (4%) 1 (1%) 0 (0%) 0 (0%) 2 (2%) 4 (3%) 





































35 (59%) 28 (37%) 62 
(50%) 
70 (46%) 
Other diplomas 4 
(0.6%) 
1 (1%) 2 (2%) 0 (0%) 0 (0%) 0 (0%) 1 (1%) 
Living area 






20 (34%) 20 (26%) 40 
(32%) 
43 (28%) 
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39 (66%) 56 (74%) 85 
(68%) 
109 (72%) 
Distance to the university hospital 








35 (59%) 45 (59%) 80 
(64%) 
75 (49%) 








20 (34%) 26 (34%) 37 
(30%) 
68 (45%) 
From two to 
five hours 
37 (6%) 8 (6%) 3 (3%) 4 (7%) 5 (7%) 8 (6%) 9 (6%) 







4 (7%) 14 (18%) 19 
(15%) 
27 (18%) 
* One missing data 
 
5.3.2. Patients’ preferences regarding the way a trial is organised 
Patients expressed their preference regarding the new trial model in which 
they could participate in a trial from their home (Table 19). For the informed 
consent process, 311 (50%) respondents indicated that they preferred to be 
given information about the trials and sign the consent form at home via the 
internet.  239 (38%) respondents preferred having information about the trial 
explained at the hospital and signing the consent form at home. Regarding 
follow-up visits, 251 (40%) wished to have all follow-up visits at home and 254 
(41%) patients preferred the combination of both on-site visits at research 
centres and home-based visits with the possibility to arrange the visit 
according to their choices. Only 122 (19%) chose to have all follow-up visits at 
the hospital. 
In contrast, most of respondents (44%) wished to have an in-person meeting 
with research investigators when receiving the results of the trials; 192 (36%) 
respondents chose to receive a summary of results by email (31%) or by post 





Preferences for the way a trial was organised also varied by patients’ 
conditions. For the informed consent process, although most patient groups 
preferred to sign informed consent at home, patients with endometriosis 
preferred to be explained about the trial at the hospital and sign the informed 
consent at home (56%). Patients with asthma, diabetes and 
hypercholesterolemia preferred to have home-based follow up visits. Patients 
with hypercholesterolemia were the only group for which most patients choose 
to receive trial results by mail (43%), the other groups wished to meet a 
research investigator in person. 




















At home 311 (50%) 73 (55%) 39 (47%) 19 (32%) 47 (62%) 58 (46%) 75 (49%) 
At hospital and 
home 
239 (38%) 32 (32%) 40 (48%) 33 (56%) 22 (29%) 40 (32%) 62 (41%) 
At hospital 78 (12%) 18 (14%) 4 (5%) 7 (12%) 7 (9%) 27 (22%) 15 (10%) 
Follow up visits * 
By choices 254 (41%)  51 (38%) 29 (35%)  28 (48%)  23 (30%)  61 (49%)  62 (41%)  
At home 251 (40%) 58 (44%)  42 (51%) 19 (32%) 41 (54%) 30 (24%) 61 (40%) 
At hospital 122 (19%) 23 (17%) 12 (15%) 12 (20%) 12 (16%) 34 (27%) 29 (19%) 
Receive results 
Meeting a 
doctor at the 
hospital 
275 (44%) 58 (44%) 39 (47%) 32 (54%) 24 (32%) 62 (50%) 60 (40%) 
Video call with 
a doctor 
126 (20%) 30 (23%) 19 (23%) 16 (27%) 16 (21%) 19 (15%) 26 (17%) 
By mail 192 (31%) 38 (29%) 25 (30%) 9 (15%) 33 (43%) 38 (30%) 49 (32%) 
By post 34 (5%) 7 (5%) 0 (0%) 2 (3%) 3 (4%) 6 (5%) 16 (11%) 
 
Figure 9 illustrates the diversity of participants’ choices for the trial as a whole. 
Among patients who wished to have informed consent process take place at 
home, 32% (100/311) preferred the combination of visits at research centre 
and home-based visits for follow-up and 11% (35/3110) selected all visits at the 
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hospital. Of 78 patients who chose informed consent at the hospital, 17% 
(13/78) would like to have all follow-up visits at home and 33% (26/78) chose 
the combination of both visits at home and at the hospital. Even for patients 
who wanted to have all procedures of informed consent and follow-up visits at 
home, they had different choices for receiving results. 
 
Figure 9. Diversity of patients’ choices for the way a trial is organised 
5.3.3. Patients’ willingness to participate in clinical trials according 
to the way a trial is organised 
The mean (SD) probability of participating in the trials when informed consent 
is signed at hospital was 53% (34%) versus 70% (31%) for informed consent at 
home (mean difference [95% CI] 17% [4 – 30]), and 64% (33%) for the 
combination of both (mean difference [95% CI] 11% [3 – 19]).  
The mean (SD) probability of participating in the trials when all follow-up 
visits took place at the hospital was 54% (34%) versus 74% (29%) when there 




were combination of research centre-based visits and home-based visits (mean 
difference [95% CI]: 20% [10 – 30]), and 70% (31%) when all follow-up visits 
took place at home (mean difference [95% CI]: 16% [2 – 30]).  
Figure 10 shows the difference in probability of participating in the trials when 
trials were organised in a way that patients’ preferred versus their non-
preferred model. Mean (SD) of probability of participating in trials was 82% 
(24%) if trials were set up according to patients’ preference, versus 55% (33%) 
if trials were set up according to patients’ non-preferred model. 
 
Figure 10. Probability of participating when a trial is performed in 
accordance with patients’ preferences 
5.3.4. Factors associated with patients’ preferences regarding the 
way a trial is organised 
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People who lived in rural area and who lived from two to five hours driving 
from the university hospital were more likely to choose the informed consent 
process online at home (57% and 65% respectively). Patients who lived in rural 
area preferred home-based follow-up visits (47%), while patients who lived in 
urban area preferred follow-up visits both at home and at the hospital. Patients 
who were less confident with the internet were more likely to select informed 
consent and follow-up visits at the hospital (Table 20, Table 21, Table 22). 
Table 20. Factors associated with patients’ preferences of informed consent 
process organisation 
 At home 
online 
At the hospital 
and at home 
At the hospital p-value 
All (n=628) 311 (50%) 239 (38%) 78 (12%)  
Living area 
Rural (n=201) 115 (57%) 71 (35%) 15 (8%) 0.00687 
Urban (427) 196 (46%) 168 (39%) 63 (15%)  
Distance to the university hospital 
Less than one hour 
(n=362) 
158 (44%) 147 (41%) 57 (16%) 0.00283 
From one to two 
hours (n=229) 
129 (56%) 82 (36%) 18 (8%)  
From two to five 
hours (n=37) 
24 (65%) 10 (27%) 3 (8%)  
Confidence with internet 
Not confident 
(n=1) 
1 (100%) 0 (0%) 0 (0%) 0.0471 
Slightly confident 
(n=7) 
1 (14%) 2 (29%) 4 (57%)  
Somewhat 
confident (n=44) 
19 (43%) 18 (41%) 7 (16%)  
Fairly confident 
(n=218) 
107 (49%) 85 (39%) 26 (12%)  
Completely 
confident (n=358) 





Table 21. Factors associated with patients’ preferences of follow-up visit 
organisation 
 All follow up 
visits at home 
Follow up 
visits at home 
or at the 
hospital by 
choices 
All follow up 
visits at the 
hospital 
p-value 
All (n=627) * 251 (40%) 254 (41%) 122 (19%)  
Living area 
Rural area (n=200) 93 (47%) 81 (40%) 26 (13%) 0.00926 
Urban area 
(n=427) 
158 (37%) 173 (41%) 96 (22%)  
Distance to the university hospital 
Less than one hour 
(n=362) 
128 (35%) 147 (41%) 87 (24%) 0.00474 
From one to two 
hours (n=228) 
108 (47%) 92 (40%) 28 (13%)  
From two to five 
hours (n=37) 
15 (41%) 15 (41%) 7 (18%)  
Confidence with the internet 
Not confident 
(n=1) 
1 (100%) 0 (0%) 0 (0%) 0.00503 
Slightly confident 
(n=7) 
1 (14%) 2 (29%) 4 (57%)  
Somewhat 
confident (n=44) 
13 (30%) 14 (32%) 17 (39%)  
Fairly confident 
(n=218) 
81 (37%) 95 (44%) 42 (19%)  
Completely 
confident (n=357) 
155 (43%) 143 (40%) 59 (17%)  
* one missing data 
  























All (n=627) * 34 (5%) 192 (31%) 275 (44%) 126 (20%)  
Living area 
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Rural area (n=201) 14 (7%) 63 (31%) 71 (35%) 53 (26%) 0.0072 
Urban area (426) 20 (5%) 129 (30%) 204 (48%) 73 (17%)  
Distance to the university hospital 
Less than one hour 
(n=362) 
14 (4%) 104 (29%) 186 (51%) 58 (16%) 0.00265 
From one to two 
hours (n=228) 
17 (8%) 76 (33%) 74 (32%) 61 (27%)  
From two to five 
hours (n=37) 
3 (8%) 12 (32%) 15 (41%) 7 (19%)  
Confidence with the internet 
Not confident 
(n=1) 
0 (0%) 1 (100%) 0 (0%) 0 (0%) 0.1095 
Slightly confident 
(n=7) 
0 (0%) 0 (0%) 7 (100%) 0 (0%)  
Somewhat 
confident (n=43) 
2 (5%) 13 (30%) 24 (56%) 4 (9%)  
Fairly confident 
(n=218) 
16 (7%) 65 (30%) 93 (43%) 44 (20%)  
Very confident 
(n=358) 
16 (4%) 113 (32%) 151 (42%) 78 (22%)  
 
5.3.5. Patients’ suggestions to improve the way a trial is organised 
256 patients responded to at least one open-ended questions expressing their 
opinions about the ways a trial is organised and providing suggestions for 
improvement. 
Challenges to trial participation at the hospital 
Respondents indicated that hospital visits as part of trial participation would 
be more practical in comparison with trial visits at home as they believed the 
tests and examinations would be completed on the same day and they wanted 
the feeling of reassurance from seeing a doctor. However, several barriers 
related to the visiting the hospital dissuaded them from this traditional model. 
Patients expressed their disappointment with long waiting time and lack of 




What is terrible at the hospital is the waiting, sometimes hours for a blood 
test, then again a few hours to see an intern... and the impossibility to make 
the appointment by ourselves, which makes us dependent, useless, and does 
not make us responsible. (A patient with diabetes/24) 
Further, as the appointments were mainly arranged during working time, 
many patients mentioned about their loss of income or that they had to use up 
annual leave to attend the visits at the hospital. Several respondents shared 
their perspectives about the distance to travel to the hospital. For some 
patients who suffered from chronic conditions, it required substantial physical 
effort for them to travel to the hospital. Another barrier related to the travel to 
the hospital was the cost of transportation.   
Challenges to trial participation at home via the internet 
Although patients considered participating in a trial from home via the 
internet as a solution to reduce travel and save time, their main concern was a 
lack of contact with research investigators. They indicated that an in-person 
conversation with research investigators would help reassure them when 
making decision related to the trial participation.  
I prefer the hospital. In the context of a clinical trial, a contact with a real 
human is important. The internet does not transmit the emotion. Everything 
done at the hospital such as blood tests is more practical for me. […] It is 
reassuring at the hospital setting. They (doctors) can see my condition and I 
also feel that I am a stakeholder and an actor of my own decisions when 
having a human in front of me. (A patient with osteoarthritis/73) 
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Several respondents spoke about their concerns about accuracy of tests and 
data collected outside the context of the hospital which might influence the 
quality of research.  Additionally, respondents expressed their concerns about 
new responsibilities if they had to arrange appointments at a nearby 
laboratory. Further, respondents also highlighted the likelihood that they 
would not have required equipment for video calls with doctors and that their 
internet connection might be unstable. 
It is preferable that all patients are followed in the same hospital to avoid 
experimental bias.  Same equipment, same follow-up staff. Only in-hospital 
follow-up makes this possible. At home, the deviations due to errors, for 
example in video cameras, should not be ignored. In remote consultation 
(video) no palpation and "organoleptic" examination (smell, sight, touch) of 
the patient is possible. The direct contact with the doctor at the hospital and 
the team involved in the trial seems to be the most efficient for the 
examination of the patient included in the study. It seems to me to be the best 
way to guarantee the confidentiality, the Internet does not allow it. The 
secured internet should be restricted to administrative aspects. If the security 
could be ensured, it could be used to collect the data (while limiting data 
manipulation) e.g. for monitoring symptoms, weight (but be careful with the 
error of patient’s equipment), temperature, etc. (A patient with 
osteoporosis/68) 
Interestingly, one patient explained her opposition to trial visits at home as she 




I do not use the webcam. I prefer the classic meeting. On the other hand, I use 
e-mail and telephone. The trial replaces the usual care. It seems important to 
me to have a familiar and reassuring context for the follow-up visits. My 
home is a place of conviviality, rest, or recreation. I do not want that my home 
to become a place of care. I already have auto injections. I prefer to go to the 
doctor, in a centre of care even if that seems more constraining. (A patient 
with asthma/4) 
Suggestions to improve patients’ experience of trial participation 
Patients made several suggestions to improve their experience when 
participating in trials (Table 23). They emphasised that research investigators 
should consider patients as partners in the trials, not solely as participants. 
Research investigators should maintain regular communication with patients 
and take into account patients’ opinions when planning their trial 
participation. 
The patient must then become a partner (a member to be taken into account, 
to listen to, to share information and results with (by mail, appointment, 
internet), to be part of everything). (A patient with endometriosis/1) 
It is important to have patient representation in scientific councils, trial 
organisation, etc. In my opinion, patients must be given more say in the 
running of the trial. (A patient with diabetes/60) 
Further, patients also spoke of the necessity of tailoring the trial procedures to 
each patient as their conditions were unique depending on their distance, 
severity of the disease and employment status. 
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I think you cannot generalize, but for each clinical trial, the patient must be 
given a choice of how to participate. This depends mainly on the distance 
between home and hospital and of course whether the person has a 
professional activity or not. The way of participating could be proposed to 
the patient at the same time as the consent and the patient will then be in 
control of whether he or she can and wants to participate. (A patient with 
asthma/125) 
Table 23. Patients’ suggestions to improve their experience of trial 
participation 
Suggestions Quotes 
General suggestion  
Improve information for 
patients 
It is important to have as much information as possible, both 
orally and in writing, and to have time for reflection whenever 
possible. (A patient with osteoarthritis/8) 
I like the idea of being able to see a video describing the 
study. It allows you to come up with more relevant questions 
in front of the doctor. (A patient with endometriosis/3) 
A video presenting the study and answering frequently asked 
questions prior to consent (A patient with osteoporosis/17) 
Create a patient 
group/forum to put 
questions about the trial to 
the investigators  
I don't know to what extent this proposal can affect the 
clinical effects, but perhaps the questioning phase could be 
done in a group setting? The questions could then be more 
varied than those asked individually, and this would free up 
time for the doctor. (A patient with endometriosis/3) 
A patient forum for patients who can ask questions I would 
not have thought of. (A patient with 
hypercholesterolemia/66) 
Improve visits at the 
hospital 
 
Keep to appointment times 
and reduce waiting time 
Make sure that appointments with doctors or ECG 
radiography departments are on time. (A patient with 
osteoarthritis/41)  
It all depends on the location of the hospital and how easy it is 
to get there by public transport (I don't drive). On the other 
hand, please respect the appointment times very strictly. (A 




Arrange a reception 
dedicated to trial 
participants 
Make sure that appointments with doctors or ECG 
radiography departments are on time, without going through 
the general reception of the hospital... In order for me to 
participate in a study, the "logistics" must be as fluid as 
possible and outside the traditional care circuit in terms of 
administration and waiting time. (A patient with 
osteoarthritis/41) 
Provide flexibility of 
appointment time 
Having the possibility to have intelligent appointments, to 
have all examination and tests in the morning or in the 
afternoon or from 10:00 to 15:00 for example, this allows 
fragile, sick and tired people to take time and take care of 
their health, when they come from far away or when they 
have difficulty to move. It is important to be able to organise 
according to our conditions. (A patient with diabetes/13) 
I would be willing to go to the hospital without any worries, 
but I do not want this to be done during my working hours as 
it should not be the concern of my employer. (A patient with 
asthma/65) 
If the date and time of the appointment are suitable with my 
schedule, I can attend the visits at the hospital. (A patient 
with endometriosis/46) 
Combine follow-up visits 
with routine care visits 
Should we combine the visit with the examination and 
radiography for osteoarthritis? (A patient with 
osteoarthritis/97) 
Reimburse transportation 
fees and provide free 
parking 
The fee of transportation and parking should be reimbursed 
for traveling to and parking at the research centre. (A patient 
with osteoarthritis/35) 
Suggestions to the home-
based visits 
 
Involve local hospitals and 
healthcare providers for 
follow-up visits 
I participated in a clinical trial. The appointments with the 
doctor took place at the hospital. The biological tests between 
appointments at the hospital were done at a laboratory near 
my home. I appreciated this organisation. (A patient with 
asthma/56) 
To not wait too long at the hospital, and to be able to do the 
visits at a hospital nearby to reduce the travel time. (A patient 
with asthma/123) 
The visit at home gave me an idea that the patients can go to 
see a nurse. (A patient with asthma/76). 
Involve primary care 
doctors for informed 
consent and follow-up 
visits 
Another suggestion is to involve the primary care doctor as an 
intermediary to explain the study. (A patient with 
osteoarthritis/82) 
To involve the primary care doctor to avoid a part of the 
travel to the hospital? (A patient with endometriosis/51) 
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Follow-up of the trial by primary care doctor and nurse for 
usual blood examination in close contact with the research 
team of the university hospital. (A patient with 
hypercholesterolemia/37) 
Apply technology to reduce 
burden of data collection 
Plan (or use an existing one) an application with file sending 
via email for patients already doing PeakFlow follow-ups if 
this can replace or complement the certain spirometry (to 
avoid sending an IDE at home). (A patient with asthma/115) 
5.4. Discussion 
The study involved 628 patients with different conditions. 50% of patients 
would like to have informed consent completely at home, while 38% wanted to 
visit the hospital to have the trial explained by a doctor or research and have 
time to consider and sign consent form at home. 40% and 41% of patients 
would like to have follow up visits completely or partially home-based. About 
60% of patients preferred to have a doctor inform them about the study results 
either in person or via a video call. The study also showed that if the trials were 
set up according to patients’ preference, it could increase the probability of 
them participating in trials by nearly 30%.  
Patients highlighted the importance of personalizing the trial processed 
according to patients’ preference and desires. Patients provided useful 
suggestions to consider when planning a trial. To improve their experience 
with trial visits at the hospital, they proposed to set up a dedicated reception 
system specifically for trial participants at the hospital to reduce waiting time. 
Patients suggested involving local healthcare providers to not only minimise 
travel to research centres, but also improve their care during the trial 
participation. They also highlighted the important role of their primary care 







The development of clinical research has been focusing on investigators’ 
research interests and the ease and feasibility for sponsors to conduct trials 
with insufficient consideration of patients’ diverse preferences and desires. 
The patient and public involvement movement has strived to bring the voices 
of patients into research planning, conducting and dissemination.  Literature 
shows that patient and public involvement in research could potentially 
improve research design, recruitment, and retention rate (41, 182). However, 
the issues of identifying patients and ensuring the representation of patients 
involved across demographic and socioeconomic dimensions remain a 
challenge to patient and public involvement (183). A systematic review showed 
that only a small number of patients ranging from two to 24 patients were 
involved in the planning stage of the trials (184). Researchers have been 
focusing on “choosing the right patients” to engage in research activities 
instead of seeking for diversity (185, 186). Our study provided a proof of 
concept of a method to leverage collective intelligence of a diverse group of 
patients (187-190). We used case-vignettes developed in collaboration with 
patient representatives to solicit patients’ preferences and ideas to improve the 
organisation of trials. We recruited patients via an online patient community 
which was not resource intensive and achieved a sample of patients with 
different conditions, a wide range of age (median 55, [min-max:21-84]), levels 
of education, employment status and place of residence . The age range and 
levels of education of our sample reflect the general population in France. For 
example, around 80% of French population have at least high school diploma 
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which is similar to our sample. The median age of general population in France 
is 42 years old, however, we included only people over 18 years old in our 
sample (191). Additionally, to ensure the diversity of patients’ perspectives, it 
is also important to create an environment that patients would be willing to 
share their opinions. By using vignette-based survey, patients could freely 
express their opinions and ideas without being influenced by other 
participants. 
Further, our study could offer solutions to the problem of poor recruitment 
and retention in trials (192-194). Our results showed that researchers could 
increase patients’ willingness to participate in trials by some modifications in 
the logistical organisation of trials without changing research questions or 
study design. Some of these modifications could be quite simple to implement 
such as respecting appointment times, minimising waiting times, involving 
local healthcare providers to reduce travel for patients. Patients showed their 
desire to discuss different choices during trial participation with investigators.  
Indeed, previous literature showed that research investigator rarely had this 
discussion with patients (195). Patients also expressed the need to be informed 
about trial results, preferably during a discussion with a doctor to have a 
chance to bring up questions and have their questions answered directly. This 
desire from patients is in line with efforts to enhance transparency of trial 
results that funders are striving for. Further, informing patients about trial 
results helps them understand the meaning of their contribution to science and 





Our study has some limitations. We recruited patients from a patient e-cohort, 
thus patients in our sample had more experience with the use of the internet 
and participating in research. The majority of participants lived in France 
(98%), thus their experience with clinical trial participation might be different 
to patients living in other countries. Nevertheless, this proof of concept study 
could be adapted to other languages and disseminated to international patient 
communities. Additionally, a limitation of online survey was that we were not 
able to clarify responses or obtain further details of the context that patients 
were referring to. However, with an online survey, we were able to include a 
relative high number of patients, thus increasing the diversity of participants’ 
opinions and ideas to improve trial organisation. Further, the use of case 
vignette-based online survey could be adopted easily by trialists to 
communicate the trial procedures to patients and solicit ideas for 
improvement at the early stage of trial planning. We used closed questions to 
solicit patients’ opinions and ideas which might restrict their ability to express 
new ideas to improve trial organisation, thus we might not have limited the 
potential of collective intelligence to elicit new ideas and perspectives of 
patients. However, the closed questions were considered as appropriate in this 
context by the steering committee and patient representatives to provide 
simple and quantifiable data on patients’ views regarding the complex 
concepts related to clinical trials as a prelude to open-ended questions 
regarding potential solutions. The results showed that patients’ opinions and 
ideas were relatively diverse, and their answers to open-ended questions 
provided insights on both pros and cons of research centre-based and home-
based trials. Another limitation of the study is that patients were not involved 
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in the final decision-making process to prioritise the solutions proposed. 
Patients’ perspectives on the prioritisation of these solutions could help 
achieve a higher level of collective intelligence by translating their ideas into 
an actionable plan to guide changes in the conduct of clinical trials. Although 
this proof-of-concept study used hypothetical scenarios, trialists could adapt 
this method by using their real protocols to solicit patients’ opinions and then 
use the feedback from patients to adapt trial organisation according to 
patients’ preferences.    
5.5. Summary 
This study provided the proof of concept of leveraging patients’ collective 
intelligence to improve patients’ experience of trial participation. In this study, 
628 patients with diverse characteristics contributed their opinion to improve 
clinical trial organisation. They indicated that the possibility to make decision 
about when and how trial visits took place would make them more willing to 
participate in the trials. Patients expressed the needs to transform the current 
one-size-fits-all approach of clinical trial participation. 
The collective intelligence of different stakeholders could be leveraged to 





Chapter 6 Discussion 
 6.1. Introduction 
Methods of mobilising collective intelligence have emerged outside the field of 
clinical research to enable thousands of experts and non-experts to contribute 
their personal experience, knowledge and skills to research (20, 63, 65, 197, 
198). My principal aim in this thesis was to describe the methods of mobilising 
collective intelligence and determine if and how they can be used to transform 
clinical trial planning. In this Chapter, I summarise the key findings for each 
of the thesis objectives. I then discuss the implications of this work, what the 
work has contributed to knowledge about methods of mobilising collective 
intelligence and its application in clinical research planning. Lastly, I propose 
future areas for research on mobilising collective intelligence. 
6.2. Key findings 
6.2.1. Framework of mobilising collective intelligence 
The first objective was to describe different methods to mobilise collective 
intelligence in various research disciplines, who participated in these research 
projects, their motivations and how they contributed to research projects. I 
conducted a scoping review to describe the methods used across research 
disciplines which is presented in Chapter 2. I identified 145 articles with 49 
from the field of biomedicine, 47 from computer science and technology and 
49 from other research fields. Most of these research projects (76%) involved 
members of the public who did not have expertise in research. They were 
involved in these research projects to create intellectual output, to generate 
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new ideas, to solve problems and to conduct evaluations. The methods used to 
collect contributions from collective intelligence participants varied depending 
on the reason for using collective intelligence. When collective intelligence 
participants contributed to conducting evaluation and solving problems, they 
often worked independently without interaction with other participants. In 
projects where participants generated new ideas, competitions were often used 
to motivate participants. Participants also received feedback from other 
participants to refine their ideas. In projects where participants contributed to 
creating intellectual products, collaborations between participants were 
encouraged. Participants also received feedback from other participants and 
organisers to improve their work.   
This review also showed that the reporting of research mobilising collective 
intelligence is suboptimal. The numbers of participants who signed up and 
actually contributed, and their demographic information were not reported in 
sufficient detail to indicate the diversity of participants. Sources of funding 
were not mentioned in nearly a third of publications and about 40% of 
retrieved articles did not report the methods used to evaluate the contributions 
of participants. A framework was developed to guide the planning and 
implementation of research mobilising collective intelligence. 
6.2.2. Practical advice on mobilising collective intelligence 
The second objective of the thesis was to identify barriers to mobilising 
collective intelligence, strategies to overcome these barriers and provide good 
practice advice for planning and conducting research using collective 
intelligence. This objective was addressed by a qualitative study and survey of 
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researchers with experience with these new methods. This study comprised an 
online survey with open ended questions and semi-structured interviews. 
Researchers explained that they were motivated to try this new way of 
conducting research by the need to involve more diverse perspectives to tackle 
research questions which were becoming ever more interdisciplinary. 
Mobilising collective intelligence also helped them to save time and costs when 
conducting research.  
Researchers reported having experienced disruptive behaviours from some of 
participants (i.e. cheating, “trolling”, use of inappropriate language) which 
they feared might discourage other participants. They commented that 
participants had concerns about intellectual property of the solutions created 
and were worried that these concerns might hinder participants from taking 
part in collective intelligence projects. Researchers also spoke of encountering 
reluctance from funders and beneficiaries to adopt the solutions contributed 
by collective intelligence participants. To overcome these barriers, researchers 
highlighted the need for more transparency in reporting of the collective 
intelligence process to help decision makers understand the methods and the 
contributions of collective intelligence projects. Clear communication with 
participants on the terms of intellectual property from the beginning of the 
projects, and dissemination of results back to participants were proposed as 
ways to address the concern about intellectual property. Researchers shared 
practical advice on identifying research questions suitable for mobilising 
collective intelligence, identifying potential participants and ways to engage 
them. Although most of research involving collective intelligence engaged 
participants virtually via internet-based platforms, researchers advised to not 
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underestimating the value of face-to-face communication to build trust and 
strengthen the sense of belonging within a community of participants. 
6.2.3. Proof of concept – mobilising patients’ collective intelligence in 
research planning 
The third objective was to evaluate the impact of mobilising collective 
intelligence on the planning of clinical trials. This objective was addressed by 
a proof-of-concept study to mobilise the collective intelligence of patients in 
clinical trial planning. The aim of this study was to involve a large number of 
patients to overcome the current challenges of patient involvement in research 
due to lack of diversity. I used case-vignettes to illustrate the context of a 
clinical trial to patients who might not have experience of taking part in a trial. 
In this study, I drew on selected protocols of clinical trials testing 
pharmacologic treatment for chronic diseases to develop case vignettes. 628 
patients who had different conditions, education levels and living places 
answered the case vignettes to indicate their preferences regarding the way a 
trial is organised. The study showed that by setting up trial procedures 
according to patients’ preferences, trialists could increase the likelihood of 
patients participating in trials by 30%.  Patients emphasised the need to 
change the one-size-fits-all approach of trial organisation and tailor the trial 
procedures to patients’ personal preferences and situations. The model of 
remote trial could be a way to bring more flexibility to trial participation. 
Patients also made several suggestions for changing the logistical organisation 
of trials to improve their experience of trial participation, such as reducing 




doctors in trials.   This study provided a proof of concept of leveraging 
collective intelligence of patients to improve trial organisation.  
6.3. Implications 
Contribution to the knowledge of methods of mobilising collective 
intelligence 
By mobilising collective intelligence, researchers can leverage experience, 
knowledge, and expertise from diverse contributors to accelerate the search for 
solutions to address complex issues (73, 199, 200). Several previous studies 
had been done to explore methods of mobilising collective intelligence. 
Nevertheless, this work often focused on one specific methods in one research 
domain, which did not provide an overview of different ways to mobilise 
collective intelligence. This, in turn,  limited the  generalizability of the findings 
to other contexts (64-66, 164, 201). The work in this thesis has systematically 
described different methods of mobilising collective intelligence across 
different research disciplines. The framework developed from the scoping 
review provided a classification of purposes of mobilising collective 
intelligence and key elements when designing a collective intelligence project. 
This thesis is also the first work to have inductively explored barriers to 
mobilising collective intelligence and ways to overcome these from 
perspectives of researchers with experience of using collective intelligence 
methods (63-65, 201). By using a  qualitative approach, I was able to identify 
issues that had not been described in previous literature on collective 
intelligence, such as the difficulties and solutions involved in motivating and 
engaging contributors in collective intelligence projects, thus deepening the 
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understanding of these new methods. For example, although previous 
literature about collective intelligence often focused on the use of online 
platform to recruit and access a wide range of participants, online platforms 
might limit the population to younger groups having better computer literacy 
or higher social economics status (i.e., be able to have a computer and access 
to the internet). To overcome this challenge, the respondents in the qualitative 
study emphasised the importance of combining these online platforms with 
traditional face-to-face events to approach the population that might not be 
familiar with the internet (160).   
Impact on clinical research planning 
Clinical research planning has been facing numerous complex challenges such 
as setting research priorities, research design, recruitment and retention of 
trial participants. The collective intelligence of different stakeholders could be 
leveraged to find solutions for these issues. Patients with their lived experience 
of conditions and their lives being influenced directly by participation in trials 
are important stakeholders who can provide insights to address challenges of 
trial planning (202-204). The work in this thesis has contributed a new way to 
involve patients and public members in trial planning. In this thesis, I have 
leveraged the collective intelligence of patients who suggested ways to improve 
the logistical organisation of clinical trials. By using vignettes, I was able to 
explain the complex process of trials to patients, thus solicit their opinions and 
ideas. Patients were able to contribute their opinions with ease at home 
without pressures from other stakeholders. This process might be replicated 
by trialists at an early stage in the design of a trial to understand patients’ 
expectation and potential challenges when participating in trial so the research 
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team can adjust the way that the trial is organised accordingly. Further, in the 
proof-of-concept study, I solicited ideas and preferences of patients about the 
organisation of clinical trials. Other research questions such as choices of study 
design, design of intervention might require a more in-depth discussion 
between stakeholders. Certain online platforms have emerged to support the 
discussion between members of the community while providing real-time 
summary of the discussion or tools for participants to rank their choices (205). 
This method can also be scaled up to involve other stakeholder groups. 
Although in this thesis, I focused on involving patients’ perspectives in trial 
planning, there are several efforts aiming to involve other stakeholders in 
clinical research as well as clinical trial. For example, in an online  competition 
that searched for solutions to improve trial recruitment, the winning team 
comprised clinicians, nurses and computer scientists who created tools to 
increase doctors’ awareness of on-going trials and to support them in 
communicating clinical about trials to patients (206). Nevertheless, the use of 
an online platform might not be an optimal choice for certain groups such as 
elderly or people who do not have access to the internet. Face-to-face meeting 
or in-person outreach communication activities would be more suitable to 
these groups (207). The framework developed in the Chapter 2 and practical 
advice in the Chapter 3 may guide researchers in identifying relevant 
stakeholders to take part in clinical research planning, how to approach and 
motivate them, and in selecting methods to solicit their contributions. 
6.4. Future work 
6.4.1. Application of collective intelligence in clinical trial planning 
Chapter 6 Discussion 
125 
 
Patients and other stakeholders can contribute to different aspects of clinical 
trial planning. The European Patients’ Academy on Therapeutic Innovation 
(EUPATI) created a roadmap describing the areas where patients and public 
members contribute to research planning, such as practical issues in the way 
research is organised, by creating patient-facing informed consent resources, 
and during the dissemination of trial findings to patients (Figure 11) (208).  
 
Figure 11. Patients involvement in medicines research and development 
(reproduced from Geissler et al (2018)) (208) 
Depending on the goals for seeking patients’ contributions, different methods 
of mobilising collective intelligence can be used. In this section, I present 
prospective projects to mobilise collective intelligence of patients and other 
stakeholders to transform clinical trial planning. 
6.4. Future work 
126 
 
Improving clinical trial protocol 
Participating in a clinical trial usually requires patients to attend more visits to 
hospitals and answer numerous questionnaires in addition to their usual 
health check-ups. Further, clinical trial procedures are becoming ever more 
complex over time. Getz K. and Campo R. reviewed nearly 10,000 clinical trial 
protocols from 2011 to 2015 and showed an increase of 25% in the number of 
trial visits and 70% in the total number of procedures performed (209). 
However, in many trials, not all follow-up visits and data collected are used 
efficiently. A systematic review of cancer trials showed that only 11-27% of data 
collected were reported in trial publications (210). This means that patients’ 
time and efforts to attend trial visits and complete questionnaires, as well as 
some of the efforts of research teams to collect and verify data, are being 
wasted. In future research, I will explore ways to simplify trial protocols by 
leveraging collective intelligence of researchers, trialists and patients. 
Researchers and patients could identify unnecessary visits and procedures in 
a trial protocol. We will then compare patients’ willingness to participate in the 
original protocol and the simplified protocol. With the use of the internet, we 
can approach a diverse group of patients including patients who might be 
underrepresented in the current models of patient and public involvement. 
(174, 205).  
Using collective intelligence to determine minimal clinically 
important treatment effects 
Clinically important treatment effects are used to determine whether an 
improvement caused by an intervention is perceived as meaningful to patients 
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(211). A clinically important treatment effect is important in interpreting the 
effect of intervention. Studies have indicated that clinical trials can show 
statistically significant treatment differences even though such differences 
have no clinical importance for patients (212). Several methods have been used 
to elicit patients’ perspectives in determining clinical important treatment 
effects such as the opinion anchor-based method and opinion seeking (213, 
214). However, these methods are often challenged on the grounds that the 
numbers of patients involved are usually limited and unrepresentative of the 
patient population. With methods of mobilizing collective intelligence, we can 
collect opinions of a large diverse group of patients who will be potential users 
of the treatment to determine the level of treatment effect which is meaningful 
to them while taking into account the adverse effects. Case vignettes for 
specific diseases and treatments could be used to illustrate the clinical cases to 
patients. Probability trade-off techniques could be used to probe patients’ 
decisions on the meaningful treatment effect against the risks of adverse events 
(215). The vignettes could be co-produced with patient representatives. 
Patients would make their decision independently. The final minimal clinically 
important treatment effect would be aggregated from patients’ decisions. 
Other ideas of mobilising collective intelligence in research 
planning  
Methods of mobilising collective intelligence could be used to address different 
challenges in clinical trial planning. From examples of initiatives using 
methods of mobilising collective intelligence to enhance research, in Table 24 
I outline areas where diverse stakeholders can advance clinical trial planning 
and ideas for ways to solicit their contribution. 
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Collection of ideas 
Competitions to 
select and reward the 
best ideas 
Priority setting 
partnership of James 
Lind Alliance (44) 
Harvard Catalyst 
competition for new 
research ideas on 
diabetes (84). 
Generate ideas: 





Collection of ideas 
Collaboration to 
aggregate and refine 
ideas 
PRIORITY I project 
(45) 
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recruitment in lung 
cancer trial (216) 
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aggregate and refine 
ideas 
PRIORITY II project 
(44) 












use technologies to 
improve patients’ 
















create videos to 
promote HIV testing 
(90) 
Research to measure impacts of mobilising collective intelligence 
Further research is needed to measure the impacts of ideas, solutions created 
by collective intelligence on to improve clinical research, clinical trials in 
particular. Tucker et al conducted a randomised controlled trial to evaluate 
the effectiveness of a video created by collective intelligence participants to 
promote HIV testing in comparison with a conventional health promotion 
campaign (218). The ideas proposed by participants in the proof-of-concept 
study could also be tested in a study within trial to measure their impacts on 
patients’ experience with trial participation (219).  There are several efforts to 
develop tools to measure patients’ experience with trial participation. These 
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tools covered different domains including patients’ satisfaction with trial 
organisation (e.g., number of visits, waiting time, research facilities) (220-
222). These domains could be used to guide the selection of outcomes in the 
study within a trial to measure patients’ experience. However, further 
research is still needed to standardise a minimum set of outcomes and tools 
to measure these outcomes to guide trialists in the planning of their studies 
and also to enable the comparison across studies (223).  
6.4.2. Further research on collective intelligence 
Reporting guideline for research involving collective intelligence 
The inadequate reporting of research projects involving collective intelligence 
highlighted the need to develop a reporting guideline for research using these 
new methods. A reporting guideline lists the minimum set of items that 
researchers should report in publications to ensure transparency of their 
research methods (224). Such a reporting guideline would not only help 
researchers to maximize the value of the dissemination of their research but 
could also be used as a checklist to support researchers in research planning. 
To develop this reporting guideline, the guidance developed by EQUATOR 
network should be followed (225). The work from the scoping review and the 
qualitative study could be used to guide the development of items in the 
checklist and followed by a Delphi survey to reach consensus on the final list.  
Registration of research to mobilise collective intelligence 
The results of the scoping review suggested that the literature on research 
mobilising collective intelligence might be influenced by publication bias. 
Registration of such research could be a way to increase transparency in 
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methods used to mobilise participants and evaluate their contributions. 
Further, the registration could also help to avoid unnecessary duplication of 
research efforts. Although it might take time and effort to establish a common 
platform for registration of research mobilising collective intelligence across 
disciplines, researchers could start by registering their research plan on public 
repository such as Open Science Framework (226). Further research is needed 
to develop templates to facilitate registration of projects involving the 
mobilisation of collective intelligence so that the fields of research and 
methods used are consistently recorded. It is also important to identify 
appropriate incentives to encourage researchers and other stakeholders such 
as funders and journals to take part in the initiative. 
6.5. Conclusion 
Methods of mobilising collective intelligence have emerged outside the field of 
biomedical research to involve a large number of diverse stakeholders to 
enhance research efficiency. The work in this thesis systematically reviewed 
different ways to mobilise collective intelligence across research disciplines 
and developed a framework outlining key elements when planning these new 
types of research. My research identified barriers to these new types of 
research, including the reluctance of researchers to adopt these new methods 
and a lack of methodological guidance. Drawing on researchers’ experience, I 
produced practical advice to guide the planning and conduct of research 
mobilising collective intelligence. The results helped identify areas for further 
development in mobilising collective intelligence to improve transparency in 




developed and implemented a proof-of-concept study to mobilise patients’ 
collective intelligence of patients to improve logistic organisation of trial. 
Methods of mobilising collective intelligence could be used to involve different 
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Invitation email to survey participants 
From:   
Cc:  
To:  
Subject: Re your study: [Study Title]  
 
Dear [author],  
 
We are conducting studies to investigate how to apply collective intelligence in clinical 
research. We hope this work will transform the way that clinical research has been conducted 
and help to reduce research waste.  
 
As an author of [study title] published in [year of publishing], we would like to invite you to 
participate in an online qualitative survey to share your experience with collective 
intelligence. Your insights on using collective intelligence in your project is invaluable to us. 
In the end of the survey, you will be able to read a random answer from another participant 
and comment to express your opinion. All answers and comments in the open discussion will 
be anonymised.  
 
We would be very grateful if you would take the time to complete our survey. Data from the 
survey will be aggregated and your responses will remain confidential.  
 
The questionnaire should take around 10 minutes to complete and can be found at [- LINK].  
 
Alternatively, you can share your experience with us through a qualitative interview which 
will last about 30 minutes and will be arranged at your convenience. Please contact the 
researcher at van.nguyen@clinicalepidemio.fr if you would like to take part in the interview. 
 
If you have any questions, comments or queries please do not hesitate to contact us at 
van.nguyen@clinicalepidemio.fr 
 
We also encourage you to please forward the link of the survey to your colleagues that you 
may know of who may be interested in participating this study. 
 




Van Nguyen, PhD fellow 





Professor Isabelle Boutron, 
 
Centre d’Épidémiologie Clinique, Hôpital Hôtel Dieu 
1, place du Parvis Notre-Dame, 75181 Paris, Cedex 4 
Tel: 33(0) 142347833  
Fax: 33(0) 142348790 
Data collected will be saved to a computer file accessible by the INSERM METHODS team 
in order to describe the characteristics of participants. 
In keeping with the "Informatique et libertés" law, you can assert your right to access data 
which concerns you and have it rectified by notifying: isabelle.boutron@aphp.fr 
This project has received funding from the European Union’s Horizon 2020 research and 






First page of the website 
Welcome to the survey! 
Your experience and knowledge of using collective intelligence is incredibly valuable to the 
research community to understand the advantages of this method and how to minimize its 
barriers. 
We conduct this survey to investigate barriers and facilitators of using collective intelligence 
in different research fields. We hope this work will help us to understand how to apply 
collective intelligence and transform the way that biomedical research is being planned and 
conducted. 
As such, we would like to ask you to answer a few questions to share your experience when 
using collective intelligence. You will also have the opportunity to comment on other 
participants' advice. Your comments will also be anonymous. The survey will take around 15 
minutes to complete. 
All your answers will be de-identified and stored in a secured repository in INSERM 
METHODS team, University Paris Decartes. To gain the greatest benefits from this study, the 
data could be shared with other academic researchers  who would have to submit a protocol 
and sign a data use agreement. The protocol will be evaluated by our research team before 
sharing the data. You will still be able to participate in the study while opting out for data 
sharing. 
This survey is part of MiRoR project which is dedicated to Methods in Research on Research 
in the field of clinical research. This project has received funding from the European Union’s 
Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant 
agreement No 676207. 
Please tick the box to have access to the survey 
I agree to take part in the study: o Yes           o No 
I agree to share my de-identified data:  o Yes           o No 
  













1. What is your age range? 
o <20 o 40–49 
o 20–29 o 50–59 
o 30–39 o ≥60 
 
2. Where are you located currently? (Dropdown list of continents) 
3. What is your research field? (Please select all that apply) 
□ Biomedicine 
□ Psychology 
□ Technology development 
□ Computer science 
□ Education 
□ Laws, politics and governance 
□ Economics, commercial, business development 
□ Environmental science 
□ Other (please specify): ___________________ 




Please refer to the most recent completed project in which you used collective 
intelligence and answer the following question 
5. What is the purpose of mobilizing collective intelligence in your project? 
□ Evaluate ideas 
□ Generate ideas 
□ Solve problems 
□ Create intellectual products 
□ Other (please specify):__________________ 
6. What are the benefits of collective intelligence that aided your decision to use 
it in your project? 
7. What were the most important factors contributing to the success of 
mobilizing collective intelligence in your project? 
8. What were the most challenging issues you had to face when using collective 
intelligence in your project and your solutions for those challenges (e.g. 
difficulties in identifying and motivating participants, designing tasks for 
participants, evaluate quality of participants’ contribution, decision making)? 
9. What three pieces of advice would you give to a colleague who intends to use 
collective intelligence in a project for the first time?  





o Definitely yes o Yes o Perhaps o No o Definitely no 
Please tell us why you choose that answer:__________________________ 
11. Do you think collective intelligence will be increasingly used in the future? 
o Definitely yes o Yes o Perhaps o No o Definitely no 
Please tell us why you choose that answer:__________________________ 
Please read the advice from another participant. (Showing an answer from another 
participant) 
What do you think of this advice? Rate from 1 to 5 stars. 







Appendix 5:  
Information sheet to participants 
PARTICIPANT INFORMATION SHEET 
Barriers and facilitators of using collective intelligence 
Your experience and knowledge of using collective intelligence is incredibly valuable to the 
research community to understand the advantages of this method and how to minimize its 
barriers. 
We conduct this qualitative study to investigate barriers and facilitators of using collective 
intelligence in different research fields. We hope this work will help us to understand how to 
apply collective intelligence and transform the way that biomedical research is being planned 
and conducted. 
As such, we would like to interview you to understand your experience when using collective 
intelligence. The interview will take around 30 minutes. If you decide at any point that you 
no longer wish to be part of the study, then you can withdraw without giving a reason. You 
can also ask for your data to be removed from the study and destroyed. 
All your answers will be de-identified and stored in a secured repository in INSERM 
METHODS team, University Paris Decartes. After the study has finished, the results will also 
be submitted for publication in an academic journal and presented at conferences and will be 
written up as part of Van Nguyen’s postgraduate research thesis and submitted for 
examination. If you would like to receive a copy of the findings, please let us know and we 
will provide you with one. 
This study is part of MiRoR project which is dedicated to Methods in Research on Research 
in the field of clinical research. This project has received funding from the European Union’s 
Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant 
agreement No 676207. 
This study has been authorised by CNIL. In keeping with the "Informatique et libertés" law, 
you can assert your right to access data which concerns you and have it rectified by notifying 
Professor Isabelle Boutron at isabelle.boutron@aphp.fr 
If you have any question about this research, please contact Professor Isabelle Boutron at the 







Appendix 6:  
Oral Consent Example Script 
We would like to take you through some main points of the project that I gave you an 
information sheet before. In summary, the aims of my project are to understand more about 
the perspective and experience of participants with QRPs. 
Are you still interested in taking part in the project? [Await confirmation]. Now I’d like to 
confirm some of the details of the project to make sure you are clear about what’s involved 
for you: 
• It’s a project about exploring your experience with collective intelligence. 
• If you take part, I’ll need you to take part in an interview where we will discuss your 
experience with collective intelligence. It will last approximately 30 minutes. 
• We do not expect there to be any risks or discomfort associated in this research study. 
However, if you feel uncomfortable then you can stop the interview at any time, without 
giving a reason.    
• You don’t have to say yes to taking part; you can ask me any questions you want before 
or throughout; you can also withdraw at any stage without giving a reason and without 
any negative consequences.  
• You do not have to answer any questions that you do not wish to. 
• You are aware that INSERM Ethics committee has approved this research project and 
how to contact research team (in the first instance) or the committee in case of any 
concerns or complaints. I have given you the project’s ethics reference number and 
relevant contact details.  
• We will not keep any of your details for longer than necessary. 
• We may use brief quotes of what you say during the interview in the write up of this 
study, but they will remain anonymous. 
• We will safely store your data electronically on encrypted, secure file stores. All 
identifiable data will be destroyed at the end of the study. 
• We will audio record you unless you say that we can’t. 
• You’re aware that our written work will be published online and this project will may 
also be published in an academic journal/ book / website. 




• Are you still willing to take part? Do you give your permission for us to re-contact you to 
clarify information?     













• To start off, could you please tell me about yourself?  
Prompt 
- What is your area of research?  
- When was the first time you heard about collective intelligence? How 
did you come up with the idea of using collective intelligence in your 
work? Do you work in a research group? What’s your role in the 
group? 
• Could you please share with me more about projects that you used 
collective intelligence?  
Prompt 
- How many projects have you used collective intelligence? 
- What was your first project using collective intelligence? Your recent 
project? 
• Taking one of your completed projects as an example, could you walk 
me through that project? 
Prompt 
- How did the initial idea come about? How did it get started? 
- What were you and the team hoping to get out of using collective 
intelligence in your project? 
- How did you and your team organize it? 
Prompt 
- Identify participants, motivations  
- Tasks given to participants  
- Evaluate contribution of participants and decision making 
 
2. Facilitators to 
mobilize 
• When looking back at projects that you used collective intelligence, 







• In your opinions, what were the factors contributing to the success of 
your project?  
Prompts 
- The community  
- The management team, expertise 
- Interface of the platform 






• What challenges did you face when using collective intelligence in your 
project? 
Prompt 
- Challenges in organization (establish core team, establish platform of 
organization, establish community)  
- Challenges in identifying and engaging participants 
- Challenges in designing tasks for participants 
- Challenges in evaluating participants’ contribution 
- Challenges with data sharing and intellectual property 
- Challenges in decision making 
 
• Did you/your team overcome the challenges that you have mentioned? 
What did you do? 
4. Future of 
collective 
intelligence 
• What advice would you give to people who intend to use collective 
intelligence for the first time? 
• Would you use collective intelligence again in your future projects? 
Please tell me more about that. 
•  Do you think collective intelligence will be increasingly used? Please tell 
me more about that. How do you think about the future of CI? 
• Should we raise awareness of collective intelligence among researchers, 
funders and community? How could we do that? 
• What do you think about the publication of methods of projects applying 
collective intelligence? What do you think about the dissemination of the 
results? 





















Advice which commentators disagreed with 




Planning is key. Make sure 
you get the CEO and 
leadership onboard, choose a 
question that can solve a big 
challenge 





Be careful about goals and 
expectations, be ready to be 
flexible and adaptive, keep in 
mind what is your particular 
goal and be honest with all 
participants beforehand 
Collective Intelligence can help refine a goal 
or redirect one that seemed good but turned 





Don't ask too much to the 
contributors, otherwise they 
won't participate (or won't 
finish their contribution) 
Depends very much on what kind of data you 
are looking for, and what kind of crowd you 
are aiming at. Some amateurs of astronomy 
can follow elaborated protocols for decades. 
The only encouragement they need is 
channels through which they can submit their 
data and some sense of being acknowledged 
for their contributions to science. Members 
of the crowd in a more general sense, 
naturally needs way more encouragement, 






Try to find the most complex 
challenge people can solve. 
I would not necessarily go for the most 
complex challenge but an important and 
societally highly relevant challenge 
Plan feasible 
time frame 
Make studies short, since 
crowdsourced users have 
short attention span.  
Mostly good, but studies don't have to be 
short. I've known projects that have been 
going for 10 years that over 30,000 people 
are still engaged with. If your project will 
take a long time, tell people that up front but 
let them know they can help as much or as 
little as they can.  
Plan feasible 
time frame 
Make studies short, since 
crowdsourced users have 
short attention span.  
We're not only talking about mass 
crowdsourcing, but collective intelligence 
can also be used with a few experts, e.g. 
divers to map lake floors or archaeologically 
interested people to think about a problem 
etc. Some citizen science projects have run 




fit the time resources people have and be 
engaging and fun. Quality control is 







Appendix 10  




I01 Biomedicine and healthcare 
I02 Open innovation 
I03 Laws, politics, governance 
I04 Computer science 
I05 Economics, commercial, business development 
I06 Biomedicine and healthcare 
I07 Environmental science 
I08 Environmental science 
I09 Biomedicine and healthcare 
I10 Computer science 
I11 Biomedicine and healthcare 
I12 Biomedicine and healthcare 
I13 Biomedicine and healthcare 
I14 Biomedicine and healthcare 
I15 Biomedicine and healthcare 
I16 Biomedicine and healthcare 
I17 Biomedicine and healthcare 
S01 Biomedicine and healthcare 
S02 Biomedicine and healthcare, Computer science 
S03 Information and communication 
S04 Education 
S05 Laws, politics, governance 
S06 Biomedicine and healthcare 
S07 Environmental science 
S16 Computer science 
S19 Economics, commercial, business development 
S20 Computer science 
S23 Education 
S25 Computer science 
S26 Computer science, Digital humanities 
S31 Computer science; Economics, commercial, business 
development; Technology development 
S32 Economics, commercial, business development 
S33 Education 
S34 Computer science; Economics, commercial, business 
development; Technology development 
S39 Technology development 
S40 Biomedicine and healthcare; Computer science 
S42 Computer science; Education 
S43 Economics, commercial, business development 





S47 Biomedicine and healthcare; Computer science 
S49 Open innovation 
S52 Biomedicine and healthcare; Computer science 
S54 Biomedicine and healthcare; Computer science 
S57 Computer science 
S59 Computational linguistics 
S62 Environmental science; Technology development 
S65 Computer science 
S66 Computer science 
S67 Astrophysics 
S70 Computer science; Economics, commercial, business 
development; Education; Technology development 
S75 Environmental science 
S83 No information 
S86 Biomedicine and healthcare; Computer science 
S88 Psychology 
S92 Complex systems 
S93 Computer science 
S95 Emergency and disaster support 
S96 Laws, politics, and governance 
S100 No information 
S101 Environmental science 
S104 Technology development 
S107 Laws, politics, governance 
S109 Computer science; Economics, commercial, business 
development; Psychology; Technology development 
S117 Social science 
S120 Economics, commercial, business development 
S122 Economics, commercial, business development 
S123 Engineering 
S128 Computer science 
S129 Technology development 
S130 Computer science 
S133 Biomedicine and healthcare 
S135 Citizen science 
S141 No information 
S142 Computer science 
S143 Library archive 
S146 Computer science 
S149 Computer science; Economics, commercial, business 
development; Environmental science 
S150 Computer science 
S151 Computer science 
S153 No information 
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Appendix 13  
Case vignette for asthma patients 
Aidez-nous à accélérer la recherche sur l’asthme ! 
Qu’est-ce qu’un essai clinique ? 
Les essais cliniques visent à déterminer si les nouveaux médicaments conçus pour soigner 
l’asthme sont sûrs et efficaces.  
Cependant, participer à un essai clinique peut-être difficile pour les patients. Ils doivent se 
déplacer à l’hôpital pour les visites, avoir des consultations et des examens en plus.  
Il arrive donc qu’à cause d’une organisation trop complexe, les patients ne participent pas 
aux essais ou n’effectuent pas les visites et sortent de l’essai. Il a été montré que 70% des 
essais cliniques s’arrêtent par manque de participation des patients. 
Cela empêche l’avancée la recherche clinique et l’identification de traitements efficaces. 
L’objectif de notre étude  
L’objectif de cette étude est de comprendre mieux les préférences des patients afin 
d'améliorer l’organisation des essais cliniques. Ainsi, les patients effectueront toutes les 
visites et les chercheurs pourront disposer de suffisamment d'informations pour évaluer le 
traitement. 
De quelle manière pouvez-vous nous aider ? 
Nous allons vous décrire un exemple d’essai clinique. Nous allons vous proposer différentes 
manières d’organiser les visites (en se déplaçant sur site ou à domicile via internet) 





Description d’un exemple d’essai clinique 
Un essai clinique vise à comparer deux traitements de l’asthme :  
− une inhalation de corticoïdes combiné avec des broncho-dilatateurs 
(budésonide/formotérol) à prendre uniquement en cas de crise  
ou 
− une inhalation de corticoïdes (budésonide) à prendre systématiquement deux fois par jour 
avec deux inhalations successives de broncho-dilatateurs (terbutaline) en cas de crise 
 
L’essai aura une durée d’un an. 
 
Imaginez que vous envisagiez de participer à cet essai. 
 
Il se déroulera à l’hôpital universitaire qui se trouve à deux heures de voiture de chez vous.  
Si vous participez à cet essai clinique, vous rencontrerez un médecin, recevrez un des traitements et 
vous aurez des prises de sang à l’hôpital universitaire. 
 
Vous avez également la possibilité de participer à l’essai à distance depuis votre domicile, de 
communiquer avec le médecin depuis votre ordinateur, de recevoir le traitement à la maison et de 
réaliser les bilans sanguins dans un laboratoire près de chez vous. 
 
Quelle est l’organisation qui vous conviendrait le mieux pour cet essai ?  
Nous allons vous présenter les différentes étapes de l’étude. Nous vous demanderons de choisir 
l’organisation qui vous semble la plus adaptée. 
 










Avant de participer à un essai clinique, l’équipe de recherche vous expliquera le déroulement de 
l’essai, vous donnera toutes les informations concernant les traitements et vous fournira le 
programme des visites d’évaluation. Vous signerez un formulaire de consentement si vous êtes 
d’accord pour participer. 






A l’hôpital  
Vous devrez : 
● Vous rendre à l’hôpital, attendre de voir un médecin  
● Rencontrer le médecin qui vous expliquera le déroulement de l’étude 
● Poser des questions au médecin pendant la visite 
● Signer le formulaire de consentement si vous souhaitez participer OU 
retourner chez vous pour en discuter avec votre famille pour ensuite 
revenir à l’hôpital afin de signer le consentement quand vous serez 
prêt(e).  
● Garder une copie du formulaire de consentement. 
O 
 À la maison par internet 
Vous devrez : 
● Regarder une vidéo en ligne qui vous présentera l’essai 
● Contacter par téléphone un médecin de l’essai clinique à n’importe 
quel moment durant les horaires de travail si vous avez des questions 
● En discuter avec votre famille si vous le souhaitez 
● Signer le formulaire de consentement sur votre ordinateur lorsque 
vous serez prêt(e) 
● Une copie du consentement vous sera envoyée par mail ou par la 
poste selon votre choix 
O 
 A l’hôpital et à la maison  
Vous devrez : 
● Vous rendre à l’hôpital, attendre de voir un médecin 
● Rencontrer le médecin qui vous expliquera le déroulement de l’étude 
● Poser des questions au médecin pendant la visite 
● Rentrer chez vous et en discuter avec votre famille 
● Contacter par téléphone un médecin de l’essai clinique à n’importe 
quel moment durant les horaires de travail si vous avez des questions 
● Signer le formulaire de consentement sur votre ordinateur lorsque 
vous serez prêt(e) 
● Une copie du consentement vous sera envoyée par mail ou par la 











(Je suis certain(e) 









Si cette étape est réalisée à la maison par internet, quelle serait la probabilité que vous 









Extrêmement fort  





Si cette étape est réalisée à l’hôpital et à la maison, quelle serait la probabilité que vous 




(Je suis certain(e) 











Si vous avez une autre idée pour améliorer votre expérience pour recevoir les informations 









Consultations dans le cadre de l’essai clinique 
 
Au cours de l’année, vous aurez un total de six visites de suivi visant à évaluer l’évolution de votre état 
de santé. 
- Lors de la première et de la dernière visite, vous répondrez à un questionnaire, vous aurez des 
prises de sang et un examen spirométrique. 
- Lors de la troisième visite, vous répondrez à un questionnaire et vous aurez un examen 
spirométrique. 
- Lors des trois autres visites, vous répondrez simplement à un questionnaire. 
 
Où souhaiteriez-vous réaliser les visites de suivi ?  
 Toutes les visites auront lieu à l’hôpital  
Pour chaque visite, vous devrez : 
● Vous rendre à l’hôpital et attendre de voir un médecin 
● Rencontrer le médecin qui réalise votre bilan de santé 
● Remplir un questionnaire avec le médecin 
● vous aurez des prises de sang et un examen spirométrique  
● Chaque visite vous prendra une demi-journée environ  
O 
 
 Toutes les visites auront lieu chez vous 
Pour chaque visite, vous devrez : 
● Avoir une consultation à distance par webcam avec le médecin qui 
réalise votre bilan de santé 
● Répondre personnellement à un questionnaire en ligne 
● Une infirmière participant à l’essai se rendra chez vous pour pratiquer 
des bilans sanguins et un test de spirométrie en fonction de vos 
disponibilités. 
O 
 La visite aura lieu à l’hôpital ou à votre domicile selon votre choix 
Cela implique que : 
● Un mois avant la visite programmée, une infirmière participant à 
l’étude vous appellera et vous lui confirmerez si vous souhaitez être 
examiné(e) à l’hôpital ou chez vous. L’infirmière organisera les visites 
en fonction de votre choix. 
O 
 





(Je suis certain(e) 

















(Je suis certain(e) 














(Je suis certain(e) 









Si vous avez une autre idée pour améliorer votre expérience de réaliser les visites de suivi, n'hésitez 









Recevoir les résultats de l’essai clinique 
 
Votre participation à l’essai clinique aura une durée d’un an. Toutefois, l’essai clinique parviendra à 
son terme seulement une fois que le dernier patient aura réalisé toutes ses visites, ce qui peut 
prendre plusieurs mois à compter de la date à laquelle votre participation sera terminée. 
Une fois l’essai clinique achevé, les chercheurs vous informeront de vos résultats personnels et des 
résultats globaux de l’essai clinique (c’est à dire le traitement est-il efficace ou non ?). 
Comment souhaitez-vous recevoir les résultats finaux de l’essai clinique ? 
o En rencontrant personnellement un membre de l’équipe de chercheurs à l’hôpital qui vous 
expliquera les résultats 
o Par un appel à distance par webcam avec un membre de l’équipe de chercheurs à l’hôpital 
qui vous expliquera les résultats 
o En recevant une synthèse des résultats par la poste 






À propos de vous 
1. Vous habitez dans : 
o Une zone urbaine (une ville ou une banlieue, une ville moyenne à grande) 
o Une zone rurale (campagne, village/petite ville) 
2. Diriez-vous que les services suivants sont situés à proximité de votre domicile ? 
o Pharmacie 
o Médecin généraliste 
o Spécialiste 
o Hôpital 
3. Combien de temps faut-il pour aller à l'hôpital universitaire le plus proche de chez vous ? 
o Moins d'une heure 
o De 1 heure à 2 heures 
o De 2 heures à 5 heures 
o Plus de 5 heures 
4. Dans quelle mesure vous sentez-vous à l'aise avec l'utilisation d'Internet ? 
o  











5. Avez-vous déjà participé à un essai clinique ? 
o Oui 
o Non 
Si Oui, quelle maladie ?  
6. Selon vous, dans quelle mesure est-il important que les patients qui participent aux essais 
cliniques puissent décider du moment et de la façon dont les visites sont organisées ? 
o  























Appendix 14  
Case vignette for patients with hypercholesterolemia 
Aidez-nous à accélérer les recherches sur l’hypercholestérolémie ! 
Qu’est-ce qu’un essai clinique ? 
Les essais cliniques visent à déterminer si les nouveaux médicaments conçus pour soigner 
l’hypercholestérolémie sont sûrs et efficaces.  
Cependant, participer à un essai clinique peut-être difficile pour les patients. Ils doivent se 
déplacer à l’hôpital pour les visites, avoir des consultations et des examens en plus.  
Il arrive donc qu’à cause d’une organisation trop complexe, les patients ne participent pas 
aux essais ou n’effectuent pas les visites et sortent de l’essai. Il a été montré que 70% des 
essais cliniques s’arrêtent par manque de participation des patients. 
Cela empêche l’avancée la recherche clinique et l’identification de traitements efficaces. 
L’objectif de notre étude  
L’objectif de cette étude est de comprendre mieux les préférences des patients afin 
d'améliorer l’organisation des essais cliniques. Ainsi, les patients effectueront toutes les 
visites et les chercheurs pourront disposer de suffisamment d'informations pour évaluer le 
traitement. 
De quelle manière pouvez-vous nous aider ? 
Nous allons vous décrire un exemple d’essai clinique. Nous allons vous proposer différentes 
manières d’organiser les visites (en se déplaçant sur site ou à domicile via internet) 





Description d’un exemple d’essai clinique  
Un essai clinique est actuellement en train de tester un nouveau traitement visant à réduire le taux 
de cholestérol dans le sang. 
 
Le nouveau traitement sera pris oralement une fois par jour au milieu du repas.  
 
Cet essai clinique durera quatre ans. 
 
Imaginez que vous envisagiez de participer à cet essai. 
 
Il se déroulera au CHU qui se trouve à deux heures de voiture de chez vous. Si vous participez à cet 
essai clinique, vous rencontrerez un médecin, recevrez un traitement et ferez des bilans sanguins au 
CHU. 
 
Vous avez également la possibilité de participer à l’essai à distance depuis votre domicile, de 
communiquer avec le médecin depuis votre ordinateur, de recevoir le traitement à la maison et de 
réaliser les bilans sanguins dans un laboratoire près de chez vous. 
 
Quelle est l’organisation qui vous conviendrait le mieux pour cet essai ?  
Nous allons vous présenter les différentes étapes de l’étude. Nous vous demanderons de choisir 
l’organisation qui vous semble la plus adaptée. 
 











Avant de participer à un essai clinique, l’équipe de recherche vous expliquera le déroulement de 
l’essai, vous donnera toutes les informations concernant votre nouveau traitement et vous fournira le 
programme d’évaluation. Vous signerez un formulaire de consentement si vous êtes d’accord pour 
participer. 






À l’hôpital  
Vous devrez : 
● Vous rendre à l’hôpital, attendre de voir un médecin  
● Rencontrer le médecin qui vous expliquera le déroulement de l’étude 
● Poser des questions au médecin pendant la visite 
● Signer le formulaire de consentement si vous souhaitez participer OU 
retourner chez vous pour en discuter avec votre famille pour ensuite 
revenir à l’hôpital afin de signer le consentement quand vous serez 
prêt(e).  
● Garder une copie du formulaire de consentement. 
O 
 
À la maison par internet 
Vous devrez : 
● Regarder une vidéo en ligne qui vous présentera l’essai 
● Contacter par téléphone un médecin de l’essai clinique à n’importe quel 
moment durant les horaires de travail si vous avez des questions 
● En discuter avec votre famille si vous le souhaitez 
● Signer le formulaire de consentement sur votre ordinateur lorsque vous 
serez prêt(e) 
● Une copie du consentement vous sera envoyée par mail ou par la poste 
selon votre choix 
O 
 
À l’hôpital et à la maison  
Vous devrez : 
● Vous rendre à l’hôpital, attendre de voir un médecin 
● Rencontrer le médecin qui vous expliquera le déroulement de l’étude 
● Poser des questions au médecin pendant la visite 
● Rentrer chez vous et en discuter avec votre famille 
● Contacter par téléphone un médecin de l’essai clinique à n’importe quel 
moment durant les horaires de travail si vous avez des questions 
● Signer le formulaire de consentement sur votre ordinateur lorsque vous 
serez prêt(e) 
● Une copie du consentement vous sera envoyée par mail ou par la poste 
selon votre choix 
O 
 








(Je suis certain(e) 










Si cette étape est réalisée à la maison par internet, quelle serait la probabilité que vous 

















Si cette étape est réalisée à l’hôpital et à la maison, quelle serait la probabilité que vous 

















Si vous avez une autre idée pour améliorer votre expérience pour recevoir les informations 









Consultations dans le cadre de l’essai clinique 
 
 
Au cours des quatre années de participation à l’essai clinique, vous aurez un total de 10 consultations 
de suivi visant à évaluer l’amélioration de votre état de santé grâce à ce nouveau traitement. Vous 
aurez une consultation tous les 6 mois.  
- Lors de la première et la dernière visite, vous serez soumis à un bilan de santé, à des bilans 
sanguins, à une analyse d’urine et vous répondrez à un questionnaire. 
- Lors des autres visites, vous serez soumis à un bilan de santé, à des bilans sanguins et vous 
répondrez à un questionnaire. 
Où souhaiteriez-vous réaliser les consultations de suivi ?  
 
Toutes les consultations auront lieu à l’hôpital 
Pour chaque visite, vous devrez : 
● Vous rendre à l’hôpital et attendre de voir un médecin 
● Rencontrer le médecin qui réalise votre bilan de santé 
● Remplir un questionnaire avec le médecin 
● Ils réaliseront des bilans sanguins et à une analyse d’urine 
● Chaque consultation vous prendra une demi-journée environ  
O  
 
Toutes les consultations auront lieu chez vous 
Pour chaque visite, vous devrez : 
● Avoir une consultation à distance par webcam avec le médecin qui réalise 
votre bilan de santé 
● Répondre personnellement à un questionnaire en ligne 
● Une infirmière travaillant à l’essai se rendra chez vous pour pratiquer des 
bilans sanguins et une analyse d’urine en fonction de vos disponibilités. 
O 
 
La visite aura lieu à l’hôpital ou à votre domicile selon votre choix 
Cela implique que : 
● Une semaine avant la visite programmée, une infirmière participant à l’étude 
vous appellera et vous lui confirmerez si vous souhaitez être examiné(e) à 








(Je suis certain(e) de 
ne pas participer) 
 
100 
Extrêmement fort  











(Je suis certain(e) 















(Je suis certain(e) 










Si vous avez une autre idée pour améliorer votre expérience de réaliser les visites de suivi, n'hésitez 









Recevoir les résultats de l’essai clinique 
 
Votre participation à l’essai clinique aura une durée d’un an. Toutefois, l’essai clinique parviendra à 
son terme seulement une fois que le dernier patient aura réalisé toutes ses visites, ce qui peut 
prendre plusieurs mois à compter de la date à laquelle votre participation sera terminée. 
Une fois l’essai clinique achevé, les chercheurs vous informeront de vos résultats personnels et des 
résultats globaux de l’essai clinique (c’est à dire le traitement est-il efficace ou non ?). 
Comment souhaitez-vous recevoir les résultats finaux de l’essai clinique ? 
o En rencontrant personnellement un membre de l’équipe de chercheurs à l’hôpital qui vous 
expliquera les résultats 
o Par un appel à distance par webcam avec un membre de l’équipe de chercheurs à l’hôpital 
qui vous expliquera les résultats 
o En recevant une synthèse des résultats par la poste 






À propos de vous 
1. Vous habitez dans : 
o Une zone urbaine (une ville ou une banlieue, une ville moyenne à grande) 
o Une zone rurale (campagne, village/petite ville) 
2. Diriez-vous que les services suivants sont situés à proximité de votre domicile ? 
o Pharmacie 
o Médecin généraliste 
o Spécialiste 
o Hôpital 
3. Combien de temps faut-il pour aller à l'hôpital universitaire le plus proche de chez vous ? 
o Moins d'une heure 
o De 1 heure à 2 heures 
o De 2 heures à 5 heures 
o Plus de 5 heures 
4. Dans quelle mesure vous sentez-vous à l'aise avec l'utilisation d'Internet ? 
o  











5. Avez-vous déjà participé à un essai clinique ? 
o Oui 
o Non 
Si Oui, quelle maladie ?  
6. Selon vous, dans quelle mesure est-il important que les patients qui participent aux essais 
cliniques puissent décider du moment et de la façon dont les visites sont organisées ? 
o  






















Appendix 15  
Case vignette for osteoporosis patients  
Aidez-nous à accélérer les recherches sur l'ostéoporose ! 
Qu’est-ce qu’un essai clinique ? 
Les essais cliniques visent à déterminer si les nouveaux médicaments conçus pour soigner 
l’ostéoporose sont sûrs et efficaces.  
Cependant, participer à un essai clinique peut-être difficile pour les patients. Ils doivent se 
déplacer à l’hôpital pour les visites, avoir des consultations et des examens en plus.  
Il arrive donc qu’à cause d’une organisation trop complexe, les patients ne participent pas 
aux essais ou n’effectuent pas les visites et sortent de l’essai. Il a été montré que 70% des 
essais cliniques s’arrêtent par manque de participation des patients. 
Cela empêche l’avancée la recherche clinique et l’identification de traitements efficaces. 
L’objectif de notre étude  
L’objectif de cette étude est de comprendre mieux les préférences des patients afin 
d'améliorer l’organisation des essais cliniques. Ainsi, les patients effectueront toutes les 
visites et les chercheurs pourront disposer de suffisamment d'informations pour évaluer le 
traitement. 
De quelle manière pouvez-vous nous aider ? 
Nous allons vous décrire un exemple d’essai clinique. Nous allons vous proposer différentes 
manières d’organiser les visites (en se déplaçant sur site ou à domicile via internet) 






Description d’un exemple d’essai clinique  
Un essai clinique est actuellement en train de tester un nouveau traitement pour prévenir les 
fractures chez les patients qui souffre d’ostéoporose.  
 
Cet essai clinique durera trois ans. 
 
Ce traitement sera administré par injection sous-cutanée une fois par mois pendant les premières 
12 mois. Après, vous prendrez de l’alendronate sous forme de cachet une fois par semaine pendant 
deux ans.  
 
Imaginez que vous envisagiez de participer à cet essai. 
 
Il se déroulera au CHU qui se trouve à deux heures de voiture de chez vous. Si vous participez à cet 
essai clinique, vous rencontrerez un médecin, recevrez un traitement et ferez des bilans sanguins au 
CHU. 
 
Vous avez également la possibilité de participer à l’essai à distance depuis votre domicile, de 
communiquer avec le médecin depuis votre ordinateur, de recevoir le traitement à la maison et de 
réaliser les bilans sanguins dans un laboratoire près de chez vous. 
 
Quelle est l’organisation qui vous conviendrait le mieux pour cet essai ?  
Nous allons vous présenter les différentes étapes de l’étude. Nous vous demanderons de choisir 
l’organisation qui vous semble la plus adaptée. 
 









Avant de participer à un essai clinique, l’équipe de recherche vous expliquera le déroulement de 
l’essai, vous donnera toutes les informations concernant votre nouveau traitement et vous fournira le 
programme d’évaluation. Vous signerez un formulaire de consentement si vous êtes d’accord pour 
participer. 






A l’hôpital  
Vous devrez : 
● Vous rendre à l’hôpital, attendre de voir un médecin  
● Rencontrer le médecin qui vous expliquera le déroulement de l’étude 
● Poser des questions au médecin pendant la visite 
● Signer le formulaire de consentement si vous souhaitez participer OU 
retourner chez vous pour en discuter avec votre famille pour ensuite revenir à 
l’hôpital afin de signer le consentement quand vous serez prêt(e).  
● Garder une copie du formulaire de consentement. 
O 
 
À la maison par internet 
Vous devrez : 
● Regarder une vidéo en ligne qui vous présentera l’essai 
● Contacter par téléphone un médecin de l’essai clinique à n’importe quel 
moment durant les horaires de travail si vous avez des questions 
● En discuter avec votre famille si vous le souhaitez 
● Signer le formulaire de consentement sur votre ordinateur lorsque vous 
serez prêt(e) 




A l’hôpital et à la maison  
Vous devrez : 
● Vous rendre à l’hôpital, attendre de voir un médecin 
● Rencontrer le médecin qui vous expliquera le déroulement de l’étude 
● Poser des questions au médecin pendant la visite 
● Rentrer chez vous et en discuter avec votre famille 
● Contacter par téléphone un médecin de l’essai clinique à n’importe quel 
moment durant les horaires de travail si vous avez des questions 
● Signer le formulaire de consentement sur votre ordinateur lorsque vous 
serez prêt(e) 













(Je suis certain(e) 










Si cette étape est réalisée à la maison par internet, quelle serait la probabilité que vous 
















Si cette étape est réalisée à l’hôpital et à la maison, quelle serait la probabilité que vous 


















Si vous avez une autre idée pour améliorer votre expérience pour recevoir les informations 









Consultations dans le cadre de l’essai clinique 
 
 
Au cours des trois années de participation à l’essai clinique, vous aurez un total de 18 consultations 
de suivi visant à évaluer l’amélioration de votre état de santé grâce à ce nouveau traitement. 
- Durant la première année, vous aurez une visite par mois. À chaque visite, vous répondrez à 
un questionnaire. Ils réaliseront des bilans sanguins à l’occasion de six visites. Ils réaliseront 
une radiographie et une mesure de la densité osseuse à la première et 12ème visites.  
- Durant la deuxième et la troisième années, vous aurez cinq visites en tout, une tous les six 
mois environ. À chaque visite, vous répondrez à un questionnaire et vous soumettrez à des 
bilans sanguins. Lors de deux visites, ils réaliseront une radiographie et une mesure de la 
densité osseuse. 
 
Où souhaiteriez-vous réaliser les consultations de suivi ?  
 
Toutes les consultations auront lieu à l’hôpital  
Pour chaque visite, vous devrez : 
● Vous rendre à l’hôpital et attendre de voir un médecin 
● Rencontrer le médecin qui réalise votre bilan de santé 
● Remplir un questionnaire avec le médecin 
● Ils réaliseront des bilans sanguins, une radiographie et une mesure de la densité 
osseuse comme prévu 
● Chaque consultation vous prendra une demi journée environ  
O 
 
Toutes les consultations auront lieu chez vous 
Pour chaque visite, vous devrez : 
● Avoir une consultation à distance par webcam avec le médecin qui réalise votre 
bilan de santé 
● Répondre personnellement à un questionnaire en ligne 
● Prendre un rendez-vous pour réaliser une radiographie et une mesure de la 
densité osseuse en fonction de vos disponibilités 
● Une infirmière participant à l’étude se rendra chez vous pour pratiquer des 
bilans sanguins en fonction de vos disponibilités. 
O 
 
La visite aura lieu à l’hôpital ou à votre domicile selon votre choix 
Cela implique que : 
● Une semaine avant la visite programmée, une infirmière participant à l’étude 
vous appellera et vous lui confirmerez si vous souhaitez être examiné(e) à 




























(Je suis certain(e) 















(Je suis certain(e) 










Si vous avez une autre idée pour améliorer votre expérience de réaliser les visites de suivi, n'hésitez 









Recevoir les résultats de l’essai clinique 
 
Votre participation à l’essai clinique aura une durée d’un an. Toutefois, l’essai clinique parviendra à 
son terme seulement une fois que le dernier patient aura réalisé toutes ses visites, ce qui peut 
prendre plusieurs mois à compter de la date à laquelle votre participation sera terminée. 
Une fois l’essai clinique achevé, les chercheurs vous informeront de vos résultats personnels et des 
résultats globaux de l’essai clinique (c’est à dire le traitement est-il efficace ou non ?). 
Comment souhaitez-vous recevoir les résultats finaux de l’essai clinique ? 
o En rencontrant personnellement un membre de l’équipe de chercheurs à l’hôpital qui vous 
expliquera les résultats 
o Par un appel à distance par webcam avec un membre de l’équipe de chercheurs à l’hôpital 
qui vous expliquera les résultats 
o En recevant une synthèse des résultats par la poste 






À propos de vous 
1. Vous habitez dans : 
o Une zone urbaine (une ville ou une banlieue, une ville moyenne à grande) 
o Une zone rurale (campagne, village/petite ville) 
2. Diriez-vous que les services suivants sont situés à proximité de votre domicile ? 
o Pharmacie 
o Médecin généraliste 
o Spécialiste 
o Hôpital 
3. Combien de temps faut-il pour aller à l'hôpital universitaire le plus proche de chez vous ? 
o Moins d'une heure 
o De 1 heure à 2 heures 
o De 2 heures à 5 heures 
o Plus de 5 heures 
4. Dans quelle mesure vous sentez-vous à l'aise avec l'utilisation d'Internet ? 
o  











5. Avez-vous déjà participé à un essai clinique ? 
o Oui 
o Non 
Si Oui, quelle maladie ?  
6. Selon vous, dans quelle mesure est-il important que les patients qui participent aux essais 
cliniques puissent décider du moment et de la façon dont les visites sont organisées ? 
o  






















Appendix 16  
Case vignette for osteoarthritis patients 
Aidez-nous à accélérer les recherches sur l'ostéoarthrite ! 
Qu’est-ce qu’un essai clinique ? 
Les essais cliniques visent à déterminer si les nouveaux médicaments conçus pour soigner 
l’ostéoarthrite sont sûrs et efficaces.  
Cependant, participer à un essai clinique peut-être difficile pour les patients. Ils doivent se 
déplacer à l’hôpital pour les visites, avoir des consultations et des examens en plus.  
Il arrive donc qu’à cause d’une organisation trop complexe, les patients ne participent pas 
aux essais ou n’effectuent pas les visites et sortent de l’essai. Il a été montré que 70% des 
essais cliniques s’arrêtent par manque de participation des patients. 
Cela empêche l’avancée la recherche clinique et l’identification de traitements efficaces. 
L’objectif de notre étude  
L’objectif de cette étude est de comprendre mieux les préférences des patients afin 
d'améliorer l’organisation des essais cliniques. Ainsi, les patients effectueront toutes les 
visites et les chercheurs pourront disposer de suffisamment d'informations pour évaluer le 
traitement. 
De quelle manière pouvez-vous nous aider ? 
Nous allons vous décrire un exemple d’essai clinique. Nous allons vous proposer différentes 
manières d’organiser les visites (en se déplaçant sur site ou à domicile via internet) 






Description d’un exemple d’essai clinique  
Un essai clinique vise à tester un nouveau traitement pour soulager la douleur liée à 
l’ostéoarthrite sur le long terme.  
L’essai se déroulera pendant un an.  
Ce nouveau traitement est administré par injection sous-cutanée tous les 2 mois, soit trois 
fois sur une année, par une infirmière agréée. 
 
Imaginez que vous envisagiez de participer à cet essai. 
 
L’essai se déroulera au CHU qui se trouve à deux heures de voiture de chez vous. Si vous 
participez à cet essai, vous rencontrerez un médecin, recevrez un traitement et ferez des 
bilans sanguins au CHU. 
Vous avez également la possibilité de participer à l’essai à distance, depuis votre domicile, 
de communiquer avec le médecin depuis votre ordinateur, de recevoir le traitement à votre 
domicile et de réaliser les bilans sanguins auprès d’un laboratoire près de chez vous. 
 
Quelle est l’organisation qui vous conviendrait le mieux pour cet essai ?  
Nous allons vous présenter les différentes étapes de l’étude. Nous vous demanderons de choisir 
l’organisation qui vous semble la plus adaptée. 
 








Avant de participer à un essai clinique, l’équipe de recherche vous expliquera le déroulement de 
l’essai, vous donnera toutes les informations concernant votre nouveau traitement et vous fournira le 
programme d’évaluation. Vous signerez un formulaire de consentement si vous êtes d’accord pour 
participer. 






A l’hôpital  
Vous devrez : 
● Vous rendre à l’hôpital, attendre de voir un médecin  
● Rencontrer le médecin qui vous expliquera le déroulement de l’étude 
● Poser des questions au médecin pendant la visite 
● Signer le formulaire de consentement si vous souhaitez participer OU retourner 
chez vous pour en discuter avec votre famille pour ensuite revenir à l’hôpital 
afin de signer le consentement quand vous serez prêt(e).  
● Garder une copie du formulaire de consentement. 
O 
 
À la maison par internet 
Vous devrez : 
● Regarder une vidéo en ligne qui vous présentera l’essai 
● Contacter par téléphone un médecin de l’essai clinique à n’importe quel 
moment durant les horaires de travail si vous avez des questions 
● En discuter avec votre famille si vous le souhaitez 
● Signer le formulaire de consentement sur votre ordinateur lorsque vous serez 
prêt(e) 




A l’hôpital et à la maison  
Vous devrez : 
● Vous rendre à l’hôpital, attendre de voir un médecin 
● Rencontrer le médecin qui vous expliquera le déroulement de l’étude 
● Poser des questions au médecin pendant la visite 
● Rentrer chez vous et en discuter avec votre famille 
● Contacter par téléphone un médecin de l’essai clinique à n’importe quel 
moment durant les horaires de travail si vous avez des questions 
● Signer le formulaire de consentement sur votre ordinateur lorsque vous serez 
prêt(e) 













(Je suis certain(e) 










Si cette étape est réalisée à la maison par internet, quelle serait la probabilité que vous 

















Si cette étape est réalisée à l’hôpital et à la maison, quelle serait la probabilité que vous 





(Je suis certain(e) 












Si vous avez une autre idée pour améliorer votre expérience pour recevoir les informations 










Consultations dans le cadre de l’essai clinique 
 
 
Au cours de l’année où vous participerez à l’essai clinique, vous aurez un total de neuf consultations 
de suivi visant à évaluer l’amélioration de votre état de santé grâce à ce nouveau traitement. 
- Dans le cadre des six visites prévues, vous devrez répondre à un questionnaire, vous 
soumettre à un bilan de santé et à un bilan sanguin, et à trois reprises ils réaliseront une 
radiographie et un ECG. 
- Lors de trois visites, vous aurez un bilan de santé et vous répondrez à un questionnaire. 
 
Où souhaiteriez-vous réaliser les consultations de suivi ?  
 
Toutes les consultations auront lieu à l’hôpital  
Pour chaque visite, vous devrez : 
● Vous rendre à l’hôpital et attendre de voir un médecin 
● Rencontrer le médecin qui réalise votre bilan de santé 
● Remplir un questionnaire avec le médecin 
● Vous soumettre à des bilans sanguins, une radiographie et un ECG comme 
prévu 
● Chaque consultation vous prendra une demi-journée environ  
O 
 
Toutes les consultations auront lieu chez vous 
Pour chaque visite, vous devrez : 
● Avoir une consultation à distance par webcam avec le médecin qui réalise 
votre bilan de santé 
● Répondre personnellement à un questionnaire en ligne 
● Prendre un rendez-vous pour réaliser une radiographie et un ECG dans un 
laboratoire près de chez vous en fonction de vos disponibilités 
● Une infirmière participant à l’étude se rendra chez vous pour pratiquer des 
bilans sanguins selon vos disponibilités. 
O 
 
Les visites auront lieu à l’hôpital et à votre domicile à votre convenance 
Cela implique que : 
● Une semaine avant la visite programmée, une infirmière participant à l’étude 
vous appellera et vous lui confirmerez si vous souhaitez être examiné(e) à 














(Je suis certain(e) 













(Je suis certain(e) 















(Je suis certain(e) 










Si vous avez une autre idée pour améliorer votre expérience de réaliser les visites de suivi, n'hésitez 









Recevoir les résultats de l’essai clinique 
 
Votre participation à l’essai clinique aura une durée d’un an. Toutefois, l’essai clinique parviendra à 
son terme seulement une fois que le dernier patient aura réalisé toutes ses visites, ce qui peut 
prendre plusieurs mois à compter de la date à laquelle votre participation sera terminée. 
Une fois l’essai clinique achevé, les chercheurs vous informeront de vos résultats personnels et des 
résultats globaux de l’essai clinique (c’est à dire le traitement est-il efficace ou non ?). 
Comment souhaitez-vous recevoir les résultats finaux de l’essai clinique ? 
o En rencontrant personnellement un membre de l’équipe de chercheurs à l’hôpital qui vous 
expliquera les résultats 
o Par un appel à distance par webcam avec un membre de l’équipe de chercheurs à l’hôpital 
qui vous expliquera les résultats 
o En recevant une synthèse des résultats par la poste 






À propos de vous 
1. Vous habitez dans : 
o Une zone urbaine (une ville ou une banlieue, une ville moyenne à grande) 
o Une zone rurale (campagne, village/petite ville) 
2. Diriez-vous que les services suivants sont situés à proximité de votre domicile ? 
o Pharmacie 
o Médecin généraliste 
o Spécialiste 
o Hôpital 
3. Combien de temps faut-il pour aller à l'hôpital universitaire le plus proche de chez vous ? 
o Moins d'une heure 
o De 1 heure à 2 heures 
o De 2 heures à 5 heures 
o Plus de 5 heures 
4. Dans quelle mesure vous sentez-vous à l'aise avec l'utilisation d'Internet ? 
o  











5. Avez-vous déjà participé à un essai clinique ? 
o Oui 
o Non 
Si Oui, quelle maladie ?  
6. Selon vous, dans quelle mesure est-il important que les patients qui participent aux essais 
cliniques puissent décider du moment et de la façon dont les visites sont organisées ? 
o  
























Case vignette for diabetic patients 
Aidez-nous à accélérer les recherches sur le diabète ! 
Les essais cliniques visent à déterminer si les nouveaux médicaments conçus pour soigner le 
diabète sont sûrs et efficaces.  
Cependant, participer à un essai clinique peut-être difficile pour les patients. Ils doivent se 
déplacer à l’hôpital pour les visites, avoir des consultations et des examens en plus. Il arrive 
donc qu’à cause d’une organisation trop complexe, les patients ne participent pas aux 
essais ou n’effectuent pas les visites et sortent de l’essai. Il a été montré que 70% des essais 
cliniques s’arrêtent par manque de participation des patients. Cela empêche l’avancée la 
recherche clinique et l’identification de traitements efficaces. 
L’objectif de cette étude est de mieux comprendre les préférences des patients afin 
d'améliorer l’organisation des essais cliniques. Ainsi, les patients effectueront toutes les 
visites et les chercheurs pourront disposer de suffisamment d'informations pour évaluer le 
traitement. 
De quelle manière pouvez-vous nous aider ? 
Nous allons vous décrire un exemple d’essai clinique. Cet essai clinique est fictif mais il 
s’inspire de l’organisation habituelle des essais cliniques dans le domaine.  Nous allons vous 
proposer différentes manières d’organiser les visites (en se déplaçant sur site ou à domicile 
via internet) 





Un exemple d’essai clinique fictif  
Nous vous présentons un essai clinique fictif qui teste un nouveau traitement de diabète.  
 
Le nouveau traitement sera pris oralement une fois par jour, le matin.  
 
Cet essai clinique durera trois ans. 
 
Imaginez que vous envisagiez de participer à cet essai. 
 
Il se déroulera  à l’hôpital universitaire. Si vous participez à cet essai clinique, vous rencontrerez un 
médecin, recevrez un traitement et ferez des bilans sanguins  à l’hôpital universitaire. 
 
Vous avez également la possibilité de participer à l’essai à distance depuis votre domicile, de 
communiquer avec le médecin depuis votre ordinateur, de recevoir le traitement à la maison et de 
réaliser les bilans sanguins dans un laboratoire près de chez vous. 
 
Quelle est l’organisation qui vous conviendrait le mieux pour cet essai ?  
Nous allons vous présenter les différentes étapes de cet essai. Nous vous demanderons de choisir 
l’organisation qui vous semble la plus adaptée. 
 











Avant de participer à un essai clinique, l’équipe de recherche vous expliquera le déroulement de 
l’essai, vous donnera toutes les informations concernant votre nouveau traitement et vous fournira le 
programme d’évaluation. Vous signerez un formulaire de consentement si vous êtes d’accord pour 
participer. 





À l’hôpital  
Vous devrez : 
● Vous rendre à l’hôpital, attendre de voir un médecin  
● Rencontrer le médecin qui vous expliquera le déroulement de l’étude 
● Poser des questions au médecin pendant la visite 
● Signer le formulaire de consentement si vous souhaitez participer OU retourner 
chez vous pour en discuter avec votre famille pour ensuite revenir à l’hôpital 
afin de signer le consentement quand vous serez prêt(e).  
● Garder une copie du formulaire de consentement. 
O 
 À la maison par internet 
Vous devrez : 
● Regarder une vidéo en ligne qui vous présentera l’essai 
● Contacter par téléphone un médecin de l’essai clinique à n’importe quel 
moment durant les horaires de travail si vous avez des questions 
● En discuter avec votre famille si vous le souhaitez 
● Signer le formulaire de consentement sur votre ordinateur lorsque vous serez 
prêt(e) 
● Une copie du consentement vous sera envoyée par mail ou par la poste selon 
votre choix 
O 
 À l’hôpital et à la maison  
Vous devrez : 
● Vous rendre à l’hôpital, attendre de voir un médecin 
● Rencontrer le médecin qui vous expliquera le déroulement de l’étude 
● Poser des questions au médecin pendant la visite 
● Rentrer chez vous et en discuter avec votre famille 
● Contacter par téléphone un médecin de l’essai clinique à n’importe quel 
moment durant les horaires de travail si vous avez des questions 
● Signer le formulaire de consentement sur votre ordinateur lorsque vous serez 
prêt(e) 




Où souhaiteriez-vous recevoir les informations concernant l’essai clinique et signer le consentement 
? 








(Je suis certain(e) 









Si cette étape est réalisée à la maison par internet, quelle serait la probabilité que vous 
















Si cette étape est réalisée à l’hôpital et à la maison, quelle serait la probabilité que vous 
















Si vous avez une autre idée pour améliorer l’organisation de cette visite, n'hésitez pas à 









Consultations dans le cadre de l’essai clinique 
 
 
Au cours des trois années de participation à l’essai clinique, vous aurez un total de 14 consultations 
de suivi visant à évaluer votre état de santé : 8 consultations dans la première année et une 
consultation tous les 4 mois dans la deuxième et troisième année.  
- Dans la première année, à chaque visite, vous aurez un bilan de santé, et vous répondrez à 
un questionnaire. À la visite du 1er, 3eme, 7eme, 10eme et 12eme mois vous aurez des bilans 
sanguins, une analyse d’urine.  À la visite de première, 7emeet 12eme mois, vous aurez en plus 
un ECG.  
- Dans la deuxième et troisième année, à chaque visite vous aurez un bilan de santé, des bilans 
sanguins, une analyse d’urine, un ECG et vous répondrez à un questionnaire. 
Il y a trois façons de réaliser les consultations de suivi ?  
 Toutes les consultations auront lieu à l’hôpital 
Pour chaque visite, vous devrez : 
● Vous rendre à l’hôpital et attendre de voir un médecin dans la matinée entre 7 
heure et 11 heures 
● Etre à jeun et ne pas prendre le médicament avant la visite 
● Rencontrer le médecin qui réalise votre bilan de santé 
● Remplir un questionnaire avec le médecin 
● Ils réaliseront des bilans sanguins, à une analyse d’urine, un ECG comme prévu  
● Chaque consultation vous prendra une demi-journée environ  
O  
 Toutes les consultations auront lieu chez vous 
Pour chaque visite, vous devrez : 
● Avoir une consultation à distance par webcam avec le médecin qui réalise votre 
bilan de santé 
● Répondre personnellement à un questionnaire en ligne 
● Une infirmière travaillant pour l’essai se rendra chez vous pour pratiquer l’ECG, 
des bilans sanguins et une analyse d’urine en fonction de vos disponibilités. Vous 
devrez être à jeun avant la réalisation de la visite.  
O 
 La visite aura lieu à l’hôpital ou à votre domicile selon votre choix 
Cela implique que : 
● Vous devez au début de l’étude indiquer les visites que vous souhaitez faire sur 
site ou à la maison. Si vous voulez changer l’organisation, vous devrez prévenir 
l’équipe environ deux mois avant. 
O 










(Je suis certain(e) 














(Je suis certain(e) 














(Je suis certain(e) 









Si vous avez une autre idée pour améliorer votre expérience de réaliser les visites de suivi, n'hésitez 









Recevoir les résultats de l’essai clinique 
 
Votre participation à l’essai clinique durera trois ans. Toutefois, l’essai clinique parviendra à son 
terme seulement une fois que le dernier patient aura réalisé toutes ses visites, ce qui peut prendre 
plusieurs mois à compter de la date à laquelle votre participation sera terminée. 
Une fois l’essai clinique achevé, les chercheurs vous informeront de vos résultats personnels et des 
résultats globaux de l’essai clinique (c’est à dire le traitement est-il efficace ou non ?). 
Comment souhaitez-vous recevoir les résultats finaux de l’essai clinique ? 
o En rencontrant personnellement un membre de l’équipe de chercheurs à l’hôpital qui vous 
expliquera les résultats 
o Par un appel à distance par webcam avec un membre de l’équipe de chercheurs à l’hôpital 
qui vous expliquera les résultats 
o En recevant une synthèse des résultats par la poste 






À propos de vous 
1. Vous habitez dans : 
o Une zone urbaine (une ville ou une banlieue, une ville moyenne à grande) 
o Une zone rurale (campagne, village/petite ville) 
2. Diriez-vous que les services suivants sont situés à proximité de votre domicile ? 
o Pharmacie 
o Médecin généraliste 
o Spécialiste 
o Hôpital 
3. Combien de temps faut-il pour aller à l'hôpital universitaire le plus proche de chez vous ? 
o Moins d'une heure 
o De 1 heure à 2 heures 
o De 2 heures à 5 heures 
o Plus de 5 heures 
4. Dans quelle mesure vous sentez-vous à l'aise avec l'utilisation d'Internet ? 
o  











5. Avez-vous déjà participé à un essai clinique ? 
o Oui 
o Non 










Appendix 18  
Case vignette for patients with endometriosis 
Aidez-nous à accélérer les recherches sur l'endométriose ! 
Les essais cliniques visent à déterminer si les nouveaux médicaments conçus pour soigner 
l’endométriose sont sûrs et efficaces.  
Cependant, participer à un essai clinique peut-être difficile pour les patients. Ils doivent se 
déplacer à l’hôpital pour les visites, avoir des consultations et des examens en plus. Il arrive 
donc qu’à cause d’une organisation trop complexe, les patients ne participent pas aux 
essais ou n’effectuent pas les visites et sortent de l’essai. Il a été montré que 70% des essais 
cliniques s’arrêtent par manque de participation des patients. Cela empêche l’avancée la 
recherche clinique et l’identification de traitements efficaces. 
L’objectif de cette étude est de mieux comprendre les préférences des patients afin 
d'améliorer l’organisation des essais cliniques. Ainsi, les patients effectueront toutes les 
visites et les chercheurs pourront disposer de suffisamment d'informations pour évaluer le 
traitement. 
De quelle manière pouvez-vous nous aider ? 
Nous allons vous décrire un exemple d’essai clinique. Cet essai clinique est fictif mais il 
s’inspire de l’organisation habituelle des essais cliniques dans le domaine. Nous allons vous 
proposer différentes manières d’organiser les visites (en se déplaçant sur site ou à domicile 
via internet) 






Un exemple d’essai clinique fictif  
Nous vous présentons un essai clinique fictif qui teste un nouveau traitement pour réduire la 
douleur liée à  l’endométriose.  
 
Cet essai clinique durera un an et demi. 
 
Le nouveau traitement sera pris oralement deux fois par jour pendant six mois.   
 
Imaginez que vous envisagiez de participer à cet essai. 
 
Il se déroulera à l’hôpital universitaire. Si vous participez à cet essai clinique, vous rencontrerez un 
médecin, recevrez un traitement et ferez des bilans sanguins  à l’hôpital universitaire. 
 
Vous avez également la possibilité de participer à l’essai à distance depuis votre domicile, de 
communiquer avec le médecin depuis votre ordinateur, de recevoir le traitement à la maison et de 
réaliser les bilans sanguins dans un laboratoire près de chez vous. 
 
Quelle est l’organisation qui vous conviendrait le mieux pour cet essai ?  
Nous allons vous présenter les différentes étapes de cet essai. Nous vous demanderons de choisir 
l’organisation qui vous semble la plus adaptée. 
 









Avant de participer à un essai clinique, l’équipe de recherche vous expliquera le déroulement de 
l’essai, vous donnera toutes les informations concernant votre nouveau traitement et vous fournira le 
programme d’évaluation. Vous signerez un formulaire de consentement si vous êtes d’accord pour 
participer. 





A l’hôpital  
Vous devrez : 
● Vous rendre à l’hôpital, attendre de voir un médecin  
● Rencontrer le médecin qui vous expliquera le déroulement de l’étude 
● Poser des questions au médecin pendant la visite 
● Signer le formulaire de consentement si vous souhaitez participer OU retourner 
chez vous pour en discuter avec votre famille pour ensuite revenir à l’hôpital afin 
de signer le consentement quand vous serez prêt(e).  
● Garder une copie du formulaire de consentement. 
O 
 À la maison par internet 
Vous devrez : 
● Regarder une vidéo en ligne qui vous présentera l’essai 
● Contacter par téléphone un médecin de l’essai clinique à n’importe quel 
moment durant les horaires de travail si vous avez des questions 
● En discuter avec votre famille si vous le souhaitez 
● Signer le formulaire de consentement sur votre ordinateur lorsque vous serez 
prêt(e) 
● Une copie du consentement vous sera envoyée par mail ou par la poste selon 
votre choix 
O 
 A l’hôpital et à la maison  
Vous devrez : 
● Vous rendre à l’hôpital, attendre de voir un médecin 
● Rencontrer le médecin qui vous expliquera le déroulement de l’étude 
● Poser des questions au médecin pendant la visite 
● Rentrer chez vous et en discuter avec votre famille 
● Contacter par téléphone un médecin de l’essai clinique à n’importe quel 
moment durant les horaires de travail si vous avez des questions 
● Signer le formulaire de consentement sur votre ordinateur lorsque vous serez 
prêt(e) 
● Une copie du consentement vous sera envoyée par mail ou par la poste selon 
votre choix 
O 











(Je suis certain(e) 









Si cette étape est réalisée à la maison par internet, quelle serait la probabilité que vous 

















Si cette étape est réalisée à l’hôpital et à la maison, quelle serait la probabilité que vous 




(Je suis certain(e) 











Si vous avez une autre idée pour améliorer l’organisation de cette visite, n'hésitez pas à 









Consultations dans le cadre de l’essai clinique 
 
 
L’essai durera un an et demi. Vous aurez un total de 11 consultations de suivi visant à évaluer votre 
état de santé. 
- Durant les premières six mois, vous aurez une visite par mois. À chaque visite, vous aurez un 
bilan de santé, des bilans sanguins, un test de grossesse et vous répondrez à un 
questionnaire. Au 1er, 3ème et 6ème mois, vous aurez un examen gynécologique. Au sixième 
mois, vous aurez en plus une échographie endovaginale, une biopsie de l'endomètre et une 
mesure de la densité osseuse.  
- Durant les six mois suivants, vous aurez trois visites au 7ème, 9ème, et 12ème mois. À chaque 
visite, vous aurez un bilan de santé, un test de grossesse et vous répondrez à un 
questionnaire. Au 7ème et 9ème mois, vous aurez des bilans sanguins.  Au 12ème mois, vous 
aurez une mesure de la densité osseuse. 
- Durant les dernières six mois, vous aurez deux visites au 15ème et 18ème mois. À chaque visite, 
vous aurez un bilan de santé et vous répondrez à un questionnaire. À la dernière visite, vous 
aurez une mesure de la densité osseuse. 
 
Il y a trois façons de réaliser les consultations de suivi :  
 Toutes les consultations auront lieu à l’hôpital  
Pour chaque visite, vous devrez : 
● Vous rendre à l’hôpital et attendre de voir un médecin 
● Rencontrer le médecin qui réalise votre bilan de santé 
● Remplir un questionnaire avec le médecin 
● Ils réaliseront des bilans sanguins, et tous les autres tests et examens  comme 
prévu 
● Chaque consultation vous prendra une demi-journée voire une journée environ  
O 
 Toutes les consultations, en dehors de la visite du 6ème mois qui aura lieu à l’hôpital, 
auront lieu chez vous 
Pour chaque visite, vous devrez : 
● Avoir une consultation à distance par webcam avec le médecin qui réalise votre 
bilan de santé 
● Répondre personnellement à un questionnaire en ligne 
● Prendre un rendez-vous avec votre gynécologue pour réaliser les examens 
gynécologiques,  
● Prendre un rendez-vous et réaliser une mesure de la densité osseuse en ville en 
fonction de vos disponibilités 
● Une infirmière participant à l’étude se rendra chez vous pour pratiquer des bilans 
sanguins en fonction de vos disponibilités. 
O 
 La visite aura lieu à l’hôpital ou à votre domicile selon votre choix 
Cela implique que : 
● Vous devez au début de l’étude indiquer les visites que vous souhaitez faire sur 
site ou à la maison. Si vous voulez changer l’organisation, vous devrez prévenir 
l’équipe environ deux mois avant. 
O 

























(Je suis certain(e) 





(Je suis certain(e) 
de participer) 
 





(Je suis certain(e) 





(Je suis certain(e) 
de participer) 
 
Si vous avez une autre idée pour améliorer l’organisation des visites de suivi, n'hésitez pas à nous en 









Recevoir les résultats de l’essai clinique 
 
Votre participation à l’essai clinique durera un an et demi. Toutefois, l’essai clinique parviendra à son 
terme seulement une fois que le dernier patient aura réalisé toutes ses visites, ce qui peut prendre 
plusieurs mois à compter de la date à laquelle votre participation sera terminée. 
Une fois l’essai clinique achevé, les chercheurs vous informeront de vos résultats personnels et des 
résultats globaux de l’essai clinique (c’est à dire le traitement est-il efficace ou non ?). 
Comment souhaitez-vous recevoir les résultats finaux de l’essai clinique ? 
o En rencontrant personnellement un membre de l’équipe de chercheurs à l’hôpital qui vous 
expliquera les résultats 
o Par un appel à distance par webcam avec un membre de l’équipe de chercheurs à l’hôpital 
qui vous expliquera les résultats 
o En recevant une synthèse des résultats par la poste 






À propos de vous 
1. Vous habitez dans : 
o Une zone urbaine (une ville ou une banlieue, une ville moyenne à grande) 
o Une zone rurale (campagne, village/petite ville) 
2. Diriez-vous que les services suivants sont situés à proximité de votre domicile ? 
o Pharmacie 
o Médecin généraliste 
o Spécialiste 
o Hôpital 
3. Combien de temps faut-il pour aller à l'hôpital universitaire le plus proche de chez vous ? 
o Moins d'une heure 
o De 1 heure à 2 heures 
o De 2 heures à 5 heures 
o Plus de 5 heures 
4. Dans quelle mesure vous sentez-vous à l'aise avec l'utilisation d'Internet ? 
o  











5. Avez-vous déjà participé à un essai clinique ? 
o Oui 
o Non 










Appendix 19  
Case vignette for patients with diabetes 
Aidez-nous à accélérer les recherches sur le diabète ! 
Les essais cliniques visent à déterminer si les nouveaux médicaments conçus pour soigner le 
diabète sont sûrs et efficaces.  
Cependant, participer à un essai clinique peut-être difficile pour les patients. Ils doivent se 
déplacer à l’hôpital pour les visites, avoir des consultations et des examens en plus. Il arrive 
donc qu’à cause d’une organisation trop complexe, les patients ne participent pas aux 
essais ou n’effectuent pas les visites et sortent de l’essai. Il a été montré que 70% des essais 
cliniques s’arrêtent par manque de participation des patients. Cela empêche l’avancée la 
recherche clinique et l’identification de traitements efficaces. 
L’objectif de cette étude est de mieux comprendre les préférences des patients afin 
d'améliorer l’organisation des essais cliniques. Ainsi, les patients effectueront toutes les 
visites et les chercheurs pourront disposer de suffisamment d'informations pour évaluer le 
traitement. 
De quelle manière pouvez-vous nous aider ? 
Nous allons vous décrire un exemple d’essai clinique. Cet essai clinique est fictif mais il 
s’inspire de l’organisation habituelle des essais cliniques dans le domaine.  Nous allons vous 
proposer différentes manières d’organiser les visites (en se déplaçant sur site ou à domicile 
via internet) 





Un exemple d’essai clinique fictif  
Nous vous présentons un essai clinique fictif qui teste un nouveau traitement de diabète.  
 
Le nouveau traitement sera pris oralement une fois par jour, le matin.  
 
Cet essai clinique durera trois ans. 
 
Imaginez que vous envisagiez de participer à cet essai. 
 
Il se déroulera  à l’hôpital universitaire. Si vous participez à cet essai clinique, vous rencontrerez un 
médecin, recevrez un traitement et ferez des bilans sanguins  à l’hôpital universitaire. 
 
Vous avez également la possibilité de participer à l’essai à distance depuis votre domicile, de 
communiquer avec le médecin depuis votre ordinateur, de recevoir le traitement à la maison et de 
réaliser les bilans sanguins dans un laboratoire près de chez vous. 
 
Quelle est l’organisation qui vous conviendrait le mieux pour cet essai ?  
Nous allons vous présenter les différentes étapes de cet essai. Nous vous demanderons de choisir 
l’organisation qui vous semble la plus adaptée. 
 











Avant de participer à un essai clinique, l’équipe de recherche vous expliquera le déroulement de 
l’essai, vous donnera toutes les informations concernant votre nouveau traitement et vous fournira le 
programme d’évaluation. Vous signerez un formulaire de consentement si vous êtes d’accord pour 
participer. 





À l’hôpital  
Vous devrez : 
● Vous rendre à l’hôpital, attendre de voir un médecin  
● Rencontrer le médecin qui vous expliquera le déroulement de l’étude 
● Poser des questions au médecin pendant la visite 
● Signer le formulaire de consentement si vous souhaitez participer OU retourner 
chez vous pour en discuter avec votre famille pour ensuite revenir à l’hôpital afin 
de signer le consentement quand vous serez prêt(e).  
● Garder une copie du formulaire de consentement. 
O 
 À la maison par internet 
Vous devrez : 
● Regarder une vidéo en ligne qui vous présentera l’essai 
● Contacter par téléphone un médecin de l’essai clinique à n’importe quel 
moment durant les horaires de travail si vous avez des questions 
● En discuter avec votre famille si vous le souhaitez 
● Signer le formulaire de consentement sur votre ordinateur lorsque vous serez 
prêt(e) 
● Une copie du consentement vous sera envoyée par mail ou par la poste selon 
votre choix 
O 
 À l’hôpital et à la maison  
Vous devrez : 
● Vous rendre à l’hôpital, attendre de voir un médecin 
● Rencontrer le médecin qui vous expliquera le déroulement de l’étude 
● Poser des questions au médecin pendant la visite 
● Rentrer chez vous et en discuter avec votre famille 
● Contacter par téléphone un médecin de l’essai clinique à n’importe quel 
moment durant les horaires de travail si vous avez des questions 
● Signer le formulaire de consentement sur votre ordinateur lorsque vous serez 
prêt(e) 




Où souhaiteriez-vous recevoir les informations concernant l’essai clinique et signer le consentement 
? 


















Si cette étape est réalisée à la maison par internet, quelle serait la probabilité que vous 

















Si cette étape est réalisée à l’hôpital et à la maison, quelle serait la probabilité que vous 
















Si vous avez une autre idée pour améliorer l’organisation de cette visite, n'hésitez pas à 









Consultations dans le cadre de l’essai clinique 
 
 
Au cours des trois années de participation à l’essai clinique, vous aurez un total de 14 consultations 
de suivi visant à évaluer votre état de santé : 8 consultations dans la première année et une 
consultation tous les 4 mois dans la deuxième et troisième année.  
- Dans la première année, à chaque visite, vous aurez un bilan de santé, et vous répondrez à 
un questionnaire. À la visite du 1er, 3eme, 7eme, 10eme et 12eme mois vous aurez des bilans 
sanguins, une analyse d’urine.  À la visite de première, 7emeet 12eme mois, vous aurez en plus 
un ECG.  
- Dans la deuxième et troisième année, à chaque visite vous aurez un bilan de santé, des bilans 
sanguins, une analyse d’urine, un ECG et vous répondrez à un questionnaire. 
Il y a trois façons de réaliser les consultations de suivi ?  
 Toutes les consultations auront lieu à l’hôpital 
Pour chaque visite, vous devrez : 
● Vous rendre à l’hôpital et attendre de voir un médecin dans la matinée entre 7 
heure et 11 heures 
● Etre à jeun et ne pas prendre le médicament avant la visite 
● Rencontrer le médecin qui réalise votre bilan de santé 
● Remplir un questionnaire avec le médecin 
● Ils réaliseront des bilans sanguins, à une analyse d’urine, un ECG comme prévu  
● Chaque consultation vous prendra une demi-journée environ  
O  
 Toutes les consultations auront lieu chez vous 
Pour chaque visite, vous devrez : 
● Avoir une consultation à distance par webcam avec le médecin qui réalise votre 
bilan de santé 
● Répondre personnellement à un questionnaire en ligne 
● Une infirmière travaillant pour l’essai se rendra chez vous pour pratiquer l’ECG, 
des bilans sanguins et une analyse d’urine en fonction de vos disponibilités. Vous 
devrez être à jeun avant la réalisation de la visite.  
O 
 La visite aura lieu à l’hôpital ou à votre domicile selon votre choix 
Cela implique que : 
● Vous devez au début de l’étude indiquer les visites que vous souhaitez faire sur 
site ou à la maison. Si vous voulez changer l’organisation, vous devrez prévenir 
l’équipe environ deux mois avant. 
O 
Où souhaiteriez-vous réaliser les consultations de suivi ?  
 

















































Si vous avez une autre idée pour améliorer votre expérience de réaliser les visites de suivi, n'hésitez 









Recevoir les résultats de l’essai clinique 
 
Votre participation à l’essai clinique durera trois ans. Toutefois, l’essai clinique parviendra à son 
terme seulement une fois que le dernier patient aura réalisé toutes ses visites, ce qui peut prendre 
plusieurs mois à compter de la date à laquelle votre participation sera terminée. 
Une fois l’essai clinique achevé, les chercheurs vous informeront de vos résultats personnels et des 
résultats globaux de l’essai clinique (c’est à dire le traitement est-il efficace ou non ?). 
Comment souhaitez-vous recevoir les résultats finaux de l’essai clinique ? 
o En rencontrant personnellement un membre de l’équipe de chercheurs à l’hôpital qui vous 
expliquera les résultats 
o Par un appel à distance par webcam avec un membre de l’équipe de chercheurs à l’hôpital 
qui vous expliquera les résultats 
o En recevant une synthèse des résultats par la poste 






À propos de vous 
8. Vous habitez dans : 
o Une zone urbaine (une ville ou une banlieue, une ville moyenne à grande) 
o Une zone rurale (campagne, village/petite ville) 
9. Diriez-vous que les services suivants sont situés à proximité de votre domicile ? 
o Pharmacie 
o Médecin généraliste 
o Spécialiste 
o Hôpital 
10. Combien de temps faut-il pour aller à l'hôpital universitaire le plus proche de chez vous ? 
o Moins d'une heure 
o De 1 heure à 2 heures 
o De 2 heures à 5 heures 
o Plus de 5 heures 
11. Dans quelle mesure vous sentez-vous à l'aise avec l'utilisation d'Internet ? 
o  











12. Avez-vous déjà participé à un essai clinique ? 
o Oui 
o Non 
13. Si vous souhaitez nous faire part d’autres commentaires, veuillez nous compléter ci-dessous 
 
 
 
 
 
 
 
